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1 ABBREVIATIONS 
 
AA   amino acid 
ATP   adenosine-5'-triphosphate 
APC   antigen presenting cell 
Bax   Bcl-2–associated X protein 
BDNF   brain-derived neurotrophic factor 
BSA   bovine serum albumin 
BSE   bovine spongiform encephalopathy 
cAMP    cyclic adenosine monophosphate 
CC1   positively charged charge cluster of PrPC (aa 23-27) 
CC2   positively charged charge cluster of PrPC (aa 95-110) 
CD   central domain (of PrPC) 
CDP   chronic demyelinating polyneuropathy 
CFA   complete Freud’s adjuvant 
CJD   Creutzfeldt-Jakob disease 
CMAP   compound muscle action potential 
CMT   Charcot-Marie-Tooth disease 
CNPase/ CNP  2',3'-cyclic nucleotide 3'-phosphodiesterase 
CNS   central nervous system 
CpG-ODN  cytidyl guanosyl (CpG) oligodeoxynucelotides (ODN) 
CWD   chronic wasting disease 
Dpl   protein doppel (doppelganger of the prion protein) 
Dhh   desert hedgehog 
DIGE   difference gel electrophoresis 
DNA   deoxyribonucleic acid 
DRG   dorsal root ganglion 
DRM    detergent-resistant membrane 
dpi   days post inoculation 
EAE   experimental autoimmune encephalomyelitis 
EGFP   enhanced green fluorescent protein 
ELISA   enzyme-linked immunosorbent assay 
EM   electron microscopy 
Erk   extracellular-signal-regulated kinase 
FDC   follicular dendritic cell 
FFI    fatal familial insomnia 
FSE   feline spongiform encephalopathy 
Fyn   p59Fyn kinase (member of the Src kinase family) 
GABA   gamma-aminobutyric acid 
ABBREVIATIONS 
 
6
gCJD   genetic Creutzfeldt-Jakob disease 
GDNF   glia cell line-derived neurotrophic factor 
GFP   green fluorescent protein 
GPI   glycosyl-phosphatidyl-inositol 
GSS   Gerstmann-Sträussler-Scheinker syndrome 
HC   hydrophobic core (of PrPC) 
HE    hematoxylin-eosin 
i.c.   intracerebral 
IEF   isoelectric focussing 
i.p.   intraperitoneal 
IPG   immobilized pH gradient 
i.v.   intravenous 
JNK   c-Jun N-terminal kinase 
kDa    kilo Dalton 
LPS   lipopolysaccharide 
LRP1   low-density lipoprotein receptor-related protein 1 
LT-   lymphotoxin-alpha 
LT-   lymphotoxin-beta 
MAG   myelin associated glycoprotein 
MALDI-TOF/TOF matrix-assisted laser desorption/ionization-tandem time-of-flight  
MAP   mitogen-activated protein 
MAPK   mitogen-activated protein kinase 
MBP   myelin basic protein 
MLN   mesenteric lymph node 
MPZ    myelin protein zero (see also P0) 
NaPTA   sodium phosphotungstic acid 
N-CAM   neuronal cell adhesion molecule 
NCV   nerve conduction velocity 
Nfasc   neurofascin 
NFH   neurofilament heavy chain 
NGF   nerve growth factor 
nNOS   neuronal nitric oxide synthase 
NRG1   neuregulin 1 
NSE   neuron specific enolase 
NT3   neurotrophin-3 
OR   octarepeat region (of PrPC) 
PBS   phosphate-buffered saline 
PBST   phosphate-buffered saline (with) Tween-20 
PCR   polymerase chain reaction 
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PK   proteinase K 
PKA   protein kinase A 
PKC   protein kinase C 
P0   myelin protein zero (see also MPZ) 
PLP/ PLP1  proteolipid protein 
PMP22  peripheral myelin protein 22  
PNS   peripheral nervous system 
PRNP   gene encoding the human prion protein 
Prnd  gene encoding the mouse doppel (doppelganger of the prion protein, Dpl) 
Prnp  gene encoding the mouse prion protein 
PrPC    cellular isoform of the prion protein 
PrPSc    pathological isoform of the prion protein 
Rag1   recombination-activating gene 1 
RIN   RNA integrity index 
RML6 (or 5) Rocky Mountain laboratory scrapie strain, passage 6 (or 5); originally 
derived from the Chandler sheep scrapie isolate 
RNA ribonucleic acid 
RT   room temperature 
sCJD   sporadic CJD 
s.d.   standard deviation 
SDS-PAGE  sodium dodecyl sulphate polyacrylamide gel electrophoresis 
s.e.m   standard error of the mean 
Shh   sonic hedgehog 
STI1   stress-inducible protein I 
SLIs   Schmidt-Lanterman incisures 
SOD   superoxide dismutase 
SSC   saline–sodium citrate 
STAT   signal transducers and activator of transcription 
STR   short tandem repeat 
TBST    tris-buffered saline (with) Tween-20 
TGF-   transforming growth factor-beta 
TME   transmissible mink encephalopathy 
TNF-   tumor necrosis factor-alpha 
TSE    transmissible spongiform encephalopathy 
vCJD   variant form of CJD 
wks   weeks 
wt   wildtype (mouse/ mice)
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2 SUMMARY 
 
Physiological Function of the Prion Protein in Peripheral Nerves 
Peripheral neuropathies are frequent and often debilitating disorders in humans. Little is known 
about the molecular events maintaining structure and function of peripheral nerves and 
treatment options are often unsatisfactory. In a previous observation, Nishida et al. showed a 
peripheral neuropathy in aged mice lacking the cellular prion protein PrPC (Ref.1), suggesting 
that it is a molecular player in peripheral nerve maintenance. The goal of this project was to 
revisit the status of peripheral nerve maintenance in mice in which the Prnp locus was 
inactivated.  
I could show that ablation of PrPC triggers a chronic demyelinating polyneuropathy (CDP) as 
identified by electron microscopy and electrophysiology. CDP was present in four independently 
targeted mouse strains. Ablation of the neighboring Prnd locus, or inbreeding to four distinct 
mouse strains, did not modulate the CDP. Furthermore, CDP in Prnp deficient mice was 
rescued by transgenic expression of PrPC. Hence, presence or absence of Prnp itself - not of 
other genes - determined the presence of the CDP phenotype. 
In order to identify on which cell type PrPC would need to be expressed to maintain peripheral 
myelin, I generated transgenic mice expressing Prnp under transcriptional control of the 
proteolipid protein (PLP) promoter in myelinating cells only. I analyzed these mice along with 
other existing transgenic lines. CDP was triggered by neuron-specific, but not by Schwann cell-
specific PrPC depletion and was fully suppressed by neuronal, but not by Schwann cell-
restricted, PrPC expression. These results show that expression of PrPC by neurons is essential 
for the long-term integrity of peripheral myelin sheaths, indicating that PrPC acts in trans on the 
myelin sheath.   
Previously, Baumann et al. had shown that transgenic expression of PrP lacking the central 
domain induced a young-onset peripheral neuropathy in the absence of wt Prnp2. In 
collaboration with my colleague, I generated and analyzed transgenic mice lacking either of two 
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parts of this central domain: the hydrophobic core or the charge cluster. In addition, I analyzed 
existing transgenic mice lacking various parts of the amino terminus of PrPC. I identified an 
association between presence of CDP and those PrPC variants nonpermissive for amino 
proximal cleavage. Complementary, transgenic mice expressing PrPC variants undergoing 
proteolytic cleavage did not show CDP. By analyzing transgenic mice, expressing a secreted 
variant of PrPC lacking its glycolipid membrane anchor, I could show that proper membrane 
anchorage is another prerequisite for proper PrP function. Not only was the trophic function of 
PrPC exerted in trans, but it also correlated with the proteolytic processing of PrPC in this large 
collection of transgenic mouse models. Hence, PrPC is a critical messenger of transcellular 
axomyelinic communication and I hypothesize that regulated proteolysis of axonal PrPC 
exposes domains that may interact with Schwann cell receptors.  
Clarifying the molecular basis of these phenomena may lead to a better understanding of 
peripheral neuropathies. However, Prnp-/- nerve transcriptome and proteome as analyzed by 
microarray and 2D gel experiments turned out to be very stable. Therefore, the molecular 
pathogenesis of the Prnp-/- neuropathy remains to be determined. 
 
Impact of Immunization on Prion Susceptibility 
The susceptibility of humans and animals to prion infections is determined by the virulence of 
the infectious agent, by genetic modifiers, and by hitherto unknown host and environmental risk 
factors. Since the immune system has an essential role in peripheral prion pathogenesis, I 
hypothesized that stimulation of the immune system might increase the susceptibility to 
peripherally administered prions. 
To test this, laboratory mice (C57BL/6) were confronted with a short-term challenge of CpG-
ODN followed by repeated immunization with bovine serum albumin (BSA) and alum. This 
experimental protocol was devised with the goal of broadly stimulating, both the innate and the 
adaptive components of the immune system for a protracted period of time. Histological, 
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hematological analysis as well as serum markers identified changes indicative of moderate 
stimulation of the immune system. 
I administered prions to these repeatedly immunized mice. Immunization greatly reduced the 
required dosage of peripherally administered prion inoculum necessary to induce scrapie in 
50% of mice. No difference in susceptibility was observed following intracerebral prion 
challenge. Due to its profound impact onto scrapie susceptibility, the host immune status may 
determine disease penetrance after low-dose prion exposure, including those that may give rise 
to iatrogenic and variant Creutzfeldt-Jakob disease. 
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3 ZUSAMMENFASSUNG 
 
Physiologische Funktion des Prion Proteins in Peripheren Nerven 
Bei Menschen sind periphere Neuropathien häufige und oft stark behindernde Erkrankungen. 
Wenig ist über die molekularen Mechanismen bekannt, die für den Erhalt von Struktur und 
Funktion peripherer Nerven verantwortlich sind. Oft sind die therapeutischen Möglichkeiten 
eingeschränkt und daher unbefriedigend. Nishida et al. hat vor über 10 Jahren gezeigt, dass 
alte Mäuse, denen das zelluläre Prion Protein (PrPC) fehlt, eine periphere Neuropathie 
aufweisen1. Dies weist darauf hin, dass PrPC an den molekularen Mechanismen zum 
Nervenerhalt beteiligt ist. Ziel dieses Projekts war es, die periphere Neuropathie in PrPC 
defizienten Mäusen erneut und eingehender zu untersuchen.  
Ich konnte in elektronenmikroskopischen und elektrophysiologischen Studien zeigen, dass das 
Fehlen von PrPC eine chronische demyelinisierende Polyneuropathie (CDP) induziert. Die CDP 
war in vier unabhängig voneinander erzeugten PrPC defizienten Mausstämmen nachweisbar. 
Weder die Beseitigung des benachbarten Doppelgens (Prnd) noch die Rückkreuzung auf vier 
genetisch verschiedene Mausstämme hatte einen modulierenden Einfluss auf die CDP.  Die 
CDP in PrPC defizienten Mäusen konnte durch transgene Expression von PrPC rückgängig 
gemacht werden. Das heisst, dass die An- oder Abwesenheit vom Prion Protein Gen (Prnp) 
alleine den CDP Phänotyp bestimmt und andere Gene offensichtlich keinen Einfluss haben.  
Um den Zelltyp zu identifizieren, von dem PrPC exprimiert sein muss, damit die Integrität 
peripherer Nerven erhalten bleibt, habe ich transgene Mäuse erzeugt, die Prnp myelinspezifisch 
unter transkriptioneller Kontrolle des Proteolipid Protein (PLP) Promotors exprimieren. Diese 
Mäuse habe ich zusammen mit bereits existierenden transgenen Mäusen untersucht. Die CDP 
wurde durch Neuron-spezifische, nicht aber durch Schwann Zell-spezifische PrPC Depletion 
induziert. Andersherum konnte die CDP durch Neuron-spezifische, nicht aber durch Myelin-
spezifische PrP-Expression vollständig unterdrückt werden.  
Diese Ergebnisse zeigen, dass die PrP-Expression von Neuronen in trans essentiell ist für den 
Langzeit-Erhalt der peripheren Myelinscheiden. 
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Zuvor hatte Baumann et al. gezeigt, dass transgene Mäuse, die eine PrP Mutante ohne 
Zentrale Domäne exprimieren, in Abwesenheit von Wildtyp PrPC eine bereits im 
Neugeborenenalter beginnende periphere Neuropathie aufweisen2. In Zusammenarbeit mit 
diesem Kollegen habe ich transgene Mäuse generiert und analysiert, denen eine der beiden 
Anteile der Zentralen Domäne fehlt: der hydrophobe Kern oder die Ladungsgruppe. Ausserdem 
analysierte ich bereits existierende transgene Mäuse, denen verschiedene Teile des PrP-
Aminoterminus fehlen. Es zeigte sich eine Assoziation zwischen der Entstehung einer CDP und 
denjenigen PrP-Varianten, bei denen die aminoterminale Spaltung gestört war. Andersherum 
zeigten die transgenen Mäuse mit PrP-Varianten mit regelrechter aminoterminaler 
Prozessierung keine Neuropathie. Die Analyse transgener Mäuse mit sezerniertem PrPC (ohne 
Glykolipid-Membrananker) ergab, dass eine regelrechte Membranverankerung ebenfalls 
essentiell ist für die regelrechte PrPC Funktion.  
Die myelinotrophische Funktion von PrPC wurde also nicht nur in trans ausgeübt, sondern 
korrelierte auch mit der proteolytischen Prozessierung in einem grossen Kollektiv transgener 
Mäuse. Demnach ist PrPC ein wichtiger Vermittler der transzellulären Axon-Glia-Kommunikation 
und ich vermute, dass die regulierte Proteolyse von axonalem PrPC zur Freisetzung von 
Faktoren führt, die mit Schwann Zell-Rezeptoren interagieren können.   
Die Aufklärung der molekularen Basis dieser Phänomene kann zu einem besseren Verständnis 
der Pathogenese peripherer Neuropathien beitragen. Sowohl Transkriptom als auch Proteom 
der Prnp defizienten Mäuse erwies sich in Microarray und 2D Gel Experimenten jedoch als sehr 
stabil, so dass die molekulare Pathogenese der Prnp-/- Neuropathie weiterhin offen bleibt.  
 
 
Auswirkung von Immunisierung auf die Prionen-Suszeptibilität 
Die Suszeptibilität, also die Empfänglichkeit von Menschen und Tieren für Prioneninfektionen 
wird durch die Virulenz des infektiösen Agenz, durch genetische Modifikatoren und durch bisher 
unbekannte Risikofaktoren des Wirts sowie durch Umweltfaktoren bestimmt. Da das 
Immunsystem eine essentielle Rolle in der peripheren Prionen-Pathogenese spielt, nahm ich 
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an, dass die Stimulation des Immunsystems die Suzeptibilität gegenüber peripher applizierten 
Prionen erhöhen kann.  
Um diese Hypothese zu testen, wurden Labormäuse (C57BL/6) durch zwei CpG-ODN-
Injektionen sowie wiederholte Injektionen von bovinem Serumalbumin und Alum immunisiert. 
Das Protokoll wurde derart gestaltet, dass sowohl das angeborene als auch das adaptive 
Immunsystem möglichst breit und langandauernd stimuliert werden. Histologische, 
hämatologische und laborchemische Untersuchungen wiesen auf eine moderate Stimulation 
des Immunsystems hin. Diesen wiederholt immunisierten Mäusen habe ich Prionen appliziert. 
Immunisierung führte zu einer Reduktion der peripher applizierten Prionendosis, die nötig ist, 
um in 50% der Mäuse Scrapie auszulösen und somit zu einer erhöhten Suszeptibilität. 
Hingegen wurde die Suszeptibilität bei Applikation von Prionen in das Zentrale Nervensystem 
durch Immunisierung nicht verändert. Der deutliche Einfluss auf die Scrapie-Suszeptibilität 
spricht dafür, dass der Immunstatus des Wirts die Erkrankungspenetranz bei Exposition 
gegenüber niedrigen Prionendosen wie bei iatrogener oder neuer Variante der Creutzfeldt-
Jakob Erkrankung bestimmen kann. 
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4 DEFINITIONS 
 
Immunization. Antigen specific immune response can be induced by active or passive specific 
immunization. In active immunization, antigens during natural infections or artificially 
administered antigens (vaccination) induce a protective immunity and generate an 
immunological memory. The adaptive immune system plays an active role - proliferation of 
antigen-reactive T and B cells results in the formation of effector and memory cells. Upon 
successful active immunization, a subsequent exposure to the pathogenic agent elicits a 
heightened immune response that eliminates the pathogen and prevents disease. In 
vaccinations, the boosting power of special non-specific stimulants or adjuvants like alum or 
CFA is sometimes used to enhance immunity. In passive immunization, preformed antibodies 
are injected to induce a rapid and specific but short-lived effect. It is usually applied in patients 
already exposed to disease, e.g. to tetanus3.  
 
LD50. The LD50 is a standardized measure for agents able to kill its host (poison, infectious 
agent etc.). LD50 (LD = “lethal dose”) is the dose that kills half (50%) of the exposed hosts and 
corresponds to the turning point of a cumulative dose-survival curve.  
 
Prion. Prions are infectious agents, causing transmissible spongiform encephalopathies 
(TSEs). They have unconventional properties, like resistance to agents known to inactivate 
nucleic acids. The word prion is a portmanteau derived from “proteinaceous infectious” particle. 
The term prion does not have structural implications other than that a protein is an essential 
component of the transmissible agent4-5.  
 
'Protein-only' hypothesis. This hypothesis maintains that the prion, the transmissible agent, 
consists merely of protein and is capable of replicating and transmitting infections without the 
need for informational nucleic acids. Several lines of evidence suggest that this protein is an 
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abnormal form of PrP, perhaps identical with PrPSc. Yet, it could not be excluded that the prion 
needs to be associated with other non-informational molecules to be infectious4-6. 
 
PrPC. The physiologically occurring form of the prion protein “PrPC” with “C” referring to cellular. 
The cellular prion protein PrPC is a GPI-linked extracellular membrane protein with two N-linked 
complex glycosylation sites. The mature PrPC protein contains a well-defined carboxy-terminal 
globular domain, consisting of three alpha helices and two beta sheets and a structurally less-
defined amino proximal region6. 
 
PrPSc. PrPSc is a conformational isoform of the normal cellular prion protein, which is almost 
invariably detected in TSE-infected tissues and cells and therefore serves as a surrogate 
marker for prions. “Sc” refers to scrapie, a prion disease occurring in sheep and goat or 
experimentally in mice. PrPSc is characterized by a beta-sheet-rich structure and is typically 
partially resistant to proteinase K (PK). It is widely accepted that prions mainly consist of PrPSc. 
However, it remains to be shown whether the infectious agent consists primarily or exclusively 
of a subspecies of PrPSc, or an intermediate form of PrP (termed PrP*), and which other non-
protein compounds (e.g. lipid or polyanionic molecules) can contribute to infectivity4, 6-8. 
 
Susceptibility. Susceptibility is a measure of the likelihood to contract disease after exposure 
to a defined inoculum of a given pathogen. 
 
Transmissible spongiform encephalopathy (TSE). A general term for diseases associated 
with the presence of prions in vacuolated central nervous system tissue, which can be 
transmitted from one affected host to another. It is a synonym for prion disease4-5. 
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5 PHYSIOLOGICAL FUNCTION OF THE PRION PROTEIN IN PERIPHERAL NERVES 
 
Parts of the ‘Introduction’, ‘Material and Methods’, ‘Results’ and ‘Discussion’ section are 
reproduced or adapted from the following publication: 
“Axonal prion protein is required for peripheral myelin maintenance” 
By Juliane Bremer, Frank Baumann, Cinzia Tiberi, Carsten Wessig, Heike Fischer, 
Petra Schwarz, Andrew D. Steele, Klaus V. Toyka, Klaus-Armin Nave, Joachim Weis, 
and Adriano Aguzzi 
Published in Nature Neuroscience March 13th 2010, issue 13, volume 3, pages 310-318. 
 
Parts of the ‘Introduction’ are adapted from the following publication: 
“The Prion’s Elusive Reason for Being” 
By Adriano Aguzzi, Frank Baumann, and Juliane Bremer 
Published in Annual Reviews Neuroscience 2008; issue 31: pages 439-477 
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5.1 Introduction 
5.1.1 Architecture and function of peripheral nerves 
In the mammalian nervous system, peripheral nerves contain a variable number of motor and 
sensory nerve fibers. Cell bodies of motor nerve fibers lie in the ventral horn of the spinal cord, 
while cell bodies of sensory neurons are localized in dorsal root ganglias (Fig. 1). Some nerves 
also contain autonomic nerve fibers. 
 
Figure 1. Organization of peripheral nerves.  Cell bodies of motor nerves lie in the ventral horn of the 
spinal cord (1). Their axons leave the spinal cord through the anterior root (4) in order to innervate 
skeletal muscles. In the peripheral nerves, motor nerve axons are accompanied by sensory nerve 
processes (5) that conduct impulses from the skin (right side) or from muscle spindles (left side). Sensory 
nerve cell bodies lie in the dorsal root ganglias (2) and enter the spinal cord via the posterior root (3). 
They further conduct the sensory information to the brain and/or are connected via interneurons with the 
motor neurons (1). Adapted from9, original source: Benninghoff / Drenckhahn: Anatomie, 16th edition © 
2004 Elsevier GmbH, Urban & Fischer Verlag München. 
 
Neurons coexist with glial cells. In the peripheral nervous system (PNS), there is one type of 
glial cell, the Schwann cell. Mature non-myelinating Schwann cells surround groups of small 
axons, forming Remak bundles. Larger axons > 1 m are surrounded by myelinating Schwann 
cells. Each myelinating Schwann cell surrounds only one axonal section with specialized cell 
membrane extensions that spirally wrap around the axon. These wraps are condensed into a 
PHYSIOLOGICAL FUNCTION OF THE PRION PROTEIN IN PERIPHERAL NERVES 
 
18
multilamellar-compacted myelin sheath. Such an ensheathed section of up to 2 mm is called an 
internode as it reaches from one node of Ranvier to the next. The resulting myelin sheath 
insulates the ensheathed axon, serves to localize voltage-gated channels into distinct neuronal 
domains and and allows rapid saltatory conduction of action potentials10-11. Myelin can be 
subdivided into compacted myelin which serves as the insulator and the non-compacted myelin, 
which is a channel system continuous with the glial cytoplasm. This channel system allows 
cellular metabolites to come close to the periaxonal space. Schmidt–Lanterman incisures (SLIs) 
are local stacks of non-compacted myelin that spiral around the axon. At the nodes of Ranvier, 
voltage-dependent sodium channels are clustered in the axonal membrane. Nodes are flanked 
by a paranodal axo-glial junction forming strong diffusion barriers. Paranodes in turn are flanked 
by the juxtaparanodal region with clusters of potassium channels (Fig. 2)12. 
 
 
Figure 2. Scheme depicting a myelinated axon.  On the right side, an unrolled sheath of a Schwann 
cell is shown. Compacted myelin (shown in pale blue) serves as an insulator of the axon (shown in 
brown), except for at widely spaced short gaps (nodes of Ranvier). Non-compacted myelin defines a 
channel system (shown in dark blue) that is continuous with the glial cytoplasm and brings cellular 
metabolites close to the periaxonal space (shown in yellow). Schmidt–Lanterman incisures (SLIs) are 
local stacks of non-compacted myelin that spiral around the axon, they are linked by gap junctions when 
stacked. Figure reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Neuroscience12, 
copyright 2010. www.nature.com/nrn. Licence number 2438450142816. 
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5.1.2 Axon-glia interactions 
Neurons and glial cells interact extensively, both structurally and functionally, in the central and 
peripheral nervous systems. During development of peripheral nerves, axonal signals are 
known to recruit glial cells to promote their differentiation into myelinating glia and to regulate 
myelination. Axonal neuregulin 1 (NRG1) and Notch signalling control Schwann cell 
differentiation, proliferation and myelination13-14. The ratio between axonal diameter and 
myelinated fiber diameter (g-ratio) is known to be well-preserved. Axon-bound NRG1 type III 
interacting with Schwann cell ErbB2 and ErbB3 receptors is essential for differentiation of the 
myelinating Schwann cell phenotype and regulation of myelin sheath thickness15-16. Axonal 
electrical activity can control myelination by releasing axonal ATP and adenosine. Schwann cell 
differentiation and myelination are inhibited by axonal release of ATP, while oligodendrocyte 
myelination is indirectly stimulated by axonally released adenosine11. In turn, glial ensheathment 
and myelination induce reorganization of axon membrane structure17. Neurotrophins are a 
family of target-derived growth factors including nerve growth factor (NGF), brain-derived 
neurotrophic factor (BDNF), neurotrophin-3 (NT3), and glia cell line-derived neurotrophic factor 
(GDNF) which are involved in regulating myelination by either promoting Schwann cell 
myelination (NGF/ TrkA and BDNF/ p75NTR) or promoting Schwann cell proliferation but 
inhibiting myelination (NT3/ TrkC receptor). Conversely, Schwann cell-derived GDNF can 
promote survival of axons11. Glial cells are also required for functional and structural axonal 
integrity and long-term survival. This fact is supported by knowledge from human diseases and 
findings in transgenic animals. In the demyelinating disorder Charcot-Marie-Tooth disease type I 
(CMT1), many disease-causing genes are exclusively expressed in Schwann cells, like 
peripheral myelin protein 22 (PMP22) and myelin protein zero (MPZ or P0). Besides 
developmental hypomyelination and segmental myelin brakedown, there is secondary, slowly 
progressive axonal degeneration which leads to denervation in CMT1. Denervation causes 
progressive muscle weakness and sensory deficits which are clinically more important than the 
reduction of nerve conduction velocities (NCV) caused by demyelination18. CMT2 is 
characterized by intact myelin (normal NCV), but reduced amplitudes, indicating axonal loss. 
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Typically, mutated genes encode proteins expressed specifically in the neuron. However, 
specific mutations affecting the extracellular domain of the myelin protein MPZ lead to 
CMT219-21. Similarly, in central demyelinating diseases, like multiple sclerosis or 
leukodystrophies, progressive axonal degeneration is common11.  
Analyses of knockout mice lacking either the myelin component proteolipid protein (PLP or 
PLP1) or 2’,3’-cyclic nucleotide 3’ phoshodiesterase (CNPase) show that axonal integrity in the 
central nervous system (CNS) strongly depends on glial cell support. In the absence of either of 
these two proteins there is impairment of axonal transport followed by severe axonal 
degeneration22-24. Similarly, in the PNS, Schwann cells support axonal integrety independently 
of myelin itself. Knockout mice lacking the myelin associated glycoprotein (MAG) have normal 
myelination, but sciatic nerves show axonal degeneration and reduced axon calibers11, 25-26. In 
mice lacking myelin peroxisomes, progressive degeneration of axonal integrity was observed 27. 
A summary of known axon-glia interactions is shown in Fig. 3. Recent findings and speculations 
hint to even more intense crosstalk between Schwann cells and axons. The finding that 
ribosomes can transfer from Schwann cells to axons indicates that Schwann cells even have 
the propensity to control axonal protein synthesis. In addition, trophic support of axons by glial 
cells has recently been hypothesized. Nave, for example, speculates that energy–rich 
metabolites like glycolysis products (pyruvate, lactate) could transfer from glia cells to axons 
and feed axonal mitochondria in long fiber tracts12. 
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Figure 3. Axon-glia interaction during myelination and long-term myelin and axon maintenance 
 axon to glia signalling glia to axon signalling 
myelination 
 
long-term 
maintenance 
 
? 
 
 
 
5.1.3 Peripheral neuropathies in humans 
Peripheral neuropathies are common in humans and encompass several different disorders 
affecting the integrity of peripheral nerves. They can be caused by a pathologic process 
occurring in neurons or Schwann cells, altered signalling or adhesion between the two cell types 
or by a pathological process in the surrounding connective tissues or vessels. Often peripheral 
neuropathies occur as the manifestation of a disorder involving the whole body (a systemic 
disease), like Diabetes mellitus, infectious diseases, or autoimmune disorders. Peripheral 
neuropathies can occur in patients with cancer as a paraneoplastic syndrome which is by 
definition not due to local effects of the tumour cells, but caused by humoral effects of tumour 
cells or autoimmunity induced by an immune response against cancer cells.   
Several toxic substances can cause peripheral neuropathies. The most common poison leading 
to peripheral neuropathies in the developed world is alcohol, but also medication (especially 
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chemotherapy) and several other intoxications can lead to degeneration of the peripheral 
nervous system (Table 1)28. 
Table 1. Cause of neuropathy in 1195 patients28 frequency in % 
diabetes 34.8 
unknown 22 
alcohol 11.1 
Guillain-Barre syndrome 6.3 
infectious 5.4 
vasculitis 4.1 
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) 4.1 
malabsorption 3.8 
paraneoplastic 2.7 
CMT 2.2 
paraproteinemia 1.1 
toxic 0.9 
amyloidosis 0.5 
hereditary neuropathy with liability to pressure palsy (HNPP) 0.2 
others 0.9 
  
Symptoms may be mild but can also cause complete paralysis. In some cases, if the causative 
agent is known, a specific therapy is possible, e.g. in infections. Though often, even if the cause 
is known, therapeutic options are poor and progression of the disease cannot be stopped. 
Hereditary peripheral neuropathies are less common, occuring in approximately one in 2500 
people. They are named after three investigators who described them: Charcot-Marie-Tooth 
diseases (CMT). Autosomal dominant inheritance occurs in the majority of CMT cases. 
Spontanous mutations are the reason for sporadic occurance. Approximately two thirds of CMT 
neuropathies are demyelinating, one third is a primary axonal disorders. At least 30 genes are 
known to cause CMT neuropathies, and more than 45 distinct loci have been identified29.  
5.1.4 Physiological function of the cellular prion protein  
The cellular prion protein PrPC is a GPI-linked extracellular membrane protein with two N-linked 
complex glycosylation sites. PrPC is highly abundant in the developing and mature nervous 
system, where it is expressed by neuronal and glial cells. This mature version originates from a 
precursor protein proteolytically processed in the endoplasmic reticulum and Golgi30. As 
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revealed by its atomic structure, the mature PrPC protein contains a well-defined carboxy-
terminal globular domain comprising residues 127-231 (murine numbering), consisting of three 
alpha helices and two beta sheets31-32 and a structurally less-defined amino proximal region 
containing a stretch of several octapeptide repeats, termed the octarepeat region (OR), and 
framed by two positively charged charge clusters, CC1 (aa 23-27) and CC2 (aa 95-110). The 
amino proximal region and the carboxy-terminal domain are linked by a hydrophobic stretch of 
amino acids [aa 111-134, also termed hydrophobic core (HC)]. PrPC, and particularly its central 
domain (CD), is well conserved between species, suggesting that it has an important function6. 
An astonishing number of independent lines of mice lacking PrPC have been generated by 
homologous recombination in embryonic stem cells in many laboratories (henceforth collectively 
referred to as Prnp-/- mice). Mice with disruptive modifications restricted to the open reading 
frame are known as Prnpoo [Zürich I]33 or Prnp [Edinburgh]34. They developed normally, and 
no severe pathologies were observed later in life. As predicted by the protein-only hypothesis, 
these mice were entirely resistant to prion infections35. In contrast with these earliest lines, three 
lines generated afterwards: Prnp [Nagasaki, PrnpNgsk/Ngsk], Rcm0, and Prnp [Zürich II, 
PrnpZrchII/ZrchII] developed ataxia and Purkinje cell loss later in life (Fig. 4). Because the 
phenotype was abolished by reintroduction of Prnp as a transgene, the originators of the 
Nagasaki mice concluded that it occurred because of the lack of PrPC. This, however, would run 
counter to the lack of pathology in Prnpoo Zurich-I mice. The discrepancy between the different 
lines of PrP knockout mice was not resolved until a novel gene (Prnd), encoding a protein called 
Doppel (Dpl), was discovered. Prnd is localized 16 kb downstream of Prnp. In all three lines of 
PrPC-deficient mice developing ataxia and Purkinje cell loss, a splice acceptor site to the third 
exon of Prnp was deleted. This placed Prnd under transcriptional control of the Prnp promoter, 
resulting in the formation of chimeric transcripts and in overexpression of Dpl in the brain36-38. 
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Figure 4. Prnp deficient mice. Different strategies 
used to disrupt the locus of the Prnp gene. The 
dotted line indicates the segment of Prnp DNA that 
has been deleted, and the yellow box indicates an 
inserted sequence. Red: open reading frame, 
turquoise: noncoding region; neo: neomycin 
phosphotransferase, HPRT: hypoxanthine 
phosphoribosyltransferase; lox: a 34-bp 
recombination site from phage P1. Adapted from 
“Weissmann, C. & Aguzzi, A. Perspectives: 
neurobiology. PrP's double causes trouble. Science 
286, 914-915 (1999), figure: Knock knock. Which 
phenotype is there?” 39. Reprinted with permission 
from AAAS, reference # 10-29817. 
www.sciencemag.org 
 
Several cellular processes in the nervous system have been reported to be influenced by the 
Prnp-genotype including neuronal survival, neurite outgrowth, synapse formation, maintenance 
and function and maintenance of myelinated fibers (Fig. 5). In addition, Nishida et al. identified 
late-onset peripheral neuropathy in PrnpNgsk/Ngsk and Prnpo/o mice1, 33. 
Figure 5. Physiological 
processes involving PrPC. 
Several processes in the 
nervous system are 
influenced by PrPC: Neurite 
outgrowth, including growth of 
axons and dendrites, was 
observed to be reduced in 
neurons lacking PrPC. PrPC 
has often been reported to 
promote neuronal survival, in 
particular following apoptotic 
or oxidative stress. Cerebellar granule cell apoptosis was observed in mice expressing toxic N-terminal 
deletion mutants of PrP. In addition, the latter transgenic mice show an impaired maintenance of 
myelinated axons in the white matter. Another site of PrPC action might be the synapse, which is often 
affected in the first stage of prion diseases and whose formation was found to be reduced in neuronal 
cultures devoid of PrPC. Furthermore, electrophysiological studies indicate a role of PrPC in synapse 
function, especially in neurotransmitter release. Adapted and reprinted, with permission, from the Annual 
Review of Neuroscience, Volume 31 ©2008 by Annual Reviews. www.annualreviews.org. 
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One of the most frequently suggested functions of PrPC is a survival-promoting effect on 
neuronal and nonneuronal cells, which has been observed in vitro as well as in in vivo studies. 
This neuroprotective function, or cytoprotective function in general [reviewed in 40], has been 
mediated by antiapoptotic or antioxidative mechanisms. 
Antiapoptotic function. Neurons derived from Prnp mice were originally reported to be more 
susceptible to the induction of apoptosis by serum-deprivation than cells expressing PrPC 
(Ref. 41), but this effect may have been brought about by Dpl overexpression rather than by 
PrPC ablation. However, several studies indicate that PrPC has a cytoprotective function by 
decreasing the rate of apoptosis after particular apoptotic stimuli such as Bax overexpression or 
TNF-. Bax overexpression induces apoptosis in human neuronal cells. Coexpression of wt 
PrPC, but not of PrP lacking the octarepeats, reversed the Bax-mediated induction of 
apoptosis42. 
The presence of PrP in the cytosol, be it due to reverse translocation from the endoplasmic 
reticulum or through direct cytosolic expression, was virulently neurotoxic43. However, other 
studies failed to confirm the toxicity of cytosolic PrP and claimed that it can instead protect 
against Bax-mediated apoptosis in human primary neurons44. In this context, PrPC inhibited the 
proapoptotic conformational change of Bax and cytochrome c release from mitochondria45. 
In a screening approach for proteins protecting cancer cells from apoptosis, researchers 
investigated the gene-expression profile in an established cell clone of MCF-7 breast cancer cell 
line resistant to TNFα-induced apoptosis: PrPC was overexpressed 17-fold. In line with this 
finding, overexpression of PrPC converted MCF-7 cells sensitive to TNFα-induced apoptosis into 
resistant cells46. 
The neuroprotective function of PrPC in the postischemic rodent brain has been intensively 
studied. Levels of PrPC after ischemia were increased compared with controls47-48. Moreover, 
adenovirus-mediated overexpression of PrPC reduced infarct size in rat brain and improved 
neurological behavior after cerebral ischemia47. Conversely, in a mouse model of ischemic brain 
injury Prnpoo mice displayed significantly increased infarct volumes after ischemic brain injury 
when compared with wt mice49-50. Two groups of researchers showed that mice lacking PrPC 
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had enhanced postischemic caspase-3 activation50-51. An increase in Erk-1-2, STAT-1, and 
JNK-1-2 phosphorylation and activation was identified, suggesting PrPC’s possible involvement 
in cellular signaling51. Also, a reduced amount of phospho-Akt in the gray matter suggested that 
PrPC deficiency brings about an impairment of the antiapoptotic phosphatidylinositol 3-
kinaseAkt pathway50. Finally, Mitteregger et al. claimed that the OR is required within PrPC for 
the neuroprotection in the ischemic mouse brain52, although the genetic homogeneity of the 
mice tested in the latter experiment was not controlled for. 
Protection against oxidative stress. Besides its possible antiapoptotic function, there are 
many reports about an antioxidative effect of PrPC. These two effects are not necessarily 
mutually exclusive. Oxidative stress may be involved in TSE pathogenesis. However, one must 
remember that oxidative stress is very unspecific and is seen in different kinds of damage to the 
nervous system with impaired mitochondrial function like defects in the ubiquitin-proteasome 
system, protein aggregation and inflammation. 
Many investigators believe that the main function of PrPC consists of protecting against 
oxidative stress (see53 for a review). First hints came from in vitro studies of rat 
pheochromocytoma cells. Those selected for resistance to copper toxicity or oxidative stress 
showed higher levels of PrPC (Ref 54). Primary neuronal cells lacking PrPC were more 
susceptible to hydrogen peroxide (H2O2) than wt cells. The increased peroxide toxicity went 
along with a significant decrease in glutathione reductase activity measured in PrPC-deficient 
neurons55. Also, PrPC-deficient primary neurons were more susceptible to treatment with agents 
inducing oxidative stress compared with wt cells, a phenomenon that was explained by a 
reduced CuZn superoxide dismutase (SOD) activity observed in vivo56-57. Higher levels of 
oxidative damage to proteins and lipids were identified in the brain lysates derived from Prnp 
compared with wt mice58-59. 
PrPC itself could have SOD activity and thereby mediate the antioxidative function60. However, 
there is significant controversy about this alleged SOD activity. Others failed to confirm this 
proposed SOD activity in vitro61 and in vivo62. Furthermore, PrPC expression level did not 
significantly influence SOD activity in vivo62-63. 
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Mitochondria play an important role not only in oxidative stress but also in the induction of 
apoptosis. Morphological alterations in mitochondria have been described in scrapie-infected 
hamsters64 and mice65 as well as in mice lacking PrP, in which the number of mitochondria was 
reduced66. 
Role of PrPC in synapses. Synapses have developed into a sort of hot spot in prion research. 
Several immuno-electron microscopy studies could show that PrPC is localized in synaptic 
boutons, where it is mainly presynaptic67-70. However, others described a much broader 
distribution of neuronal PrPC (Ref 71-72). Because PrPC is processed and broken down into 
various fragments, not all of which are recognized by the antibodies used in these studies, one 
might speculate that some PrPC degradation products acquire distinct subcellular topologies. 
Early pathologic changes occurring in prion diseases involve synapse loss and PrPSc deposition 
in synaptic terminals73-77. Synaptic vesicle proteins associated with exosomes and 
neurotransmission are reduced in brains of patients with spongiform encephalopathy78. Synaptic 
disorganization and loss are fundamental and constant features of prion disease, irrespective of 
the presence or absence of spongiform change, neuronal loss, and severe gliosis79. Abnormal 
electrophysiological recordings in scrapie-infected mouse and hamster hippocampal and 
cortical slices further support the synaptic dysfunction during the course of prion disease80-81. In 
a terminal disease state, PrPSc accumulation in synaptosomes correlated with alterations in the 
GABAergic system82. Despite the above evidence, it should be noted that synaptic changes can 
represent nonspecific phenomena that are seen in essentially all brain diseases at one stage or 
another. 
The generally held view that PrPC is an important protein in synapses is supported by 
electrophysiological studies of CA1 hippocampal neurons derived from PrPC-deficient mice. 
Excitatory glutamatergic synaptic transmission, GABAA receptor--mediated fast inhibition, long-
term potentiation, and late afterhyperpolarization were reduced or absent in mice lacking PrPC 
83-86. Some of the findings could be explained by alterations in Ca-activated K+ currents84, 87. 
However, these alterations in synaptic transmission were not confirmed by others88, and 
glutamatergic synaptic transmission was even observed to be increased in PrPC-deficient mice 
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by yet another laboratory89-90. Another report underscores the impact of aging on these 
alterations, describing a reduction in the level of posttetanic potentiation and long-term 
potentiation only in old PrPC-deficient mice91. In summary, the impact of the loss of PrPC on 
hippocampal electrophysiological parameters is still being hotly debated despite a full decade of 
research efforts. Some of the discrepancies may depend on additional genetic modifiers for 
which investigators have not rigorously controlled. 
Other alterations in PrPC-deficient mice might be related to synaptic dysfunction such as altered 
circadian rhythms and sleep92 and impaired hippocampal-dependent spatial learning93. The 
neuromuscular junction is another site where PrPC is concentrated, primarily enriched in 
subsynaptic endosomes94. A potentiation of acetylcholine release from presynaptic axon 
terminals was observed after administration of recombinant PrP at nanomolar concentrations to 
mouse phrenic-diaphragm preparations95. The suggestion of an involvement of PrPC in synapse 
formation originated from in vitro observations in hippocampal neurons, in which synapse-like 
contacts were increased after addition of recombinant PrP96. 
It is unknown whether the role of PrPC in synapses is related to its previously mentioned 
antiapoptotic or antioxidative effects or whether it is mainly due to the involvement of PrPC in 
neurotransmitter release (e.g., via direct interaction with synapsin1 and synaptophysin). 
However, it is also possible that a yet unidentified process could be responsible or several of 
these processes could be interrelated. 
Neurite outgrowth. Several lines of evidence indicate PrPC’s involvement in neuronal 
development, differentiation, and neurite outgrowth. Axon or dendrite outgrowth was associated 
with PrPC-dependent activation of signal transduction pathways including p59Fyn kinase (Fyn), 
cAMPprotein kinase A (PKA), protein kinase C (PKC), and MAP kinase (MAPK) activation 96-99. 
Fyn activation in this context was dependent on the recruitment of neural cell adhesion 
molecule (N-CAM) to lipid rafts99. Recent studies show that PrPC positively regulates neural 
precursor proliferation during development and adult mammalian neurogenesis100. 
Maintenance of white matter. Central nervous system white matter, composed mainly of 
myelinated axons, might be disrupted in prion diseases and prionopathies. In some cases of 
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GSS, cerebellar and frontal white matter are affected101. In an experimental model of human 
TSEs in rodents, vacuolation in myelinated fibers with splitting of myelin lamellae was observed 
102-103. PrPC is present in purified myelin fractions derived from brain homogenates104. Several 
transgenic mice expressing deletion mutants of PrPC (Refs 2, 105-106) as well as Prnp mice 
accidentally overexpressing Dpl1 show vacuolation and degeneration of myelinated fibers in the 
central nervous system.  
Molecular mechanisms mediating the function of PrPC. Despite the overwhelming number 
of reports about alterations in mice and cells lacking PrPC summarized above, little is known 
about the molecular mechanisms involved in these cellular processes. 
One explanation for the diversity of the suggested physiological functions of this PrPC is that it 
may exert pleiotropic effects, thereby modulating the function of several cellular pathways. 
Examples for such a general cellular process would be stabilization of protein complexes and 
the targeting of cell components to certain cellular sites, such as rafts or endosomes. 
Signaling. The attachment of PrPC to the membrane by a GPI anchor, its localization in 
detergent-resistant membranes, also known as lipid rafts, in many cell types may suggest an 
involvement in cellular signaling106 as is the case for other raft-associated proteins. Moreover, 
as I describe below, PrPC could also influence cellular signaling events by its involvement in 
endocytic pathways. 
Several signaling pathways or signaling components, such as Akt, Fyn, cAMP, and Erk12, are 
modulated by PrPC expression, its cross-linking, or its interaction with another protein. Antibody-
mediated cross-linking of PrPC induced activation of the Fyn, a family member of nonreceptor 
Src-related kinases, in neuronal differentiated cells in a caveolin-1-dependent manner107. As a 
downstream event, the same group claims to have identified Erk12 phosphorylation108. PrPC 
cross-linking additionally modulates serotonergic receptor activity in differentiated neuronal 
cells109. The finding that PrPC cross-linking modulates activity of serotonergic receptors in 
differentiated neuronal cells awaits replication and in vivo confirmation. However, Fyn activation 
and downstream activation of Erk12 were also seen in a hypothalamic cell line110. 
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Several studies indicated PrPC involvement in neurite outgrowth and neuronal survival. Chen et 
al. reported increased neuronal survival and neurite outgrowth from neurons when cultured on 
Chinese hamster ovary (CHO) cells transfected to express mouse PrPC. Although Fyn activity in 
this context was involved mainly in neurite outgrowth, the PI3 kinaseAkt pathway as well as 
regulation of Bcl-2 and Bax expression contributed to the survival effect elicited by PrPC. Cyclic 
AMP PKA and Erk signaling pathways contributed to both neurite outgrowth and neuronal 
survival97, 99. 
Some investigators suggested that engagement of PrPC with stress-inducible protein I (STI1) 
induces neuroprotective signals that rescue cells from apoptosis via cAMPprotein kinase A and 
the Erk signaling pathways111-112. Interaction with STI1 induced different signaling pathways, 
promoting neuroprotection by PKA activation and neuritogenesis by activation of the MAPK 
pathway98. 
Endocytosis and Internalization of PrPC. PrPC is rapidly internalized from the cell membrane. 
This internalization of PrPC could be crucial for its function, e.g., by influencing signal 
transduction pathways. Endocytosis of membrane receptors does not necessarily downregulate 
receptor activity. While being internalized, both tyrosine kinase and G protein-coupled receptors 
may remain activated and produce intracellular responses along the endosome-lysosome 
pathway113. Internalization of tyrosine kinase receptors was functionally important in studies: 
TrkA receptors, for example, mediate NGF-dependent cell survival while they are located at the 
cell membrane, whereas internalization is required for induction of neurite outgrowth114-115. 
The mechanism of PrPC internalization is still controversial because both raftcaveolae and 
caveolae-like116-119 as well as clathrin-dependent endocytosis may be operative120-121. These 
mechanisms may be equally important. In addition, internalization of the same ligandreceptor 
complex by distinct endocytotic pathways can result in different signaling outcomes. TGF-β 
receptor, for example, is degraded after endocytosis via caveolae, but internalization via 
clathrin-coated pits promotes its signaling122. However, in lymphocytes and neuronal cells that 
do not express caveolin, internalization can occur in a lipid raft-associated noncaveolar, clathrin-
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independent process123-124. Therefore additional, less well-characterized endocytosis pathways 
including caveolae-like endocytosis might be involved in internalization of PrPC. 
For endocytosis by clathrin-coated pits, PrPC would need to leave the lipid rafts prior to 
internalization because the rigid structure of raft lipids is unlikely to accommodate the tight 
curvature of coated pits. This phenomenon occurred after binding of copper to the OR121, 125, but 
its physiological significance is unknown. Low-density lipoprotein receptor-related protein 1 
(LRP1) was later described to mediate PrPC endocytosis126, and CC1 region was essential for 
its internalization in neuroblastoma cells121, 125. Sunyach et al. suggested that heparin sulfate 
proteoglycans are part of the endocytotic complex involving PrPC (Ref 125). Glypican-1, a GPI-
anchored heparan sulfate-containing cell-associated proteoglycan, interacts and cointernalizes 
with PrPC in N2a after induction with copper ions. In cells expressing PrP, which lacks the OR, 
internalization of glypican-1 is reduced, suggesting a possible role for PrPC in the 
cointernalization of other cellular components127. 
PrPC might participate in the correct localization of some other proteins in lipid rafts. Neuronal 
nitric oxide synthase (nNOS), for example, involved in various nervous system processes such 
as development, synaptic plasticity, regeneration, and regulation of transmitter release was 
associated with lipid rafts in wt mice. In contrast, in brains of PrPC-deficient as well as scrapie-
infected mice, nNOS was not associated with rafts, and activity of nNOS was reduced. 
Therefore PrPC could be important for the proper cellular localization of other proteins128. 
Similarly N-CAM was recruited to lipid rafts by PrPC (Ref 99). 
However, PrPC is involved in a number of cellular functions and how endocytosis influences 
them in vivo remains widely unknown; internalization of PrPC could contribute to downregulation 
of a signaling event but could also be necessary for signaling. However, a general involvement 
of PrPC in vesicle formation could be a possible explanation for most of the suggested molecular 
functions of PrPC because it could regulate signaling and influence synaptic transmission. 
PrP and cell adhesion. Several reports are consistent with a possible function of PrPC as a cell 
adhesion or recognition molecule. Some interaction partners of PrPC identified so far have a role 
in adhesion, including laminin129-130, a structural component of basement membrane, laminin-
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receptor precursor131-132, and N-CAM133. These three molecules are involved in adhesion in a 
diversity of signal transduction pathways, in differentiation, and in neurite outgrowth134-135. 
Interaction of laminin or N-CAM with PrPC has been associated mainly with its suggested role in 
neuritogenesis and neurite outgrowth99, 129-130. Sales et al. also proposed that PrPC in its 
synaptic location might stabilize opposing synaptic membranes through adhesive 
mechanisms69. 
The evidence reported so far could indicate that PrPC is involved in adhesive mechanisms, but 
this is likely not its sole function. Adhesion molecules that interact biochemically with PrPC could 
additionally transduce a PrPC-dependent signal. The neurite-outgrowth-promoting interaction 
between PrPC and N-CAM, for example, was associated with activation of Fyn99. 
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5.2 Scientific aims  
The peripheral neuropathy observed by Nishida et al. suggests that PrPC plays a role in 
peripheral neuropathies.  
The goal of this project was to revisit the status of peripheral nerves in mice from which the 
Prnp locus was inactivated.  
I aimed to identify the cell type, neuron or Schwann cell, which is structurally or functionally 
affected by the lack of PrPC and at which age this occurs.  
Since PrPC was reported to be expressed by neurons and Schwann cells, I sought to identify 
the cell type on which PrPC would need to be expressed to maintain peripheral nerves.  
By transcriptomics and proteomics approaches, I intended to unravel a molecular signature of 
the Prnp-/- neuropathy. 
Furthermore, I sought to pinpoint PrP’s function in peripheral nerves to certain protein domains.  
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5.3 Mice, material and methods 
5.3.1 Mice 
I housed mice and performed animal experiments in accordance with the Swiss Animal 
Protection Law and in compliance with the regulations of the veterinary office (canton Zurich). 
Prnpo/o mice33 were kept on a mixed background (C57Bl/6;129Sv), or backcrossed to Balb/c for 
>17 generations. PrnpEdbg/Edbg and wt mice (both 129/Ola) were kindly provided by Jean 
Manson. Sciatic nerves of PrnpEdbg/Edbg mice136 backcrossed for >8 generations to C57Bl/6 
mouse strain were provided by Andrew Steele and PrnpGFP/GFP mice137 by Walker Jackson. 
TgGPI¯PrP mice (line 44)138 were kindly provided by Bruce Chesebro and Michael Oldstone. 
Tga20 mice139, tgNSE-PrP and tgMBP-PrP mice104, tgC4, tgE11, tgF35 (ref. 106), Prno/o140, and 
Prnd-/- mice141, were kept on a mixed genetic background (C57Bl/6;129Sv). Apart from the 
tgGPI¯PrP, tgE11, and tgF35 lines, mice were maintained homozygous for the transgene. 
Rag1-/- mice 142 were intercrossed twice with Prnpo/o mice to obtain Rag1-/- Prnpo/o mice. TgDhh-
Cre mice were provided by Dies Meijer, tgNFH-Cre and tgPrnpflox by Giovanna Mallucci. TgDhh-
Cre mice were first bred to Prnpo/o mice on an FVB background, provided by John Collinge and 
subsequently crossed to tgPrnpflox. TgPrnpflox were either kept in homozygous breedings or 
crossed to Prnpo/o mice (FVB). TgNFH-Cre were bred to tgPrnpflox mice. For generation of 
tgPLP-PrP, the Prnp open reading frame was amplified by PCR using the following primers 
(forward [fw]: AscI-PrP GGG GGC GCG CCa att tag gag agc caa gca ga; reverse [rev]: PmeI-
PrP: CAG GTT TAA ACc acg aga atg cga agg aac a) and cloned (using restriction enzymes 
AscI and PmeI) into a PLP promoter cassette kindly provided by Wendy B. Macklin. The 
transgenic construct was linearized by ApaI and SacII. Transgenic constructs for generation of 
tgPrPHC and tgPrPCC are based on pPrPHG139. A PmeI/NheI fragment of pPrPHG was 
subcloned in pMECA backbone. To create PrnpHC and PrnpCC cDNA, this plasmid was used 
as template to obtain two PCR fragments for each construct. For PrnpHC primer sets RAMP fw 
(CTA TCA GTC ATC ATG GCG AAC C)/ RAMP 111 ex-rc (CCA AAA TGG ATC ATG GGC 
CTC ACA TGC TTG AGG TTG GTT T) and RAMP 111–134 fw (AAA CCA ACC TCA AGC ATG 
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TGA GGC CCA TGA TCC ATT TTG G)/ RAMP rc (CAT CAT CTT CAC ATC GGT CTC G) and 
for PrnpCC the sets RAMP fw/ RAMP 111-93 ex-rc (GCT GCC GCA GCC CCT GCC ACA CCC 
CCT CCT TGG CCC CAT C) and RAMP 93-111 fw (GAT GGG GCC AAG GAG GGG GTG 
TGG CAG GGG CTG CGG CAG C)/ RAMP rc were used. The resulting PCR product pairs 
either for PrnpHC or PrnpCC were purified, mixed in stoichiometric amounts, and annealed. The 
flanking primers RAMP fw and RAMP rc were then added and the fusion products were 
amplified. These products were purified, cloned into pMECA pPrPHG subcloning vector (using 
XmaI/BstEII), and subsequently PmeI/NheI were used to clone the constructs into the pPrPHG 
plasmid. All linearized transgenic constructs were injected into fertilized Prnp+/+ or Prnp+/- 
oocytes (C57Bl/6;DBA/2) and bred to Prnpo/o (B6/129Sv) and maintained as heterozygous lines. 
Transgene positive mice were identified by PCR using the following primer pairs: tgPLP-PrP (fw: 
TCA TTT TTA AGA ATG GGA CAG CTG G; rev: TTT GCT GGG CTT GTT CCA CT); tgPrPCC 
and tgPrPHC (exon 2 primer pE2 fw CAA CCG AGC TGA AGC ATT CTG CCT; exon 3 primer 
Mut217 rev: CCT GGG ACT CCT TCT GGT ACC GGG TGA CGC). 
 
5.3.2 Short tandem repeat (STR) analysis 
Genome-wide STR analysis of 206 distinct STRs was performed using fluorescently labeled 
primers (Supplementary Table 1). Genomic DNA was purified from tail biopsies and amplified 
by PCR using 1-5 ng of DNA, 7.5 ml of 2x PCR colorless Taq-mastermix (Promega), 1.5 l 
fluorescently labeled primer mix (FAM, VIC, NED, all from Applied Biosystems). Cycling 
conditions were: 95°C 5 min, 30 repetitions of 95°C for 30 s, 60°C for 30 s and 72°C for 30 s, 
followed by 72°C for 7 min. PCR reactions were diluted 1:100 in deionized water. Subsequently, 
2 l of the diluted reactions were added to 10 l of Hi-Di Formamide (Applied Biosystems) 
containing 0.04 l GeneScan 600LIZ size standard (Applied Biosystems) per well. Samples 
were denatured at 94°C for 2 min and subjected to electrophoresis on a 16-capillary sequencer 
3130xl (Applied Biosystems). Analysis, allele-calling, binning and calibration of various mouse 
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strains was done manually and in combination with an in-house developed software (Applied 
Biosystems). 
 
5.3.3 Ultrastructural investigations 
Mice were anesthetized and transcardially perfused with PBS followed by fixative (3.9% 
glutaraldehyde in 0.1 M phosphate buffer, pH 7.4). Tissues were embedded in Epon using 
standard procedures. Semithin sections (500 nm) were stained with 1% toluidine blue. Ultrathin 
sections (70-90 nm) were mounted on copper grids coated with Formvar membrane and 
contrasted with uranyl acetate and lead citrate. The specimens were examined using a Philips 
CM12 electron microscope (FEI, Eindhoven, The Netherlands) operating at 80 kV and pictures 
were taken with a Gatan Bioscan 1k x 1k digital camera (Gatan GmbH, Munich, Germany). For 
morphometrical analysis of axon size-density distribution, semithin sections of at least three 
different mice per genotype were photographed and analyzed by a semi-automatized software 
developed in-house. Axonal density or cumulative axonal density was plotted against axonal 
size (area in µm2). Mean and standard error of the mean (s.e.m.) are displayed. S.e.m. did not 
always result in visible error bars. G-ratio and onion bulb formation were assessed on electron 
microscopy images and quantified using Analysis software (Olympus) and homebred scripts. 
 
5.3.4 Immunohistochemistry 
Sciatic nerves were dissected and either fixed in 4% formalin and embedded in paraffin, or snap 
frozen in OCT medium. Longitudinal paraffin sections (2 µm) and frozen sections (10 µm) of 
sciatic nerves were incubated with the following antibodies: rat anti-CD68 for macrophages 
(Serotec MCA 1957; 1:100), rabbit anti-CD3 for T-cells (clone SP7, NeoMarkers; 1:300) or rat 
anti-B220/CD45R for B-cells (Pharmingen; 1:400). Secondary antibodies were: goat anti-rat IgG 
(Caltag lab R40000; 1:150) followed by donkey anti-goat, conjugated with alkaline phosphatase 
(Jackson lab 705-055-147; 1:80) or followed by donkey anti-goat conjugated with peroxidase 
(Jackson lab 705-035-147; 1: 200) or goat anti-rabbit conjugated with peroxidase (Jackson lab 
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111-035-144; 1:200). Slides were mounted in DAKO aqueous mounting medium and analyzed 
on an Axiophot microscope (Zeiss), equipped with a JVC digital camera (KY-F70; 3CCD). 
 
5.3.5 Electrophysiological investigations 
Motor nerve conduction of sciatic nerves in 12, 28, 35, or 53-week old anesthetized mice was 
investigated as described143. Upon supramaximal stimulation of the tibial nerve at the ankle 
(“distal”) and stimulation of the sciatic nerve at the sciatic notch (“proximal”), the compound 
muscle action potentials (CMAP) were recorded with needle electrodes in the foot muscles. 
Nerve conduction velocities in meter per second were calculated from distal and proximal 
latencies. F-wave latencies were recorded and the shortest latencies were taken upon repeated 
stimulation at the ankle.  
 
5.3.6 Western Blots and ELISA 
Sciatic nerves were homogenized in buffer (1% Triton X 100, 137 mM NaCl, 2 mM EDTA, 20 
mM Tris HCl pH 8) using a polytron PT 3100 (kinematica). Protein concentration was measured 
using BCA protein assay (Pierce). 20 µg of total protein were boiled in LDS (Invitrogen) 
containing 5% -mercaptoethananol and electrophoresed through a NuPAGE® Novex 12% Bis-
Tris Gel (Invitrogen). For PNGase F treatment, 20ug of protein were incubated in denaturation 
buffer and subjected to a 2 hours PNGase f (NEB) digest at 37°C. All gels were transferred to 
nitrocellulose (Schleicher & Schuell) using XCell II Blot Module (Invitrogen). Membranes were 
blocked with TBST containing 5% Top-Block (Sigma), decorated with monoclonal antibody 
POM1 or POM3144, antibodies against CNPase (Abcam), MPZ (P0), MAG (Zymed), PMP22 
(Abcam), NRG-1 (C20 and H210, Santa Cruz), Erk, p-Erk, Akt, p-Akt (Cell Signaling 
Technology), flotillin (BD Bioscience) followed by incubation with the secondary anti-mouse IgG1 
(Zymed) or anti-rabbit IgG (Calbiochem) and visualized using SuperSignal West Pico 
Chemiluminescent Substrate System (Pierce) and Amersham Hyperfilm ECL films (GE 
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Healthcare). In addition, PrPC concentration was determined by sandwich ELISA with 
biotinylated mAbs as previously described144. 96-well plates were coated with 400 ng/ml of 
POM1 antibody overnight at 4°C. Plates were washed with PBS containing 0.1 % (v/v) Tween 
20 (PBST) and blocked with 5% TopBlock in PBST for 2 h at room temperature.  After washing, 
wells were incubated with nerve homogenates 150 µg/ml in 1% TopBlock/ PBST for 2 h at room 
temperature or with serially diluted recombinant PrP as standard. After washing, plates were 
incubated with biotinylated POM2 antibody for detection (1:10,000), followed by incubation with 
avidin-HRP (Pharmingen No. 554058; 1:10,000), both in 1% TopBlock/ PBST. Plates were 
developed with 2.2-azino-diethy-benzothiazolinsulfonate (Boehringer), and optical density was 
measured at 405 nm. Homogenates from Prnpo/o sciatic nerves served as control.  
 
5.3.7 Extraction of detergent-resistant membranes and step density 
gradient centrifugation 
Experimental procedure was performed as previously described2 with slight modifications. 
Sciatic nerves were homogenized in PBS with 9% sucrose including protease inhibitors 
(complete, Roche) to produce a 10 % (w/v) homogenate. After centrifugation (5 min, 2,500 rcf, 
4°C), protein concentration was measured with BCA (Pierce). Triton X-100 extraction was 
performed with 100 µg of total protein for 1 h on a rotation wheel at 4°C in a final volume of 100 
µl lysis buffer (PBS with 9% sucrose and final concentration of 1% Triton X-100). Extracts were 
mixed with two volumes (200 µl) of 60% Optiprep (Axonlab) to reach a final concentration of 
40%. All lysates were loaded at the bottom of Beckman ultracentrifuge tubes. The lysate was 
then overlaid with an Optiprep step gradient in MES Buffer (10mM MES, 2mM EDTA, 1mM 
DTT, protease inhibitors): 1.6 ml of 30% Optiprep and 300 µl of 5%. Total volume of the 
gradient was 2.2 ml, gradients were centrifuged for 2 h at 55,000 rpm at 4°C in a TLS55 
Beckman rotor. Fractions of 200 µl were collected and analyzed by Western blot.  
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5.3.8 RNA isolation and quantitative PCR 
Sciatic nerves were homogenized in trizol (Invitrogen) by using polytron PT 3100 (kinematica). 
RNA was extracted and subsequently purified on RNeasy columns (Qiagen) as described by 
the manufacturers. Synthesis of cDNA was performed with QuantiTect, Reverse Transcription 
kit (Qiagen). Samples were analyzed by real-time PCR using QuantiFast SYBR Green PCR kit 
(Qiagen) and 7900HT (Fast Real-Time PCR systems; Applied Biosystems). The following 
primer combinations were used: Prnp fw: TGGCTACATGCTGGGGAGC, Prnp rev: 
TTCTCCCGTCGTAATAGGC; Prnd fw: CTA CGC GGC TAA CTA TTG, Prnd rev: CGC CGG 
TTG GTC CAC; GAPDH fw: CCA CCC CAG CAA GGA GAC T; GAPDH rev: GAA ATT GTG 
AGG GAG ATG CT. 
 
5.3.9 Immunofluorescence 
Freshly cut frozen sections (10 µm, air-dried) and dissociated mouse DRG cultures on cover 
slips were fixed/ permeabilized using ice-cold ethanol or methanol (-20°C). Sections were 
blocked in either 5% BSA and 0.3% Triton X-100 (Sigma) in PBS, 3% BSA and 3% donkey 
serum (Jackson ImmunoResearch Laboratories), 3% BSA and MOM Blocking reagent (Vector 
lab), or 2% FCS. Antibodies were diluted in blocking buffer or in antibody diluent (Ventana). 
Antibodies against the following antigens were used: sodium channel (Sigma), PrPC (POM1)144, 
Neurofascin (Abcam), paranodine/Caspr (provided by J.A. Girault), Versican (V1, provided by 
M.T. Dours-Zimmermann), JamC (Santa Cruz), Neurofilament NF-H (Calbiochem), MBP 
(Serotec). POM1 antibody was directly labelled with Alexa Fluor dye 488 (Invitrogen) as 
previously described for Cy5-labelling of POM2137. For detection of the remaining primary 
antibodies, the following secondary antibodies were used: biotinylated anti-mouse IgG (Vector 
laboratories)/ streptavidin Alexa 488 (Invitrogen), anti-rabbit Alexa 594 and anti-rat Alexa 488 
(Invitrogen). Slides were mounted in DAKO aqueous mounting medium. Images were acquired 
on an Olympus BX61TRF fluorescent microscope equipped with an F-View camera. JamC 
positive area was quantified with Analysis software (Olympus). Each data point represents the 
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mean value of one mouse, which is derived from three independent visual fields per mouse. At 
least n=3 mice were analyzed. 
 
5.3.10 In situ hybridization 
Sense and antisense probes for Prnp were derived from a pBluescript KS plasmid containing a 
290bp Asp718/ BstEII fragment of mouse Prnp. Probes were digoxygenin (DIG) labelled as 
described by the manufacturer with a DIG-labeling kit (Roche). In situ hybridization was 
performed on freshly cut frozen sections (10µm, air-dried) post fixed in 4% PFA in PBS. 
Following treatment with 0.1M HCl and acetylation, sections were prehybridized for 2 h in 
hybridization buffer without probe (50% formamide, 5x SSC, 5x Denhardt’s solution, 250µg/ml 
E. coli t-RNA (Roche)). Hybridization was performed with hybridization buffer containing 50ng x 
50µl-1 DIG-labelled RNA sense or antisense probe which was previously denatured at 85°C for 
5 min. Sections were incubated first for 30 min. at 85°C, and then over night at 58°C. Washing 
was performed in pre-warmed SSC of different concentrations. Sections were incubated with 
AP conjugated anti-DIG antibody (Roche) diluted 1:3,000 in buffer 1 (100mM Tris-HCl pH 7.5; 
150mM NaCl) containing 1% blocking reagent (Roche). Detection was performed in buffer 3 
(100mM Tris-HCl pH 9.5; 150mMNaCl; 50mM MgCl2) containing 1mM Levamisol; NBT and 
BCIP (Sigma). Slides were mounted in DAKO aqueous mounting medium and analyzed by 
microscopy as described above. 
 
5.3.11 In vitro myelination 
Cultures and analyses of dissociated mouse DRG cultures were performed as described145 with 
slight modifications. Prior to culturing, round coverslips (18mm, Menzel-Gläser, Merck AG, 
CB00180RA1) were placed in 12 well plates (Nunc) and coated with Poly-D-Lysine (PDL, 
Sigma P6407-5MG) and collagen (BD Bioscience, #354236). For PDL coating, PDL was 
dissolved in sterile water at 1 mg/ml. Aliquots were stored at –20 ºC as 100x stock solution or 
diluted in tissue culture grade sterile water. 400 µl of the final solution were placed on each 
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cover slip and left in the tissue culture hood for at least 1 h. After removing the PDL solution, 
coverslips were washed twice with sterile tissue culture grade water. After removing the last 
wash, they were left to dry in the tissue culture hood. Prior to collagen coating, the collagen 
solution was diluted 2:1 (20 ml collagen solution plus 10 ml 0,02% acetic acid in water) to a 
concentration of 2.2 mg/ml. 400 µl were put onto each coverslip. 300 µl of the collagen solution 
were sucked back into the pipette. When all the coverslips were covered, the collagen is gelled 
by exposure to ammonia fume. The 12-well plates were placed without the lid in a styrofoam 
box with a Whatman paper on the bottom. Several drops of ammonia solution (28%) were 
spotted on the Whatman paper, the lid of the styrofoam box was closed and left for 15 minutes 
in the hood. After removing them from the styrofoam box, 12-well plates were left in the hood to 
dry completely (usually overnight). Embryos (embryonal day 13) were dissected under the 
binocular in ice-cold L-15 Medium (Leibovitz's L-15 Medium, Invitrogen, 31415-029). DRGs 
were separated and collected on the bottom of a 15 ml tube by centrifugation (700 rpm, 3 min). 
DRGs were washed with 1 ml Trypsin 0.25% w/o EDTA in PBS and centrifuged again (700 rpm, 
1 min). 1.5 ml Trypsin 0.25% w/o EDTA in PBS were added and DRGs were incubated for 45 
min at 37°C. DRGs were again collected by centrifugation (700 rpm, 5 min). DRG cells were 
separated and resuspeded in 1 ml of M1-medium: MEM (#41090, Invitrogen), containing 
Glutamax (Invitrogen), 10% FCS (Perbio Science), Penicillin/ Streptomycin (Invitrogen), and 
nerve growth factor (mouse NGF 2.5S grade II, N-100, alomone labs) at a concentration of 50 
ng/ml. Cells were counted and 30.000 dissociated living cells were seeded in the middle of the 
PDL/collagen coated coverslip in a drop of 80 µl M1-medium. After overnight incubation in the 
tissue culture incubator, 1 ml of M1-medium is added. Medium needs to be replaced every other 
day. At day 6-7 in culture, myelination was initiated by supplementing the medium with 50 μg/ml 
Ascorbic acid (Sigma A4544). Again, the medium needs to be replaced every other day. 
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5.3.12 Behavioral tests 
Hot plate test: To measure pain threshold, mice were placed on a hot plate (constant 
temperature: 52 ± 0.5°C). The parameter recorded was the latencies to lick a hind-paw, or jump. 
If no licking or jumping responses occurred, mice where removed after 60 seconds. Each 
animal is tested only once and mice are not habituated to the apparatus prior to testing. Grip 
strength test: To test grip strength, mice were carefully picked up by the base of the tail and 
lowered towards a horizontal wooden bar (diameter 3 mm). After grasping the bar they were 
gently pulled back until they let go of the bar. The bar was attached to a spring balance 
(maximum 300 g) that allowed determining the force at which the mice released their grip. Grip 
strength was tested five times in a row with an interval of two minutes between trials. 
Accelerating rotarod test: Mice were placed on a rotating rod with a speed slowly accelerating 
from 4 to 40 rpm (Ugo Basile, model 47600, Comerio, Italy). Maximum speed was reached after 
245 s. The latencies at which the animal fell off the rod were recorded. Animals not falling off 
were removed after 300 s. Mice were tested five times in a row with an interval of 30 minutes 
between trials. The median is recorded (untrained mice). Fourty-eight hours later, the same 
mice are tested again five times, again the median latency to fall is recorded (trained mice). 
 
5.3.13 2D Difference gel electrophoresis (2D DIGE) of peripheral myelin  
An overview over the experimental setup is shown (Fig. 6). Myelin was extracted from sciatic 
nerves of 7 mice per genotype in the age of 28 days. Nerves were homogenized in 0.29 M 
sucrose including protease inhibitors (complete, Roche). Sucrose gradient was set up by filling 
17 ml 0.85 M sucrose in a centrifugation tube, and adding homogenate in 17 ml 0.29 M sucrose 
on top. Samples were separated by centrifugation at 75,000 g for 45 min. Interphases were 
collected and transferred into a new centrifugation tube which was filled with distilled water and 
centrifuged (15 min, 75,000 g). Supernatant was removed, again. For osmotic shock, water was 
added to the myelin pellet and the sample is incubated for 10 min. The sample was centrifuged 
15 min, 12,000 g. The pellet was dissolved in the appropriate buffer: TBS (137 mM NaCl, 20 
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mM Tris/HCl, pH 7.4) for DIGE or nerve lysis buffer (137 mM NaCl, 20 mM Tris/HCl, pH 8, 2mM 
EDTA, 1% Triton X100), including complete protease inhibitors (Roche) for confimatory Western 
blots. For DIGE experiments, myelin (containing 480 g proteins in 300 l) was delipidated by 
adding 600 l of methanol and vortexing, followed by addition of 300 µl chloroform and 
vortexing, and addition of 450 l of water and centrifugation (1 min., 9,000 g). Upper phase was 
discarded. Again, 450 l of methanol were added, sample was vortexed and centrifuged (5 min., 
16,100 g). Supernatant was discarded. The pellet was dried and dissolved in lysis buffer (7M 
Urea, 2M Thiourea, 2% ASB-14, 20mM Tris pH 9.0), protein concentration was determined 
using 2D Quant Kit (GE Healthcare). 80 g of each sample (2x wt, 2x Prnp-/-) was used for each 
gel. A pool of all the samples served as control and was labelled with Cy2. The four samples 
were once labelled with Cy3 and once with Cy5 (for dye switch), resulting in 8 aliquots for 4 gels 
(on each gel a pair of wt and Prnp-/- beside the standard was loaded). CyDyes (GE Healthcare) 
was dissolved in DMF (Dye working solution: 400 pmol/µl). For labelling, 1 µl of Dye working 
solution was added to each sample, or 4µl Cy2 to the standard, mixed by vortexing, briefly 
centrifuged, incubated at 4°C for 30 min. Then, 1 µl of lysine solution was added to each 
sample, vortexed, briefly centrifuged, 10 min. incubated at 4°C. The same volume of sample 
buffer (7 M Urea, 2 M Thiourea, 2 % ASB-14, 1.5 % DTT, 1% Ampholytes 10µl/ml) was added 
(total volume 153 l) and sonication was performed. Rehydration buffer (7 M Urea, 2 M 
Thiourea, 2% ASB-14, 0,5% Immobiline/Ampholytes 5µl/ml) was added to a total volume of 360 
l, sample was centrifuged. For isoelectric focussing (IEF) an IPGphor (GE Healthcare) was 
used, 340 ml of sample were loaded onto an IPG (immobilized pH gradient)-strip (GE 
Healthcare, 18 cm, pH 3-11), covered with mineral oil and exposed to an electric field: 50V, 12h, 
12 µA (8-9 µA at the beginning); 300V, 1h, 13 µA; 1000V, 1h, 14 µA; 1000-3000V, 0.5h, 14.5 
µA; 3000V, 3h, 17,5 µA (12 µA at the end of this step); 3000-8000V, 0,5h, 18 µA; 8000V, 4h, 22 
µA (31 µA at the beginning, and 26-27 µA at the end). IGP-strips were equilibrated in SDS-
Equilibration buffer (50 mM Tris/HCl pH 8.8, 6 M Urea, 30 % Glycerol, 2 % SDS, 0.002 % 
bromphenol blue), including 1 % DTT (equilibration 2 x 5 min.) or 4% Iodacetamid (equilibration 
1 x 10 min.). IGP-strip was loaded on top of a 8-16 % gradient gel and run at 6 mA per gel (200 
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V) over night. SeeBlue® Plus2 Pre-Stained Standard (Invitrogen) was used as a molecular 
weight standard. Gels were scanned using a Typhoon-Scanner (GE Healthcare), data was 
analyzed using proteomweaver 3.1 software (Definiens, Munich, Germany).  
 
 
 
Figure 6. Experimental setup of the DIGE experiment. Setup is shown for one pair of wt and Prnp-/- 
samples, the schema shows the principle of dye switch and use of the standard sample in each of the two 
gels. 
 
5.3.14 mRNA microarray experiment of peripheral nerves 
RNA was extracted from sciatic nerves by homogenizing them in Trizol (Invitrogen), extracting 
RNA with chloroform, and further purification using RNeasy (Qiagen) as described by the 
manufacturer. RNA quality was tested by Bioanalyser (Agilent), only samples with RNA integrity 
index (RIN) of at least 7.45 were used for further analysis. For microarray, 600 ng of RNA were 
used. RNA was first reversely transcribed into cDNA which was then transcribed into fluorescent 
cRNA using Cyanine 3-CTP and the Low RNA Input Linear Amplification Kit (Agilent) as 
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described by the manufacturer. RNA Spike-In Kit, one color, was added to each RNA sample 
for control. Fluorescent cRNA was purified using RNeasy (Qiagen). Quality of labelled cRNA 
was tested using Nanodrop (Thermo Scientific). For further analysis only those samples with a 
yield of at least 2 g were accepted. Dye incorporation rate – calculated as 1000 x (pmol/ l 
divided by ng/ l) – was between 9.0 and 14.3 pmol/ ng. Hybridization was performed using 
whole mouse genome 4x44K microarrays (Agilent) and the gene expression hybridization kit 
(Agilent) as described by the manufacturer. Assembled chambers of sandwiched slides were 
placed in the hybridization oven for 17 hours at 65°C at 10 rpm. After hybridization, chambers 
were disassembled in wash buffer 1 (Agilent), washed in buffer 1 followed by buffer 2 (Agilent) 
and placed into the scanner (Agilent).  
 
5.3.15 Statistical analysis 
For comparison of normally distributed data, including density of digestion chambers, and 
electrophysiological measurements of Prnpo/o compared to wt mice, I performed unpaired, two-
tailed student’s t-tests after equality of variances was tested by the F-test. In the case of 
unequal variances (density of digestion chambers in 30-week old mice), unpaired t-test with 
Welch’s correction was used. For comparison of JamC positive area of tgNSE-PrP, tgPLP-PrP, 
wt and Prnpo/o, I performed first one-way ANOVA followed by Bonferroni’s post-test for multiple 
comparisons. For statistics on behavioral test results, and on STR analysis, I performed Mann-
Whitney tests. For statistical analysis of fibers with g-ratio > 0.81, I performed square root 
transformation, followed by two-tailed student’s t-test. For statistics on onion bulb formation, 
two-tailed Fisher’s exact test was used. P-values were as indicated in the figures. SPSS (SPSS 
Inc.) and Prism software (GraphPad Software) were used for statistical tests. Error bars in the 
graphs and numbers following the ± sign represent standard deviation (s.d.) unless otherwise 
indicated. 
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5.4 Results 
5.4.1 Peripheral polyneuropathy in Prnp-/- mice 
At 60 weeks of age, all investigated PrPC-deficient mice (Prnpo/o; n=52) showed extensive 
chronic demyelinating polyneuropathy (CDP) (Fig. 7). CDP was 100% penetrant and was 
evident in all investigated peripheral nerves including sciatic and trigeminal nerves as well as 
dorsal and ventral spinal roots. Identical pathologies were detected in sciatic nerves of Prnpo/o 
mice on a C57Bl/6;129Sv (B6/129Sv) hybrid background (data not shown), Prnpo/o mice 
backcrossed to Balb/c mice for >17 generations (Fig. 7), PrnpEdbg/Edbg mice (inbred 129/Ola; 
n=6, Fig. 7), PrnpEdbg/Edbg backcrossed to C57Bl/6 mice for >8 generations (n=2, data not 
shown), and PrnpGFP/GFP mice carrying a targeted substitution of Prnp with EGFP137 (n=3; Fig. 
7). No signs of neuropathy were detected in age- and strain-matched wt mice (C57Bl/6, 
B6/129Sv, Balb/c, 129/Ola; Fig. 7 and data not shown). Axon morphometry showed that large 
fibers (Fig. 8) were predominantly affected. Genetic reintroduction of PrPC via crosses to tga20 
mice139 (n=3), or introduction of one hemizygous Prnp allele (n=4), fully prevented the 
polyneuropathy (Fig. 7-8). The Prnd gene encodes the PrPC analogue, Dpl, whose 
overexpression can induce neurodegeneration in certain Prnp-/- strains36. However, it was also 
suggested that Dpl might partly compensate for loss of function in Prnp-/- mice36. In order to 
uncover any potential contribution of Dpl to the CDP, I investigated Prno/o mice lacking both 
Prnd and Prnp140. Morphology, extent of degeneration (or demyelination), and ultrastructural 
features of the CDP in 60-week old Prno/o mice were similar to those of Prnpo/o mice, whereas 
mice selectively lacking Prnd but retaining Prnp141 showed normal sciatic nerve morphology 
(Fig. 9). In contrast to PrnpNgsk/Ngsk mice, I did not detect any Prnd mRNA in sciatic nerves of 
Prnpo/o mice (Fig. 9). 
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Figure 7. Peripheral polyneuropathy in Prnpo/o mice. Toluidine blue-stained semithin cross sections of 
sciatic nerves of wt (Balb/c and 129/Ola), Prnpo/o (Balb/c), Prnp+/-(Balb/c), and tga20 (B6/129Sv), 
PrnpEdbg/Edbg (129/Ola), PrnpGFP/GFP (C57Bl/6) mice, all at 60 to 70 weeks of age (wks). 
 
 
 
Figure 8. Axonal density-size distribution. 
Axonal density within nerves (number of 
axons/mm2) was quantified morphometrically and 
plotted against the cross-sectional areas (µm2) of 
axons. 
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Figure 9. No role for Doppel in Prnpo/o polyneuropathy. Semithin cross sections of sciatic nerves of 
mice lacking Doppel gene (Prnd-/- mice), and mice lacking both, Prnp and Prnd (Prno/o mice) at 60 weeks 
of age, both on a mixed B6/129Sv background (a and b). Quantitation of cumulative axonal density-size 
distribution is shown compared to wt, and Prnpo/o mice (c). Prnd mRNA expression in wt, Prnpo/o, Prnd-/- 
compared to PrnpNgsk/Ngsk mice. Scale bar = 50 m. 
 
CD68 immunostaining detects macrophages ingesting myelin debris of degenerating nerve 
fibers (“digestion chambers”), and proved to be a sensitive marker of early pathology in PrPC-
deficient nerves. CD68+ digestion chambers were significantly more prevalent in sciatic nerves 
of 10-, 30- and 60-week old Prnpo/o mice than in age-matched wt mice (Fig. 10), indicating that 
the onset of polyneuropathy was much earlier than previously appreciated. 
PHYSIOLOGICAL FUNCTION OF THE PRION PROTEIN IN PERIPHERAL NERVES 
 
49
 
Figure 10. CD68+ gigestion chambers. CD68-immunostained longitudinal sections of sciatic nerves. 
More digestion chambers with macrophages and myelin debris are visible in Prnpo/o (Balb/c) than in wt 
(Balb/c) nerves at 60 and 10 weeks of age, respectively (a). Quantification shows significantly more 
digestion chambers in sciatic nerves of 30- and 60-week old Prnpo/o mice (b). All scale bars = 50m. 
 
5.4.2 The polyneuropathy of Prnpo/o mice is demyelinating 
Peripheral neuropathies can target either axons, myelin sheaths, or both. Disruption of each of 
these structures gives rise to stereotypical, ultrastructurally and electrophysiologically 
recognizable phenotypes. I therefore analyzed nerves by electron microscopy (EM) and 
electrophysiology. Sciatic nerves of 60-week old Prnpo/o mice showed characteristic 
ultrastructural signs of demyelination. Whereas the ratio between myelin thickness and axonal 
diameter was constant in sciatic nerves of wt mice (Fig. 11), Prnpo/o nerve fibers displayed 
thinned myelin sheaths despite normal axonal morphology (Fig. 11). Quantification of the g-ratio 
(axonal diameter/fiber diameter) revealed a higher percentage of fibers with thinned myelin (g-
ratio > 0.81) in Prnpo/o than in wt mice (Fig. 12). Several axons were covered only by a single 
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layer of myelin, suggesting incipient remyelination. “Onion bulbs”, resulting from repeated cycles 
of de- and remyelination and eventual Schwann cell degeneration, encircled 2.1 ± 0.54% of 
fibers in 4 of 4 Prnpo/o nerve but no fibers of wt nerves (Fig. 11b-c, p=0.029). Demyelinated 
axons were occasionally surrounded by remyelinating Schwann cells with prominent rough 
endoplasmic reticulum (Fig. 11d). Some Prnpo/o nerve fibers were covered by abnormally thick 
myelin sheaths resulting from focal myelin folding, often associated with nodes of Ranvier (Fig. 
11e). Macrophages occasionally invaded the space between myelin sheaths and axons (Fig. 
11f). In wt Remak bundles, several unmyelinated nerve fibers were ensheathed by single 
Schwann cells (Fig. 11g). In contrast, Prnpo/o Remak bundles often displayed reduced numbers 
of unmyelinated fibers combined with abnormal branching of Schwann cell processes (Fig. 
11h). Collagen pockets, possibly indicating axon loss, were present in Prnpo/o nerves but absent 
from wt nerves (data not shown).  
I then determined the onset of CDP by investigating younger mice. Electron microscopy of 30-
week old Prnpo/o mice revealed morphological alterations and g-ratio deviations that were less 
pronounced, yet qualitatively similar, to those of 60-week old Prnpo/o mice (Fig. 12 and data not 
shown). In contrast, morphological alterations were absent from 10-week old mice with the 
exception of a small number of digestion chambers (Fig. 10), suggesting disrupted myelin 
maintenance rather than impaired myelination. Accordingly, expression and phosphorylation of 
the Akt and Erk kinases, which are crucially involved in myelination146, were unaffected in 10- 
and 30-day old Prnpo/o nerves (Fig. 13), and there was no difference in the expression of the 
major peripheral nerve myelin proteins CNPase, MPZ/P0, MAG, and PMP22 (Fig. 13). 
In order to assess myelin biogenesis and homeostasis using an additional independent method, 
I cultured dissociated mouse dorsal root ganglia (DRG) and induced myelination. 
Morphologically normal myelin was formed in both wt and Prnpo/o cultures. There was no 
difference in the density of MBP-positive segments (data not shown). However, the length of the 
latter was slightly reduced in Prnpo/o compared to wt in two independent experiments (Fig. 14). I 
did not observe reduced cell survival in Prnpo/o cultures as determined by propidium iodide (PI) 
incorporation (data not shown). 
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Figure 11. Ultrastructural alterations in Prnpo/o sciatic nerves. Electron microscopy of sciatic nerves 
of 60-week old Prnpo/o (b-f and h) and wt (a and g) mice (both on Balb/c). Cross sections of wt mice show 
normally myelinated nerve fibers (a) and regular unmyelinated axons in Remak bundles (R) (a and g). 
Cross sections of Prnpo/o nerves show thinly myelinated axons, surrounded by onion bulb formations 
(arrows) (b-c), axons (A) surrounded by Schwann cells with prominent rough endoplasmic reticulum 
(arrow) and increased density of other organelles (d), as well as loss of unmyelinated axons in Remak 
bundles (h). Schwann cells ensheathing unmyelinated axons (A) frequently show abnormal branching of 
cytoplasmic processes (arrows). Longitudinal sections of Prnpo/o nerves reveal macrophages (M) within 
the axon-glia interface (f) and focally folded myelin (white arrows) in the vicinity of a node of Ranvier 
(black arrow) (e). The right internode displays thinner myelin than the left one, indicating de- and 
remyelination. Scale bars: a-b = 8 m, c-h = 5 m. 
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Figure 12. Time course analysis of g-ratio distribution in Prnpo/o mice. G-ratio was quantified on EM 
images of 10-, 30-, and 60-week old Prnpo/o compared to wt mice, both on a Balb/c background. 
Percentages of fibers in each g-ratio class are shown. 
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Figure 13. Akt/Erk phosphorylation, 
and myelin protein expression in 
Prnpo/o nerves. No difference in 
expression and phosphorylation of the 
kinases Akt and Erk by Western blot in 
10- and 30-day old Prnpo/o compared to 
wt mice. Similarly, no difference in 
expression of myelin proteins CNPase, 
myelin protein zero (P0; MPZ), 
peripheral myelin protein 22 (PMP22), 
and myelin associated glycoprotein 
(MAG) is found by Western blot in 10- 
and 30-day old Prnpo/o compared to wt 
mice.  
 
 
 
 
 
 
Figure 14. In vitro myelination. Myelination was induced in dissociated mouse DRG cultures. Forty days 
following induction of myelination, cultures derived from wt and Prnpo/o mice expressed myelin basic 
protein (MBP) and formed ultrastructurally normal myelin, as shown by immunofluorescence co-staining 
for neurofilament (NF) and MBP, as well as electron microscopy (EM). Length of MBP positive segments 
in two independent experiments was measured and mean values for each cover slip are plotted and 
compared. 
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Electrophysiological investigations were performed on sciatic nerves of 11, 28, and 53-week old 
Prnpo/o and wt mice. Nerve conduction velocities were significantly reduced in Prnpo/o mice at 
11, 28, and 53 weeks of age (Fig. 15). F-wave latencies, a further indicator of nerve conduction 
velocity, were marginally increased in 11 and 28-week old Prnpo/o mice and significantly 
prolonged in 53-week old mice (Fig. 15). There were no significant reduction in compound 
muscle action potential (CMAP) amplitudes in Prnpo/o mice (28 wks: Prnpo/o: 10.5 ± 2.6 mV vs. 
wt: 10.8 ± 3.1 mV; 53 wks: Prnpo/o: 10.6 ± 2.1 mV vs. wt: 11.5 ± 3.7 mV, following distal 
stimulation). Reduced nerve conduction velocities with unaltered or only slightly altered CMAP 
amplitudes are typically observed in demyelinating neuropathies. These combined 
electrophysiological and ultrastructural findings strongly support the conclusion that myelin 
sheaths, rather than axons, were primarily affected in Prnpo/o mice. 
 
Figure 15. Electrophysiology of Prnpo/o mice. Motor nerve conduction velocities (NCV) were 
significantly reduced in Prnpo/o at 11 wks (33.0 ± 3.5 m/s [Prnpo/o] vs. 42.3 ± 4.4 m/s [wt]), at 28 wks 
(37.5 ± 1.5 m/s [Prnpo/o] vs. 50.5 ± 2.8 m/s [wt]), and at 53 wks (25.1 ± 0.87 m/s [Prnpo/o] vs. 54.2 ± 5.6 
m/s [wt]) (a). F-wave latencies were only marginally increased in Prnpo/o mice at 11 wks (5.6 ± 0.5 ms 
[Prnpo/o] vs. 5.1 ± 0.4 ms [wt]) and 28 wks (4.2 ± 0.2 ms [Prnpo/o] vs. 4.0 ± 0.3 ms [wt]), but were 
significantly prolonged at 53 wks (6.0 ± 0.5 ms [Prnpo/o] vs. 4.4 ± 0.4 ms [wt]). 
 
In a further set of experiments, I found that the altered NCV and F-wave latencies of one-year 
old Prnpo/o mice were restored to normal by transgenic expression of Prnp in tga20 mice139 (Fig. 
16). 
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Figure 16. Electrophysiology of tga20 and tgNSE-PrP mice. Motor nerve conduction velocities (NCV) 
and F-wave latencies of one-year old tga20, and tgNSE-PrP in comparison to wild type and Prnpo/o. All 
mice in this experiment were on a mixed B6/129Sv background. 
 
I then assessed the clinical consequences of CDP with a battery of behavioral assays. On 
accelerating rotarods, the latency to fall of female 12, 30 and 60-week old Prnpo/o mice 
backcrossed >17 times to Balb/c mice (n=8 to 11) was similar to that of female wt Balb/c mice 
(n=8 to 10; Fig. 17). In the hot plate test, time was measured until mice started to lick their hind 
paw. After 60 s (endpoint of the test) 8 of 9 wt mice, but only 2 of 11 Prnpo/o mice (all 60-week 
old), had licked their feet. The time lag of licking was significantly longer in Prnpo/o mice with 
median value, first and third quartile at 60 s (Fig. 17). Heat response was marginally delayed 
also in 12 and 30-week old Prnpo/o mice. However, these relatively subtle results of the hot-plate 
findings were not confirmed in 60-week old C57Bl/6 PrnpEdbg/Edbg mice which fared similarly to 
C57Bl/6 wt mice in both hot-plate and rotarod tests (data not shown). The grip strength test 
revealed a highly significant difference between 60-week old wt and Prnpo/o mice. Younger 
Prnpo/o mice (12-and 30-week old) also showed somewhat reduced grip strength (Fig. 17). 
Assuming that these abnormalities were primarily caused by the CDP, this finding suggests that 
both afferent and efferent fibers were functionally affected in Prnpo/o mice. 
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Figure 17. Behavioral tests of Prnpo/o mice. Behavioral tests of 12, 30, and 60-week old Prnpo/o mice: 
No difference in the performance on the rotarod test when compared to wt mice. There was some training 
effect, as both mouse groups displayed slightly longer latencies to fall two days after the first test. At the 
age of 60 weeks, significantly worse performance in the hot plate and at the age of 12 and 60 weeks 
significantly lower grip strength. All mice were kept in the Balb/c background. 
 
5.4.3 Neuronal expression of PrPC is required for myelin sheath 
maintenance 
I then sought to define the cell types in which PrPC expression is required to prevent 
demyelination. I first investigated sciatic nerves of Prnpo/o mice expressing the tgNSE-PrP 
transgene104 which drives PrPC expression from the neuron-specific enolase promoter. Prnp 
mRNA in tgNSE-PrP nerves was 1.9 ± 0.2% of wt (Fig. 18b, p<0.0001), indicating little or no 
Prnp transcription by Schwann cells. Nevertheless, ELISA measurements and immunoblots 
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(Fig. 18a) indicated PrPC protein concentration in tgNSE-PrP sciatic nerves (113 ± 5.98 ng/mg 
total protein) approached that of wt nerves (132 ± 1.22 ng/mg). I conclude that essentially all 
PrPC in tgNSE-PrP mice was of axonal origin. Accordingly, PrPC immunoreactivity of tgNSE-PrP 
nerves was exclusively found along axons, whereas in wt mice it was also detectable in non-
compact myelin (Fig. 18e). Semithin cross sections of sciatic nerves of 60-week old tgNSE-PrP 
mice showed no pathology (Fig. 18f), and axon size morphometry, quantification of thinly 
myelinated nerve fibers (g-ratio > 0.81) and onion bulb formation confirmed complete rescue of 
CDP (Fig. 19). Therefore, neuronal expression of PrPC suffices to prevent Prnpo/o 
polyneuropathy. 
To study the effects of myelin-restricted PrPC expression, I created transgenic mice expressing 
PrPC under the control of the proteolipid protein (PLP) promoter, which is active in myelinating 
Schwann cells and oligodendrocytes. Seven tgPLP-PrP lines were derived. Line 159, 
henceforth shorthanded as tgPLP-PrP, displayed similar levels of total PrPC as wt mice in sciatic 
nerves (126 ± 1.54 ng/mg total protein) and by Western blot (Fig. 18a) despite 12-fold higher 
Prnp mRNA levels (Fig. 11b, p=0.0007), and was used for further analysis. 
Immunofluorescence confirmed myelin-specific expression of PrPC in tgPLP-PrP mice (Fig. 
18e). I also investigated tgMBP-PrP mice that express PrPC under control of the myelin basic 
protein promoter147. TgMBP-PrP mice expressed approximately 5% of wt PrPC protein in sciatic 
nerves (data not shown). At 60 weeks of age, both tgPLP-PrP Prnpo/o (Fig. 19) and tgMBP-PrP 
Prnpo/o mice (data not shown) showed CDP qualitatively similar to that of Prnpo/o mice. Again, 
CDP of tgPLP-PrP mice was fully suppressed by introducing a hemizygous wt Prnp allele 
(tgPLP-PrP Prnp+/o; data not shown). TgPLP-PrP Prnpo/o mice had significantly more thinly 
myelinated fibers (g-ratio > 0.81) and onion bulbs than tgNSE-PrP and wt mice, but somewhat 
less than Prnpo/o mice (Fig. 19), indicating a weak anti-CDP effect of the tgPLP-PrP transgene. 
At the age of 35 weeks, Prnpo/o mice displayed significantly prolonged F-wave latencies which 
were completely normalized by introduction of the tgNSE-PrP transgene (Fig. 18c). Similarly, in 
one-year old mice the NSE-PrP transgene normalized the electrophysiological alterations of 
Prnp-/- mice (Fig. 16). F-wave latencies of tgPLP-PrP mice were not significantly different from 
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those of Prnpo/o mice (Fig. 18c). These data support the surprising notion that the demyelinating 
polyneuropathy of Prnpo/o mice is rescued by neuron-restricted expression of PrPC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Mice with cell-type specific expression of PrPC. a-b, e: Prnp mRNA and PrPC protein 
content of tgNSE-PrP and tgPLP-PrP sciatic nerves investigated by Western blot (a) and real-time PCR 
(b; values on ordinate are normalized against wt mRNA). PrPC localization was studied by 
immunofluorescence (e). Normal F-wave latencies in 35-week old tgNSE-PrP (4.1 ± 0.09 ms [tgNSE-PrP] 
and 4.2 ± 0.2 ms [wt]), prolonged latencies in age-matched B6/129Sv Prnpo/o (4.5 ± 0.2 ms) and tgPLP-
PrP mice (4.3 ± 0.2 ms) (c). Quantitation of cumulative axonal density-size distribution indicates nearly 
normal distribution in tgNSE-PrP and reduced large size axon density in Prnpo/o and tgPLP-PrP (d). 
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Figure 19. Expression of PrPC by neurons is essential for myelin sheath maintenance. a-b: 
Semithin sections of 60-week old tgNSE-PrP, and tgPLP-PrP stained with toluidine blue. c: Percentage of 
fibers with g-ratio > 0.81 and onion bulb formation in wt, Prnpo/o, tgNSE-PrP, and tgPLP-PrP mice. 
 
I then investigated the effects of neuron-specific PrPC depletion on peripheral myelin 
homeostasis. Transgenic mice carrying a floxed Prnp minigene on a Prnpo/o background (line 
tg37), henceforth termed tgPrnpflox, were crossed to mice expressing Cre under control of the 
neuron-specific neurofilament heavy chain promoter, termed tgNFH-Cre86. Recombination 
efficiency was tested in DRG and spinal cord by in situ hybridization: whereas tgPrnpflox mice 
displayed robust Prnp transcription in spinal cords and in DRG neurons, the signal was 
completely abrogated from all spinal cord neurons and ≈70% DRG neurons of tgPrnpflox x 
tgNFH-Cre mice (Fig. 20). Accordingly, total PrPC protein expression in sciatic nerves was 
markedly reduced following neuronal depletion of Prnp (Fig. 21). 
TgPrnpflox and tgPrnpflox x tgNFH-Cre sciatic nerves displayed similar Prnp mRNA expression 
(data not shown), excluding that Cre genotoxicity had affected endogenous Prnp transcription 
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by Schwann cells. TgPrnpflox x tgNFH-Cre mice developed a CDP similar to that of Prnpo/o mice, 
featuring frequent thinly myelinated fibers and prominent onion bulb formation (Fig. 22).  
 
 
Figure 20. Prnp in situ hybridization of mice with neuron-specific depletion of PrPC. Expression of 
Prnp mRNA was analyzed by in situ hybridization in 60-week old tgNFH-Cre and tgPrnpflox x tgNFH-Cre 
mice. Prnp antisense probe and Prnp sense probe are shown as indicated. TgPrnpflox mice display 
expression of Prnp in dorsal root ganglia (DRG) neurons and in spinal cord neurons. After recombination, 
Prnp was undetectable in ~70% of DRG neurons and in all spinal cord neurons. 
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Figure 21. Western blot of PrPC expression in tgPrnpflox and following conditional depletion of 
Prnp. Samples were treated with PNGase or left untreated; antibody: POM1. 
 
 
I then removed PrPC from Schwann cells by breeding tgPrnpflox mice with the pan-Schwann cell 
deletor tgDhh-Cre (backcrossed to Prnpo/o). I detected a profound depletion of PrPC from 
Schwann cells in 6-week old tgDhh-Cre x tgPrnpflox. In contrast to age-matched tgPrnpflox mice 
on the Prnpo/o background, which showed PrPC in both Schwann cells and axons, tgDhh-Cre x 
tgPrnpflox showed PrPC only along axons (Fig. 23). In addition, Prnp mRNA expression was 
significantly reduced in tgDhh-Cre x tgPrnpflox in sciatic nerves (19 ± 11% of wt expression in 
tgPrnpflox and 6 ± 1% in tgDhh-Cre x tgPrnpflox mice; p=0.016). Quantification of g-ratio and 
onion bulb formation in the resulting mice revealed no difference against tgPrnpflox mice (Fig. 
22). Hence, Schwann cell PrPC is dispensable for peripheral myelin maintenance. 
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Figure 22. Neuron-specific but not Schwann cell-specific depletion of PrPC induces CDP. Prnpo/o 
mice carrying a floxed Prnp transgene, termed tgPrnpflox, were crossed to tgNFH-Cre expressing Cre in 
neurons or to tgDhh-Cre expressing Cre in Schwann cells. a-f: Morphological analysis of sciatic nerves at 
60 weeks of age. Toluidine blue-stained semithin sections showing demyelinating polyneuropathy in 
sciatic nerves of tgPrnpflox x tgNFH-Cre mice with neuronal PrPC depletion (c). Electron microscopy (EM) 
showing onion bulb formation in a tgPrnpflox x tgNFH-Cre mouse (d). In contrast, tgPrnpflox x tgDhh-Cre 
and tgPrnpflox on a Prnpo/o background showed normal morphology of sciatic nerves in semithin sections 
(a and e) and EM (b and f). Scale bar in a = 50 µm; scale bar in b, d, and f = 2 µm. Quantification of 
cumulative axonal density-size distribution indicating severe reduction of large axons in tgPrnpflox x 
tgNFH-Cre as seen in Prnpo/o nerves (g). Percentage of fibers with g-ratio > 0.81 and onion bulb 
formation in tgPrnpflox x tgNFH-Cre was significantly increased compared to tgPrnpflox x tgDhh-Cre and 
tgPrnpflox mice (h). 
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Figure 23. Depletion of Schwann cell 
PrPC in tgDhh-Cre x tgPrnpflox mice. 
Immunofluorescence staining of sciatic 
nerve sections for PrPC, using POM1 
(anti-PrPC-antibody) labelled with 
Alexa488 (green). Neurofascin (Nfasc) 
staining for control (red). While PrPC was 
localized in Schwann cells and along 
axons in tgPrnpflox, in tgPrnpflox x tgDhh-
Cre it was detectable only along axons. 
Prnpo/o served as control. 
 
 
 
5.4.4 PrPC biogenesis in peripheral nerves 
Monoclonal antibodies POM1 and POM3, which recognize epitopes in the C-terminus of PrPC 
(around aa 140-152) and within the charge cluster (aa 95-100), respectively144, were used to 
investigate the relative prevalence of full-length PrPC and of its C-terminal fragments C1 and C2 
by immunoblotting. In contrast to brain, sciatic nerve contained more C1 fragment than full-
length PrPC (Fig. 24). C1 is generated by -cleavage at aa 110/111/112, whereas C2 is derived 
by -cleavage in the octarepeat region or at position 96 (ref. 148, 149). Neuronal depletion of Prnp 
in tgPrnpflox x tgNFH-Cre mice reduced the amount of C1 fragment (Fig. 21). The POM1 
antibody, which recognizes all three forms of PrPC, revealed their presence in non-compact 
myelin, Schmidt-Lanterman incisures (SLIs), paranodes, and along axonal surfaces (Fig. 18). 
Therefore, PrPC immunoreactivity was associated with both neurons and Schwann cells. 
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Figure 24. PrPC expression and proteolytic processing in sciatic nerves.  Western blot analysis 
comparing PrPC protein expression in the sciatic nerve with that in brain of wt mice, using two different 
monoclonal antibodies, POM1 and POM3, for detection. Following PNGase treatment of protein lysates, 
two bands were recognized by POM3 antibody, while POM1 detected three bands (a). This band pattern is 
explained by the localization of antibody epitopes and by the existence of three PrP isoforms, each 
containing an intact carboxy terminus: full length PrP, C2, and C1 fragment (b). 
 
5.4.5 Domains of PrPC required for myelin maintenance 
Might a secreted, soluble PrPC variant rescue the CDP? I addressed this question in tgGPI¯PrP 
mice (line #44) lacking the GPI anchor138.The concentration of GPI¯PrP in sciatic nerves was 
determined by Western blot (POM11) to be ca. 20-25% of wt full-length PrPC (Fig. 25a). 
TgGPI¯PrP mice lacked any detectable C-terminal fragments C1 and C2 (Fig. 25b), suggesting 
that membrane anchorage is essential for regulated PrPC proteolysis in peripheral nerves. 
Sciatic nerves of 68-week old tgGPI¯PrP (n=3) displayed CDP similarly to Prnpo/o nerves (Fig. 
26). 
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Figure 25. PrPC expression and proteolytic processing in sciatic nerves of tgGPI¯PrP mice.  
TgGPI¯PrP mice were analyzed for PrPC expression with POM11 antibody, before and after PNGase 
treatment in comparison to serially diluted Prnp+/- sciatic nerve lysates (a). For analysis of PrP processing, I 
used antibody POM1 which detects all holo-PrPC and all C-terminal fragments (b). POM1 detected 
GPI¯PrP to a lesser extent than POM11. However, no formation of C-terminal fragments was observed, 
even after very long exposures (right side). 
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Figure 26. Peripheral neuropathy in transgenic mice expressing PrP deletion mutants. Toluidine 
blue-stained semithin cross sections of sciatic nerves of transgenic mice are shown. 60-week old wt (a), 
tgC4 x Prnpo/o (b), tgCC x Prnpo/o (c) all showed a normal morphology of the sciatic nerve fibers. In 
contrast, terminally sick tgE11 x Prnpo/o (30-week old; e), tgF35 x Prnpo/o (90-day old; f), tgPrPHC x 
Prnpo/o (109-day old; g), as well as 60-week old tgGPI¯PrP x PrnpEdbg/Edbg (i) showed peripheral 
neuropathy. Scale bar = 20 m. 
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The flexible amino proximal domain of PrP comprises a charge cluster (CC1), the octarepeat 
region (OR) and a central domain with a second charge cluster (CC2) and a hydrophobic core 
(HC) (Fig. 24b and 27a). I found that PrPC lacking the octarepeats (PrPC, line tgC4)106 fully 
rescued the CDP (Fig. 26), indicating that the octarepeat region is unnecessary for myelin 
maintenance. In addition to full-length PrPC, tgC4 sciatic nerve lysates contained the two 
proteolytic fragments C1 and C2 (Fig. 27). 
 
Figure 27. Role of amino-terminal domains in the pathogenesis of Prnpo/o polyneuropathy. 
Transgenic constructs, presence of PrP C-terminal fragments in the respective transgenic mice, presence 
of peripheral neuropathy, and life expectancy (a). Mice expressing deletion mutants of PrP were analyzed 
for PrP expression and processing in sciatic nerves. Western blots before and after PNGase treatment of 
lysates are shown. Full-length PrP is marked by *, C2 fragment by #, and C1 fragment by °. A Western 
blot with better separation of full-length and C2 fragment for tgC4 mice is shown (all lanes are from the 
same blot, but intervening lanes were deleted for clarity) (b). Detergent-resistant membranes (DRM) were 
prepared from sciatic nerves of different transgenic and wt mice and subjected to step density gradient 
centrifugation. Fractions containing DRM were analyzed by Western blot for presence of PrPC and flotillin 
as control (c). Western blots of the various fractions from this experiment are shown in Fig. 28. 
 
I then used the “half-genomic” pPrPHG backbone139 to derive a PrPC variant lacking the CC2 
domain (aa 94-110) termed tgPrPCC. Transgenic mice were generated by microinjection of the 
tgPrPCC construct; offspring of founder #46 were used for analysis. Sciatic nerves of tgPrPCC 
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mice contained C1 fragment, albeit less than wt nerves, and were devoid of C2 fragment (Fig. 
27). Upon crossing to Prnpo/o mice, tgPrPCC mice did not develop CDP at 60 weeks of age (Fig. 
26). In contrast, Prnpo/o mice expressing PrPC variants devoid of aa 32-134 and aa 32-121 
(termed tgF35 and tgE11, respectively)106 completely lacked C1 and displayed a CDP 
qualitatively similar to that of Prnpo/o mice (Fig. 26-27). I prepared detergent-resistant 
membranes (DRMs) from sciatic nerves of wt, Prnpo/o and the various PrP deletion-mutant 
transgenic mice by detergent extraction followed by step density-gradient centrifugation. The 
buoyancy of the PrP deletion-mutants was similar to that of PrPC, indicating that they reside in 
similar membrane microdomains (Fig. 27c and 28). 
 
Figure 28. PrPC and PrP deletion mutants co-localize with flotillin in detergent-resistant 
membranes (DRM) in sciatic nerves. DRM were extracted using 1% Triton X100. Homogenates were 
subjected to step density gradient ultracentrifugation. Set up of the Optiprep gradient is shown (a). After 
the separation, 11 fractions of 200 l each were recovered and analyzed by Western blot with anti-PrP 
antibody POM1 or anti-flotillin antibody. Non-specific bands, detected also by the secondary antibody 
only, are marked with a star (b). 
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Finally, I generated transgenic mice expressing a PrP variant lacking the hydrophobic core HC 
(aa 111-134). The transgenic construct was again based on pPrPHG, and transgenic mice were 
termed tgPrPHC (line 1146). TgPrPHC x Prnpo/o mice showed a reduced life expectancy 
(survival 80 ± 3.5 days; data not shown) and displayed severe CDP (Fig. 26). In addition, 
terminally sick tgPrPHC mice developed central nervous white-matter vacuolation and intensive 
astrogliosis in cerebellum, brain stem and corpus callosum (Fig. 29). The brain of tgPrPHC mice 
lacked all C-terminal fragments (data not shown).  
 
Figure 29. Vacuolation and astrogliosis in terminally sick tgPrPHC mice. GFAP 
immunohistochemistry of cerebellum, brain stem, and corpus callosum sections of tgPrPHC mice and 
age-matched wt mice. 
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5.4.6 No involvement of lymphocytes in Prnp-/- polyneuropathy 
In order to determine whether an altered lymphocyte function could play a role in the Prnpo/o 
neuropathy, I crossed Prnpo/o mice to Rag1-/- mice that lacked the Rag1 gene and therefore all 
B- and T-cells. At the age of 60 weeks, double knockout mice (Prnpo/o Rag1-/-) displayed a 
peripheral polyneuropathy identical to the one found in Prnpo/o mice (Fig. 30). For control, I 
analyzed Rag1-/- mice with wt Prnp expression and observed no signs of polyneuropathy (Fig. 
30). This indicates that functional B- and T-cells are not a prerequisite for the pathogenesis of 
the Prnpo/o polyneuropathy. Accordingly, immunohistochemical stains failed to reveal increased 
CD3+ or B220+ lymphocytes in sciatic nerves of 60-week old Prnpo/o mice (data not shown).  
 
 
 
 
 
 
 
 
 
Figure 30. Role of lymphocytes in the pathogenesis of Prnpo/o polyneuropathy. Toluidine blue-
stained semithin cross sections of sciatic nerves of 60-week old Rag1-/- x Prnp+/+ showed a normal 
morphology of the sciatic nerve (a) and peripheral neuropathy in Rag1-/- x Prnpo/o (b). 
 
5.4.7 Increased number of SLIs in Prnpo/o mice 
The structure and saltatory conduction of peripheral nerve fibers depend on the proper 
arrangement of nodes of Ranvier and paranodes. I therefore assessed expression and 
localization of nodal and paranodal proteins by immunofluorescence. Sodium channels, 
neurofascin, the paranodal proteins Caspr and JamC, and the extracellular versican were 
normally distributed in Prnpo/o mice (Fig. 31), and JamC showed the normal pattern of 
association with paranodal myelin and SLIs. However, I observed an increased density of SLIs 
along internodes of 8-month old Prnpo/o mice. In 8-month old tgNSE-PrP, SLI density was similar 
to wt mice, whereas SLI density in tgPLP-PrP x Prnpo/o mice, which expressed PrPC exclusively 
in Schwann cells, was similar to that of Prnpo/o nerves (Fig. 32). 
PHYSIOLOGICAL FUNCTION OF THE PRION PROTEIN IN PERIPHERAL NERVES 
 
71
Figure 31. Architecture of Prnpo/o 
nerves. Immunofluorescence of 
10-week old Prnpo/o compared to wt 
mice show normal localization of 
nodal proteins [sodium (Na) 
channels, neurofascin 186 (Nfasc)], 
of paranodal Caspr, and of versican 
as a component of the extracellular 
matrix. JamC, present in non-
compact myelin of both Prnpo/o and 
wt, shows higher density of SLIs in 
Prnpo/o compared to wt. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Increased density of SLIs in Prnpo/o mice. JamC 
immunofluorescence of longitudinal sciatic nerve sections of 
35-week old C57Bl/6, Prnpo/o (B6/129Sv) tgNSE-PrP, and 
tgPLP-PrP. JamC positive areas include SLIs and paranodes 
of non-compact myelin (a). Percentage of JamC positive area 
(b). In contrast to wt and tgNSE-PrP, Prnpo/o sciatic nerves 
show an increase in JamC positive area. Similarly, in tgPLP-
PrP, percentage of JamC positive area was increased. Scale 
bar = 50 m. 
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5.4.8 Normal Neuregulin-1 expression in developing Prnpo/o nerves 
Neuregulin-1 (NRG1) type III regulates Schwann cell development and myelination. By western 
blot analysis, I did not observe any difference in NRG1 expression or processing in developing 
peripheral nerves (Fig. 33). 
 
 
 
Figure 33. Normal neuregulin-1 expression and processing in Prnpo/o sciatic nerves. Western blot 
using anti-NRG1 against the carboxy- (a) or against the amino-terminus (b) showed no difference in 
expression and processing in wt, Prnpo/o, and tgNSE-PrP at 11 (p11) and 35 (p35) days of age. 
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5.4.9 No morphological alterations in central Prnpo/o myelin 
Since prion diseases mainly affect the CNS, I analyzed whether myelinopathy in Prnpo/o extends 
to the central nervouse system. In white matter of spinal cord, corpus callosum and optic nerve, 
I failed to detect myelin degeneration in 60-week old Prnpo/o mice (Fig. 34). 
 
 
Figure 34. Normal ultrastructure 
of Prnpo/o central nervous 
system white matter at 60 weeks 
of age. Sixty-week old Prnpo/o 
compared to wt mice were 
analyzed by electron microscopy. 
No morphological abnormalities 
were observed in corpus callosum, 
spinal cord white matter and optic 
nerve. Scale bar = 2 m. Corpora 
callosa were analyzed in mixed 
B6/129Sv mice whereas spinal 
cords and optic nerves belonged to 
Balb/c mice. 
 
 
 
 
 
 
5.4.10 Genomic analyses 
I analyzed DNA short tandem repeats (STR) in 37 mice for the presence of mouse strain- 
specific polymorphisms that may contribute to the observed phenotypes. Twenty-two STRs 
covered chromosome 2 (on which Prnp resides) and 184 STRs covered the rest of the genome. 
I was unable to identify any genetic association other than Prnp that would explain the CDP 
phenotype. The genetic markers not flanking the Prnp locus were similar in mice with and 
without neuropathy. This was true for mice on the mixed background B6/129Sv (tgNSE-PrP, 
Prnpo/o, tgPLP-PrP, tgDelC4, tgPrPCC, tgF35) and for mice on FVB (tgPrnpflox, tgPrnpflox x 
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tgNHF-Cre, tgPrnpflox x tgDhh-Cre; Fig. 35). When comparing wt and Prnpo/o mice on the Balb/c 
background, STR polymorphisms delineated a genomic region of ca. 14 cM segregating with 
the Prnpo allele and CDP. Since this region was preserved in Prnpo/o mice whose neuropathy 
was suppressed by an unlinked Prnp transgene (e.g. tgNSE-PrP), it is unlikely that it 
determined the CDP phenotype (Fig. 36-38). 
 
Figure 35. Analysis of polymorphic STR in the entire genome in transgenic mice. Percentage of 
strain-specific STR in the entire genome (without chromosome 2) are shown by box plots in transgenic 
mice with or without neuropathy, on B6/129Sv mixed background (upper plot) or those mice backcrossed 
to FVB (lower plot). Mann-Whitney U-test (2-tailed) did not reveal any significant difference in the 
composition of genetic background in mice with and without neuropathy. 
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5.4.11 Stability of early Prnpo/o myelin proteome 
Myelin extracts from PrnpO/O compared to wt mice did not show any gross alteration in myelin 
protein composition in 1D gels (SDS-PAGE) stained with Coomassie blue (Fig. 39). To analyze 
more subtle differences in the myelin proteome, I performed DIGE experiments and identified 
eight proteins which were differentially expressed in myelin of 4-week old PrnpO/O compared to 
wt mice (proteins with fold change ≥ 1.3, p<0.05). Spots of differentially expressed proteins 
were excised from the gel and analyzed by MALDI-TOF/TOF. A representative gel is shown in 
Fig. 40. The eight proteins and the ratio of protein amount in PrnpO/O compared to wt myelin are 
listed in Tab. 2. 
 
Figure 39. Myelin extracts of Prnpo/o 
compared to wt mice. Different amounts of 
myelin extracted from 4-week old Prnpo/o 
compared to wt mice were analyzed by SDS-
PAGE. Gels were stained with Coomassie 
blue. No gross alteration in the protein 
composition was visible.  
 
 
 
 
Figure 40. Myelin extracts of Prnpo/o 
compared to wt mice. Myelin proteins were 
extracted from 4-week old Prnpo/o and wt 
mice, dye-labelled and analyzed by DIGE. 
Eight protein spots were differentially 
expressed, excised and analyzed by MALDI-
TOF/TOF. 
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Table 2. Differentially expressed proteins identified by DIGE/ MALDI-TOF/TOF 
Proteins with fold change ≥ 1.3, p<0.05 PrnpO/O/ wt 
enolase B  0.6 
creatine kinase M (CKM) 0.6 
septin 9  1.4 
tubulin alpha 1A 1.5 
actin related protein 2/3 (ARPC2) 1.3 
PIP transfer protein alpha  1.5 
dynein light chain 1/2/ DLC8 1.5 
alpha Crystallin B  1.7 
 
For confirmation of the DIGE results, I performed regular Western blots with independent myelin 
protein extracts of 4-week old mice. The only protein whose differential expression could be 
verified by Western blot was septin 9 (Fig. 41, Tab. 3). On mRNA level, there was no significant 
difference in septin 9 expression (data not shown). Interestingly, the differential protein 
expression level of septin 9 was associated with a differential localization of septin 9 in PrnpO/O 
compared to wt myelin. Immunofluorescence showed septin 9 in SLIs of PrnpO/O mice, in 
contrast, septin 9 was absent from wt SLIs. However, septin 9 was also present in SLIs of 
tgNSE-PrP mice (Fig. 42). Therefore, absence of PrPC from the myelin sheath correlates with 
the presence of septin 9 in SLIs. Since tgNSE-PrP mice lack signs of neuropathy, the 
differential localization of septin 9 in SLIs did not correlate with neuropathy and is therefore 
unlikely to be pathogenetically relevant for the PrnpO/O neuropathy. In addition, septin 7, a 
known binding partner of septin 9 was expressed at wt levels in sciatic nerves of PrnpO/O mice 
(Fig. 41). 
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Figure 41. Myelin extracts of Prnpo/o compared to wt mice. Myelin proteins were extracted from 
seven-week old Prnpo/o and wt mice, and analyzed by Western blots. Those proteins identified by DIGE to 
be differentially expressed in PrnpO/O compared to wt were analyzed. In addition, septin 7 expression was 
analyzed. Only septin 9 was confirmed to be differentially expressed.  
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Table 3. Western blot results of myelin proteins identified by DIGE  
 PrnpO/O/ wt (p value) DIGE: PrnpO/O/ wt 
enolase B  1.10 (p=0.56) 0.6 
creatine kinase M (CKM) 0.65 (p=0.23) 0.6 
septin 9  5.35 (p=0.0034) 1.4 
tubulin alpha 1A no difference 1.5 
actin related protein 2/3 (ARPC2) 1.09 (p=0.62) 1.3 
PIP transfer protein alpha  0.73 (p=0.15) 1.5 
dynein light chain 1/2/ DLC8 not determined 1.5 
alpha Crystallin B  1.41 (p=0.12) 1.7 
 
 
Figure 42. Localization of septin 9 in Prnpo/o, wt, and tgNSE-PrP nerves. Immunofluorescence 
images of longitudinal sections of PrnpO/O, wt, and tgNSE-PrP nerves. Co-staining for JamC and septin 9 
is performed, showing that septin 9 is present in PrnpO/O and tgNSE-PrP SLIs, but absent from SLIs of wt 
mice.  
 
5.4.12 Stability of early Prnpo/o nerve transcriptome 
Since there was no relevant difference in the early PrnpO/O myelin proteome, I investigated the 
early myelin transcriptome – in 5-week old mice. To exclude that genes unlinked to the Prnp 
locus (“genetic background genes”) cause transcriptome alterations, I analyzed PrnpO/O sciatic 
nerve transcriptome compared to wt in two different genetic backgrounds (five PrnpO/O 
backcrossed to C57Bl/6 compared to five C57Bl/6 and five PrnpO/O backcrossed to Balb/c 
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compared to five Balb/c). Only nine mRNAs were identified to be differentially expressed (>1.5 
fold change, p < 0.01) in PrnpO/O compared to wt on both genetic backgrounds, C57Bl/6 and 
Balb/c (Fig. 43). Of these nine mRNAs, one was Prnp, four genes were localized around the 
Prnp gene. These genes originate most likely from the ES cell genome, which is derived from a 
129Sv substrain and cannot be compared to Balb/c and C57Bl/6 wt genes. One mRNA is 
currently unidentified. One mRNA was upregulated on one background and downregulated in 
the other. The remaining two mRNAs (neuregulin 1 and adiponutrin) were further analyzed by 
real time PCR. Differential expression could not be verified by real time PCR (data not shown). 
Therefore, I analyzed the original data again with less stringent criteria (genes identified in one 
background > 2 fold change, p < 0.01 and in the other background > 2 fold change, 0.05 > p > 
0.01 as well as genes identified in one background > 2 fold change, p < 0.01 and undetected in 
other background; Fig. 44). 
 
Figure 43. Genes identified by microarray to be differentially expressed in Prnpo/o (KO) compared 
to wt nerves. Sciatic nerves of 5-week old PrnpO/O mice were analyzed by microarray for alterations in 
their transcriptome when compared to wt mice. Mice on two different genetic backgrounds (Balb/c and 
C57Bl/6 = Bl6) were analyzed and only those genes with alterations > 1.5 fold and p values < 0.01 in both 
genetic backgrounds are listed. On the right side the chromosomal localization is indicated. For genes on 
chromosome 2, the localization is indicated by a black arrow, localization of Prnp is shown by a red arrow.  
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Figure 44. Genes identified by microarray to be differentially expressed in Prnpo/o (KO) compared 
to wt nerves. Mice on two different genetic backgrounds (Balb/c and C57Bl/6 = Bl6) were analyzed and 
those genes identified in one background > 2 fold change, p < 0.01 and in the other background > 2 fold 
change, 0.05 > p > 0.01 as well as genes identified in one background > 2 fold change, p < 0.01 and 
undetected in the other background are listed. 
 
The only gene whose differential expression could be verified on both genetic backgrounds by 
real time PCR was sonic hedgehog (Shh; Fig. 45). However, in older mice (35 weeks, mixed 
background) this difference was reversed – there was a lower Shh expression in PrnpO/O: ~30% 
of wt expression, p=0.06; ~25% of tgNSE-PrP p=0.01 (data not shown).  
 
 
 
Figure 45. Sonic hedgehog was differentially expressed in PrnpO/O mice compared to wt. 
Differential expression of sonic hedgehog (Shh) was verified in independently extracted sciatic nerve 
mRNA on two different genetic backgrounds (Balb/c and C57Bl/6 = Bl6; 5-week old).  
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5.4.13 Increased amounts of IgG1 in Prnpo/o nerves 
In Western blot studies, I detected a higher amount of IgG1 in peripheral nerves of young (10- 
and 35-day old) PrnpO/O compared to wt and tgNSE-PrP nerves. Absence of the signal in Rag1-/- 
nerves indicates that the signal was indeed an immunoglobulin (Fig. 46). In tgNSE-PrP nerves 
lacking signs of neuropathy, the increase of IgG1 was reversed to wt levels (Fig.47). However, 
as indicated by the presence of neuropathy in PrnpO/O Rag1-/- mice (Fig. 30) which lack 
immunoglobulins, the presence of IgG1 alone does not explain development of neuropathy. A 
similar amount of other serum proteins, like albumin and IgG2a, in PrnpO/O and wt nerves 
indicates that the blood-nerve barrier is intact in PrnpO/O mice (Fig. 48).  
 
Figure 46. IgG1 in sciatic nerves of 10-
day old PrnpO/O and wt mice. Higher 
amount of IgG1 in sciatic nerves of 10-day 
old PrnpO/O compared to wt mice. Signal 
was absent in Rag1-/-nerves. Molecular 
weight is shown on the left side (in kDa).  
 
 
 
 
Figure 47. IgG1 in sciatic nerves of 10-
day old tgNSE-PrP, PrnpO/O and wt 
mice. The NSE-PrP transgene reversed 
the higher amount of IgG1 in sciatic 
nerves of 10-day old PrnpO/O mice. 
Amount of IgG1 relative to control protein 
Nfasc is shown. 
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Figure 48. IgG1, IgG2a and albumin in 
sciatic nerve myelin of PrnpO/O and wt 
mice. Higher amount of IgG1 myelin 
extracted from sciatic nerves of 35-day old 
PrnpO/O compared to wt mice. In contrast, 
amount of albumin and IgG2a was similar. 
Molecular weight is shown on the left side 
(in kDa).  
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5.5 Discussion 
5.5.1 Absence of genetic confounders in Prnp-/- CDP 
CDP was associated with four independently targeted Prnp knockout lines, including pure 
129/Ola PrnpEdbg/Edbg mice. Prnp-flanking genes in PrnpEdbg/Edbg and PrnpGFP/GFP mice did not 
cause CDP, as both strains were made in 129/Ola-derived ES cells, and 129/Ola wt mice did 
not develop any neuropathy. Breeding to various strains and genome-wide STR analyses failed 
to identify any role for genes outside of the Prnp locus in the pathogenesis of CDP. Prnpo/o and 
PrnpEdbg/Edbg mice suffered from CDP despite normal expression of Dpl, indicating that Dpl 
upregulation did not cause the polyneuropathy. CDP was present in mice lacking both Prnp and 
Prnd140 but absent from mice selectively lacking Prnd141. Therefore Dpl, unlike PrPC, is 
dispensable for the maintenance of peripheral nerves.  
 
5.5.2 Time course of Prnp-/- CDP 
The first signs of CDP (mild electrophysiological alterations, reduced grip strength, and CD68+ 
digestion chambers) became detectable around 10 weeks of age, i.e. immediately after 
completion of peripheral myelination. Accordingly, ultrastructural examinations confirmed the 
initial formation of morphologically normal myelin in the absence of PrPC. I conclude that 
demyelination is early but not congenital. Akt and Erk phosphorylation, which is regulated during 
myelination146, was indistinguishable between Prnpo/o and wt myelinating nerves. Assuming that 
any differences have not been obfuscated by neuronal Akt/Erk, these results suggest that PrPC, 
even if it modulates Akt, Fyn, cAMP, and Erk1/2 (ref. 97, 99, 107, 108, 110), exerts its effects on myelin 
through different pathways. 
 
5.5.3 Bahavioral tests of Prnp-/- mice 
The clinical manifestations of the polyneuropathy were limited to reduced grip strength and 
nociception. These phenotypes are consistent with incomplete demyelination and may explain 
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some of the reported behavioral abnormalities of Prnpo/o mice150-151. Nazor et al. reported 
vacuolation and astrogliosis in Prnp-/- mice152. Interestingly, they also observed a decreased 
latency-to-fall in accelerating rota-rod tests of Prnp-/- mice. This is in contrast to my observation 
of an unaltered performance in rotarod test. No difference in non-accelerating rota-rod was also 
described by others153. A possible explanation is the difference in the genetic background, as 
Nazor et al. investigated mice on FVB background while I and others used mice on a C57/Bl6, 
Balb/c or a mixed genetic background (C57Bl/6;129Sv). In contrast, I observed a difference in 
the response to thermal stimulus in the hot plate test. In another study, Meotti et al. proposed an 
involvement of PrPC in nociceptive transmission, based on the finding that Prnp -/- mice were 
more resistant than wt mice to thermal nociception in the tail-flick test150. However, in contrast to 
my results, no significant difference was found on the hot plate test in the latter study. This 
again may indicate background-dependent differences in the clinical manifestation of the 
neuropathy. It should be noted that the hot plate test measures the response to a thermal 
stimulus which requires both nociception and motor response. I hypothesize that worse 
performance of Prnp-/- in the hot plate test in my study is the consequence of impaired motor 
function, since the effort of mice to lick paws was visible and the mice showed signs of pain in 
their paws (slight elevation of feet to avoid contact to hot plate, crying noise when mice were 
touched afterwards). This might be more pronounced on Balb/c background than on other 
backgrounds. Consistent with the apparent motor impairment in the hot plate test, in the grip 
strength test I observed reduced muscle strength in Prnp-/- mice. In summary, behavioral tests in 
my study together with the findings of others suggest that Prnp-/- mice may have altered 
nociception and strength, but to which extent these behavioral alterations manifest strongly 
depends on the genetic background and/or the environmental conditions. Prnp-/- neuropathy is a 
likely explanation for the observed behavioral phenotype. In general, performance in behavioral 
tests is known to depend strongly on the genetic background of mice, for nociception154, motor 
function155 and cognition156. Nico et al. reported that some behavioral abnormalities in Prnp-/- 
mice compared to wt are observed only in situations of acute stress, indicating that 
environmental conditions might also influence behavior151. 
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5.5.4 Rescue of Prnpo/o neuropathy in trans 
Since PrPC-deficient sciatic nerves showed classic ultrastructural and electrophysiological 
features of demyelinating neuropathies, I was surprised to discover that CDP rescue required 
expression of PrPC by neurons, but not by Schwann cells. This unexpected result was 
confirmed in five genetic paradigms: tissue-restricted Prnp expression in neurons or Schwann 
cells, and tissue-specific ablation of Prnp by neuron- or Schwann-cell-restricted Cre transgenes. 
Therefore, peripheral myelin requires neuronal PrPC in trans, suggesting that PrPC is involved in 
directional communication from axons to Schwann cells (Fig. 49). 
 
 
Figure 49. Hypothetical mechanisms of myelin maintenance by neuronal PrPC. A-B: Neuronal PrPC 
may interact in trans with Schwann cells. This interaction could be mediated by direct binding of full length 
PrPC to an adaxonal myelin surface component (A) or by a neuronal protein complex containing PrPC 
which in turn interacts with myelin (B). C: Regulated proteolysis may liberate a bioactive, myelinotrophic 
amino-terminal PrPC fragment that travels to, and interacts directly with, the myelin sheath. This model 
may account for the observed correlation of PrPC cleavage with myelin homeostasis. D: Alternatively, 
PrPC may exert indirect effects on Schwann cells, e.g. by modulating the activity of sodium channels, 
without causing visible and electrophysiologically measurable alterations of the axon. 
 
Although the tgPLP-PrP transgene produced a partial rescue of CDP, the lack of pathology after 
Schwann-cell specific depletion argues against an essential role of PrPC in Schwann cells. The 
partial rescue may be explained by the excessive myelin-specific expression of PrPC in tgPLP-
PrP mice. Some of this surplus PrPC may be transferred to neurons by “GPI painting”157, or may 
release myelinotrophic fragments from adaxonal myelin into the axon-glia interspace. 
PHYSIOLOGICAL FUNCTION OF THE PRION PROTEIN IN PERIPHERAL NERVES 
 
89
Alternatively, PrPC might have an additional, cell-autonomous role in Schwann cells which may 
be related to the localisation of SLIs. 
 
Tissue-specific expression patterns of transgenes do not always accurately reflect those of the 
parental genes. I therefore investigated whether PrPC expression in the above mice was as 
intended. Since peripheral nerves consist mostly of Schwann cell bodies and neuronal 
processes, their extracts contain predominantly Schwann cell mRNA, whereas neuronal mRNA 
is localized mainly in DRGs and spinal cord neurons. Indeed, quantitative RT-PCR analyses 
revealed abundant Prnp transcripts in tgPLP-PrP nerves, but only little in tgNSE-PrP sciatic 
nerves. In contrast, PrP protein levels in tgPLP-PrP and tgNSE-PrP nerves were similar to wt 
nerves. Hence, transgenic expression in tgNSE-PrP is largely restricted to the neurons, and 
suppression of polyneuropathy is not due to illegitimate PrPC expression in Schwann cells. 
Furthermore, in situ hybridization confirmed that the floxed Prnp transgene was excised in most 
tgPrnpflox x tgNFH-Cre neurons, whereas the similar levels of Prnp mRNA in tgPrnpflox x tgNFH-
Cre and tgPrnpflox in sciatic nerves excludes ectopic recombination events. 
 
Signaling from neuron to ensheathing glial cells (axon-to-glia signal) during myelination has 
been studied extensively, namely the initial formation of myelin sheaths involving the principle 
known mediator, Neuregulin. In contrast, signalling in the opposite direction, from myelin to the 
axon (glia-to-axon signal) has been shown to be essential for long-term maintenance of axonal 
functional integrity11. One example of the latter is CNPase; despite its localization in non-
compact myelin, CNPase deficient mice develop axonal rather than myelin degeneration22. 
Other myelin components essential for long-term functional integrity of axons are intact myelin 
peroxisomes, and PLP in the CNS, as well as MAG and ciliary neurotrophic factor (CNTF) in the 
PNS25, 27, 158-160. In addition, the anterograde myelin sheath degradation occurring after axonal 
cuts indicates that myelin health depends on axonal signals whose molecular nature is largely 
unknown. Importantly, the evidence reported here identifies PrPC as a previously unknown 
crucial neuronal mediator of peripheral myelin maintenance. 
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Whereas neuronal NRG1 type III regulates Schwann cell development and myelination via ErbB 
receptors on myelinating cells161, PrPC appears to fulfill a different role: rather than disrupting 
primary myelination, its absence impairs long-term myelin maintenance. Therefore, these two 
proteins are unlikely to utilize identical transduction pathways. However, PrPC modulates the 
activity of BACE162 which cleaves NRG1 type III and regulates myelination163-164, begetting the 
question whether PrPC may influence myelin maintenance via BACE and NRG1 type III. 
However, I failed to detect any difference in NRG1 expression in Prnpo/o nerves and in PrPC 
catabolism in BACE1–/– nerves (data not shown). PrPC might interact with myelin components 
directly or through other axonal proteins (Fig. 35). Some of the reported PrPC interacting protein 
have a role in myelin homeostasis165 and represent candidate mediators of its myelinotrophic 
effects. Laminin, laminin receptor, and components of the dystroglycan complex, which is also a 
laminin receptor, have been reported to interact with PrPC 129-130, 166-167. Signals emanating from 
laminins have a profound impact on Schwann cells (reviewed by 168), including myelin 
maintenance169. Mutations in 2-laminin cause demyelinating neuropathies in mice and 
humans. However, there are some morphological differences between mice with altered 
laminin/ laminin receptor function and Prnp-/- mice. Nodal abnormalities and inability of Schwann 
cells to radially sort axons are typical for alterations in laminin function that are not observed in 
Prnp-/- mice. However, neuronal PrPC could directly or indirectly interact with or modulate 
Schwann cell laminin receptors to maintain the myelin sheath. Due to its localization in the 
adaxonal myelin, MAG is also a very interesting canditate protein reported to interact 
biochemically with PrPC in the CNS165. However, its role in the molecular function of PrPC in 
peripheral nerves remains to be determined.  
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5.5.5 Structural motifs and cleavage of PrPC in myelin maintenance 
The octarepeat region has often been reported to be required for the function of the PrPC, for 
example in the neuroprotective effect of PrPC in brain ischemia52 and for the internalization of 
PrPC (Ref 121). Mechanistically, copper binding and/or protection against oxidative stress has 
been ascribed to this region. However, the octarepeat repeat region was dispensable for the 
maintenance of the myelin sheath in the peripheral nerves, whereas mice expressing PrP 
lacking the central domain (aa 94–134) developed CDP2. The hydrophobic core (HC), but not 
the charge cluster (CC2), of this central PrPC domain was essential for peripheral myelin 
maintenance. Consistent with this finding, transgenic mice expressing toxic mutant PrP lacking 
amino acids 94-121 were shown to display a peripheral neuropathy2. The earlier onset and the 
stronger phenotype in these transgenic mice imply a gain-of-function rather than a loss-of-
function as this seen in Prnp-/- mice. This shows that distinct domains within PrPC can exhibit 
distinct functions.  
PrPC undergoes regulated proteolysis in late secretory compartments148, 170-172. I observed an 
association between presence of CDP and lack of C1-fragment in sciatic nerves. All transgenic 
mice showing CDP (tgE11, tgF35, tgGPI¯PrP, tgPrPΔHC) lacked C1, whereas all PrP mutants 
rescuing the CDP (tgC4 and tgPrPΔCC) produced abundant C1. Cleavage of PrPC appears 
therefore to be linked to its myelinotrophic function. This conjecture may also explain the 
requirement for membrane anchorage of PrPC for myelin maintenance revealed using 
tgGPI¯PrP mice, since anchorless PrPC did not undergo regulated proteolysis. 
Analogous to NRG1, cleavage of axonal PrPC may produce bioactive fragments which in turn 
may transmit signals to Schwann cells (Fig. 35). Alternatively, cleavage might suppress a PrPC-
mediated signal, whose abrogation may result in uncontrolled signaling and toxicity. 
Theoretically, axonal PrPC may exert indirect actions on myelin. However, this would require the 
unlikely assumption that lack of PrPC damages axons to an extent that it affects myelin 
maintenance, while being morphologically and electrophysiologically undetectable. 
Several studies have suggested an involvement of PrPC in synaptic function (reviewed in 173). 
However, the amplitudes of foot muscle CMAPs following distal stimulation were not 
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significantly altered in 53-week old Prnpo/o, arguing against a major presynaptic defect in 
neuromuscular synaptic transmission. This of course does not exclude a synaptic function of 
PrPC in the central nervous system. Furthermore, since it is well established that neuronal 
electrical activity has an impact on Schwann cells and the myelin sheath 174, it is possible that 
synaptic dysfunction in the spinal cord or modulation of axonal ion channel or pump activities 
along the nerve fibers contributes to the observed myelin damage in Prnp -/- mice. In this context 
it is of interest that PrPC has been shown to interact at least biochemically with the catalytic 
subunit of P-type ATPase175. 
 
5.5.6 Increased density of SLIs in Prnp-/- nerves 
As an early alteration in Prnp0/0 nerves, I indentified an increased density of SLIs. Like the 
neuropathy, the latter was dependent on the neuronal PrPC. Increased density of SLIs was 
previously reported in different myelin mutant mice: Shiverer176, cerebroside sulfotransferase 
knockout mice177, desert hedgehog-null mice178, Caspr-null mice179. However, the molecular 
mechanism behind the increased density of SLIs in the absence of neuronal PrPC in peripheral 
nerves remains to be determined. 
 
5.5.7 No role of lymphocytes in pathogenesis of Prnp-/- neuropathy 
It has often been suggested that PrPC has a physiological function in the immune system180. 
Some neuropathies in humans are mediated by auto-antibodies or auto-reactive T-cells. 
Lymphocytes have been reported to aggravate the neuropathy in mice overexpressing 
proteolipid protein (PLP) in oligodendrocytes181. However, as indicated by the presence of 
peripheral neuropathy in Prnp0/0 Rag1-/- mice, the presence of functional T- and B-lymphocytes 
is not required for Prnp-/- neuropathy. 
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5.5.8 CNS in Prnp-/- mice 
I did not observe any morphological alterations in central Prnp-/- myelin. Nevertheless, 
subliminal myelin pathologies may extend to central myelin in Prnp–/– mice152, and transgenic 
mice expressing toxic PrPC mutants show both peripheral and central myelinopathy2, 104. PrPC 
deficiency was reported to affect synaptic function85-86. However, the amplitudes of foot muscle 
CMAPs following distal stimulation were not significantly altered in 53-week old Prnpo/o, arguing 
against a major presynaptic defect in neuromuscular synaptic transmission. Recently, an 
involvement of neuronal PrPC in olfactory function was reported182. Non-myelinating Schwann 
cells and olfactory ensheathing cells are morphologically similar and both cell types are 
intensively studied for their potential to promote axonal regeneration following spinal cord injury 
183. Therefore, the underlying mechanism of peripheral neuropathy and olfactory dysfunction 
might be similar. Potentially, as in the PNS, communication between axon and olfactory 
ensheathing cells is disrupted in the absence of PrPC. However, until now, a morphological 
analysis of the olfactory bulb has not been performed. This could help to identify which cell type 
is primarily affected in this system. 
 
5.5.9 PrPC in peripheral nerves of humans and livestock 
PrPC has been linked previously to peripheral neuropathies in humans. Preclinical peripheral 
neuropathy often occurs in patients suffering from sporadic CJD184. A genetic form of CJD 
(E200K) is associated with a demyelinating neuropathy185. However, with regard to isolated 
peripheral neuropathies, in one study, scientists failed to identify any mutations in the PRNP 
gene in humans186. PRNP mutations could be rare and therefore not present in the investigated 
cohort. More likely is that PRNP mutations cause a CNS abnormality with peripheral 
involvement merely being an accompanying symptom (as in CJD E200K). 
Recently, scientists have succeeded in generating Prnp deficient farm animals, such as cattle187 
and goats188-190. It has been reported that these animals are phenotypically and 
histopathologically normal. However, to my knowledge, investigation of peripheral nerves in 
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these animals, electrophysiologically or ultrastructurally, has not been reported. This would 
certainly be interesting, as it might have important implications on the use of these animals for 
agriculture. 
 
5.5.10 Stability of Prnpo/o nerve transcriptome and myelin proteome 
The sciatic nerve transcriptome and proteome of PrnpO/O mice, as analyzed by microarray and 
DIGE did not appear to harbour any obvious abnormalities. The only protein found to be 
differentially expressed in myelin of wt and Prnpo/o nerves was Septin 9. Higher amounts of 
septin 9 protein were associated with SLIs in Prnpo/o nerves. However, this abnormal 
localization correlated with absence of PrPC from myelin (in Prnpo/o nerves and tgNSE-PrP), but 
not with presence of neuropathy (neuropathy in Prnpo/o mice, but not in tgNSE-PrP mice). 
Therefore, the significance of this finding remains unknown. Interestingly, septin 9 is associated 
with hereditary neuralgic amyotrophy, a recurrent, painful brachial plexus neuropathy with 
axonal degeneration191. Several isoforms of septin 9 are known to be generated by alternative 
splicing, and septin 9 is believed to promote tumorigenesis. Septins are members of a 
conserved family of cytoskeletal GTPases. Different members of the septin family, e.g. septin 7, 
9 and 11, form complexes192-193. Although the function of septin 9 in myelinated nerves fibers is 
unknown, the expression of septins in myelin and myelinating cells was recently reported192.  
By microarray, only sonic hedgehog (Shh) expression was found to be higher in young PrnpO/O 
compared to wt nerves in a background-independent manner. However, in nerves of 35-week 
old PrnpO/O mice, Shh expression was lower than in in wt, and it is therefore unclear what the 
significance of Shh signaling is in the PrnpO/O neuropathy. Shh was previously found to be 
upregulated following sciatic nerve injury and to induce BDNF expression, which in turn 
improved survival of motor neurons194. In PrnpO/O mice it could simply represent an early marker 
of nerve damage. If and how Shh contributes to PrnpO/O neuropathy could be tested by 
pharmacological inhibition of Shh signalling with cyclopamine in mice, by local administration of 
the drug with pumps as described previously in rats194. First the impact of this drug on PrnpO/O 
PHYSIOLOGICAL FUNCTION OF THE PRION PROTEIN IN PERIPHERAL NERVES 
 
95
nerve structure and electrophysiological properties could be tested. If nerves showed a more or 
a less severe neuropathy compared to nerves of untreated Prnp0/0, one could further investigate 
which factors are involved.  
I observed several differences between the Prnpo/o and wt transcriptomes on a single genetic 
background (C57Bl/6 or Balb/c) only. This exemplifies the importance of correct genetic 
controls, when performing microarray analyses. In addition, of the genes found to be altered in 
Prnpo/o compared to wt on both genetic backgrounds, many were localized around Prnp on 
chromosome 2, suggesting that embryonic stem cell-derived genes not eliminated by genetic 
backcrossing caused artifical transcriptional changes.  
Incidentally, I detected a higher amount of IgG1 in PrnpO/O nerves compared to wt. Since 
albumin and IgG2a did not show a similar difference, this finding was most likely not caused by 
an increased permeability of the blood-nerve barrier. Elevated IgG1 was not caused by local 
expression of IgG1 because (1) the difference was observed before newborn mice produce their 
own IgG1 – all the IgG is derived from the mother at this age, and (2) by real time PCR, I failed 
to detect IgG1 mRNA (data not shown). Since serum levels in wt and PrnpO/O newborn mice 
were similar (data not shown), it is unlikely that elevated IgG1 levels were due to increased 
amounts of circulating immunoglobulins. In any case, the presence of IgG1 was not a 
prerequisite for developing neuropathy, as indicated by the presence of neuropathy in PrnpO/O 
Rag1-/- mice. A current hypothesis is that macrophages infiltrating PrnpO/O nerves import IgG1 
(but not IgG2a) bound to their Fc receptors. Alternatively, clearance of immunoglobulins from 
peripheral nerves may be altered in PrnpO/O mice.  
There are several possible explanations for why I was unable to detect early alterations in 
Prnp0/0 myelin proteome or nerve transcriptome. First, the chosen time points for the analyses 
may have been too early. However, the first histological, behavioral and electrophysiological 
signs of neuropathy were observed only shortly thereafter at the age of 10 weeks, marked by an 
increased number of digestion chambers, reduced grip strength, and reduced NCV. By 
analyzing mice younger than 10 weeks, I intended to prevent secondary changes due to 
activation and/or increased density of macrophages in 10-week old PrnpO/O nerves. Other 
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possible explanations for the inability to detect any difference are (1) alterations affected mainly 
cellular molecules that were not analyzed, e.g. lipid components, (2) alterations involved 
signaling molecules that are too short-lived to be detected, or (3) that the methods used were 
not adequate for the detection of all existing transcriptomic or proteomic alterations. Concerning 
the latter, the incidental finding of higher amount of IgG1 in PrnpO/O mice compared to wt 
showed that DIGE was not sufficient to detect all the proteome differences in PrnpO/O nerves. In 
the future, additional methods will be used, including ICAT (isotope-coded affinity tag), LC-
MS/MS (lipid chromatography-tandem mass spectrometry), and 2D-16-BAC (2D-16-
benzyldimethyl-n-hexadecylammonium chloride)/ SDS-PAGE to detect early alterations. It has 
previously been shown that one method alone does not suffice to detect all myelin proteins 
being present195.  
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6 IMPACT OF IMMUNIZATION ON PRION SUSCEPTIBILITY 
 
‘Introduction’ (in parts), ‘Material and Methods’, ‘Results’ and parts of the ‘Discussion’ 
are taken from the following publication: 
“Repetitive Immunization Enhances the Susceptibility of Mice to Peripherally 
Administered Prions“ 
By Juliane Bremer, Mathias Heikenwalder, Johannes Haybaeck, Cinzia Tiberi, Nike 
Julia Krautler, Michael O. Kurrer, Adriano Aguzzi 
Published in PLoS one 2009 Sep 25; issue 4 (9); e7160 
 
Parts of the ‘Introduction’ are adapted from the following publication: 
“The Prion’s Elusive Reason for Being” 
By Adriano Aguzzi, Frank Baumann, and Juliane Bremer 
Published in Annu Rev Neurosci. 2008; issue 31: pages 439-477 
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6.1 Introduction 
6.1.1 Prion diseases 
Prion diseases, or transmissible spongiform encephalopathies (TSE), are infectious 
neurodegenerative conditions that typically lead to cognitive and motor dysfunction 196-197. With 
the exception of rare, chronically presymptomatic carriers198, prion diseases are progressive, 
fatal, and presently incurable. Prions propagate during the course of the disease and form 
aggregates containing PrPSc, a misfolded, beta-sheet-rich isoform of the cellular prion protein 
PrPC, which is encoded by the PRNP gene6, 199. Although the normal cellular prion protein PrPC 
can easily be digested with proteinase K (PK), the beta-sheet-rich, misfolded form PrPSc is 
partially proteinase K (PK) resistant. Typical neuropathological features include neuronal loss, 
astrogliosis and spongiform changes196-197.  
 
 
Figure 50. Histopathology of Creutzfeldt Jakob Disease. Frontal cortex sections of the brain of a 
patient who died of non-cerebral cause (upper row) and of a patient suffering from Creutzfeldt–Jakob 
disease (CJD; lower row). Sections are stained with haematoxylin-eosin (H-E, left panels), with antibodies 
against glial fibrillary acidic protein (GFAP, middle panels) and with antibodies against the prion protein 
(PrP, right panels). Neuronal loss and prominent spongiosis are visible in the H-E stain. Strong 
proliferation of reactive astrocytes (gliosis) and perivacuolar prion protein deposits are detectable in the 
GFAP and PrP immunostains of the CJD brain samples. Figure reprinted by permission from Macmillan 
Publishers Ltd: Nature Reviews Molecular Cell Biology200, copyright 2001. http://www.nature.com/nrm. 
Licence number 2438450274580. 
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The word “prion” is a portmanteau derived from “proteinaceous infectious” particle. Naturally, 
the latter is by no means a qualifying attribute, because all conventional infectious agents - 
including all viruses and bacteria - are proteinaceous to some degree. What sets prions apart, 
as proposed by Prusiner, is that the actual infectious particle consists merely of protein and is 
capable of replicating and transmitting infections without the need for informational nucleic 
acids. This postulate counters the established molecular biological central dogma, which 
predicates that nucleic acids are the basis for self-replicating biological information in all living 
beings, including even the most elementary infectious particles. 
Prion diseases have occurred in humans and animals for many years. A disease similar to 
scrapie was recorded in the mid-eighteenth century, and scholars heavily debated its origin. A 
crucial experiment showing incontrovertible transmissibility of scrapie to goats was performed 
by Cuille & Chellè in the 1930s201. The first cases of human prion disease, Creutzfeldt-Jakob 
disease (CJD), were reported in the 1920s202-203. The number of human and animal diseases 
recognized as TSEs has increased steadily and now includes Gerstmann-Sträussler-Scheinker 
syndrome (GSS), fatal familial insomnia (FFI), and Kuru in humans; bovine spongiform 
encephalopathy (BSE) in cattle; chronic wasting disease (CWD) in deer and elk; and 
transmissible mink encephalopathy. BSE has been inadvertently transmitted to a variety of 
captive animals, causing feline spongiform encephalopathy (FSE) and a plethora of diseases in 
zoo animals including kudus, nyalas, and greater cats, for example. 
Creutzfeldt-Jakob disease CJD was initially described as a sporadic disease with no known 
cause (sCJD). The incidence of CJD is low in all ethnicities and typically affects ~1 person in 
one million each year. Very rapid cognitive decline, causing dementia, is the main symptom. 
Cerebellar symptoms, including ataxia and myoclonus, are also frequent presenting symptoms. 
Death often occurs within few weeks of the first signs of disease, and a fulminant, 
“apoplectiform” course of disease has been documented in the past. Somatic mutations in the 
PRNP gene analogous to those in the germline of genetic CJD patients (see below) have been 
hypothesized to underlie cases of sporadic CJD. Alternatively, Aguzzi & Glatzel204 suggested 
that some cases of alleged sCJD derive from heretofore unrecognized prion infections. Finally, 
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PrPC may possess a finite, albeit extremely low, propensity to self-assemble into ordered 
aggregates of PrPSc, thereby stochastically initiating prion replication and, ultimately, a sporadic 
form of disease. The latter scenario could be regarded as the bad-luck hypothesis. However, 
none of this has been proven, and therefore the cause of sCJD is still unknown. 
Variant Creutzfeldt-Jakob disease and Bovine Spongiform Encephalopathy. Public 
understanding of prion disease remained limited for a long time. However, this mindset changed 
completely when BSE was first reported in the early 1980s205. In the following years until mid 
2009, BSE affected ~190,500 cows (http://www.oie.int/). Some investigators suggested that 
BSE could cause a new variant form of CJD (vCJD) in humans. A direct experimental proof that 
vCJD represents transmission of BSE prions to humans cannot be produced. However, 
epidemiological, biochemical, neuropathological evidence and transmission studies strongly 
suggest that BSE has transmitted to humans in the form of vCJD206-209. The incidence of vCJD 
rose between 1994, when the first patients suffering from vCJD presented with their initial 
symptoms, and 2001, raising fears that a very large epidemic may be looming. Currently, vCJD 
has affected 225 individual victims worldwide (http://www.cjd.ed.ac.uk/). Most of the affected 
individuals lived in United Kingdom and France. Fortunately, in the United Kingdom, the 
incidence appears be decreasing since the year 2001 to one diagnosed case yearly in 2007 and 
2008. In France, the number of probable and definite cases of vCJD increased from 0-3 
diagnosed cases per year in 1996-2004 to 6 per year in 2005 as well as in 2006. In 2007-2009, 
the number of cases was back to 0-3 again, totaling 25 cases 
(http://www.invs.sante.fr/publications/mcj/donnees_mcj.html). Almost all vCJD patients to date 
have been found to be homozygous for methionine (Met) at codon 129 of the PRNP gene. 
Some scientists have predicted a multiphasic human BSE endemic with a second increase in 
the incidence of vCJD affecting people heterozygous at codon 129 of the PRNP gene assuming 
a 30-year mean incubation time210. Others believe the incidence of vCJD is subsiding211 (Fig. 
51). 
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Figure 51. BSE and vCJD cases reported worldwide. (a) Reported cases of bovine spongiform 
encephalopathy (BSE) in the United Kingdom (UK) (blue), and in countries excluding the UK (red). Non-
UK BSE cases include cases from countries both within and outside of the European Union (EU). Data 
are as of mid 2009. (b) Reported cases of variant Creutzfeldt-Jakob disease (vCJD) in the UK (blue) and 
in countries outside the UK (red). Non-UK vCJD cases include those reported in France, Republic of 
Ireland, Italy, United States, Canada, Saudi Arabia, Japan, the Netherlands, Portugal, and Spain. Data 
are as of December 2009 and include cases of vCJD in patients who resided in the UK in the 1980s or 
1990s (see the National Creutzfeldt-Jakob Disease Surveillance Unit Web site for vCJD data 
(http://www.cjd.ed.ac.uk/). Adapted and reprinted, with permission, from the Annual Review 
of Neuroscience, Volume 31 ©2008 by Annual Reviews. www.annualreviews.org. 
 
It is important to note, however, that the above considerations apply primarily to the 
epidemiology of primary transmission from cows to humans. By now, a pool of preclinically 
infected humans may have been built. Human-to-human transmission may present with 
characteristics very different from those of primary cow-to-human transmission, including 
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enhanced virulence, shortened incubation times, disregard allelic prion gene barriers, and 
unconventional modes of infection, including blood-borne transmission. Considering the time it 
will take to eradicate these secondary transmissions in the population, vCJD is not likely to 
disappear entirely in the coming four decades. 
Iatrogenic CJD is inadvertently transmitted during the course of medical or surgical 
procedures. The first documented case of iatrogenic prion transmission occurred in 1974 and 
was caused by corneal transplantation of a graft derived from a patient suffering from sCJD212. 
Iatrogenic CJD is also rare, most often observed in individuals that have received cadaveric 
dura mater implants and human growth hormone. Some of these individuals received 
gonadotrophin extracted from human pituitary glands or had stereotactically placed electrodes 
in their brains213. Four cases of vCJD transmission by blood transfusions have been reported 
recently in the United Kingdom214-216 (see also http://www.cjd.ed.ac.uk/TMER/TMER.htm) The 
fact that preclinically infected individuals can transmit vCJD underscores the important medical 
need for sensitive diagnostic tools, which could be used for screening blood units prior to 
transfusion, for example. 
Kuru. In the mid 1950s, when the remote parts of Papua New Guinea were first explored by 
Australians and Westerners, Kuru was first described in research217. Kuru was, at that time and 
at least since 1941, an endemic disease among some tribes of New Guinea aborigines, 
especially among the Fore linguistic group and neighboring tribes218. Kuru in the Fore language 
means “to shiver,” and along with other signs of cerebellar ataxia, shivering is a hallmark of the 
disease. The ritual consumption of dead relatives as a symbol of respect and mourning is the 
attributed route of transmission. As a consequence, the incidence has steadily fallen after 
cessation of cannibalism in Papua New Guinea210. In a concise and extremely clairvoyant 
observation published in 1959, Bill Hadlow noted the epidemiological, clinical, and 
neuropathological similarities between Kuru and scrapie219. These were followed up by Carleton 
Gajdusek who, in 1966, succeeded in transmitting Kuru to three chimpanzees220. Soon 
thereafter, serial passage of Kuru and of several other prion diseases was demonstrated in 
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chimpanzees and other primates221-222. Investigators have since transmitted human prion 
disease to various species, including laboratory rodents. 
Genetic CJD and Gerstmann-Sträussler-Scheinker syndrome. Several mutations in the 
prion protein gene (PRNP) have been found in families with hereditary or genetic CJD (gCJD). 
gCJD occurs with point mutations mostly affecting the region between the second and the third 
helix of the carboxy-terminus. However, insertions in the octarepeat region (OR) in the amino-
terminus, and even one instance of a premature termination codon at position 145, have also 
been associated with human prion disease. The inheritance was, in all cases, autosomal 
dominant, often with very high penetrance. The clinicopathological disease phenotype varies 
depending on the actual mutation, as well as on polymorphisms at codon 129, and most likely 
on a plethora of yet unidentified modifiers and cofactors223.  
The first descriptions of Gerstmann-Sträussler-Scheinker syndrome (GSS) originate from 1928 
and 1936 in an Austrian family224-225. In the following years, analogous disorders have been 
described, but its classification as a TSE lagged until 1981, when Masters and colleagues 
reported that inoculation of brain tissue from three patients with GSS resulted in spongiform 
encephalopathy in nonhuman primates226. The authors also defined clinical hallmarks of GSS 
(earlier age at onset, longer disease duration, and prominent cerebellar ataxia) differentiating 
the disease from CJD. Nowadays, GSS is considered an autosomal dominantly-inherited TSE 
caused by mutations in the prion protein open reading frame, manifesting typically with 
progressive cerebellar ataxia or spastic paraparesis and cognitive decline. In addition to the 
regions affected in gCJD, mutations altering the sequence of the central domain can cause 
GSS. Its distinctive neuropathological feature is the presence of widespread, large and 
multicentric amyloid plaques227. 
GSS is generally transmissible226, 228-229; therefore, its classification as a TSE is widely accepted. 
However, the overall experimental transmissibility of GSS to nonhuman primates and rodents is 
low. Only for the most common GSS-associated mutations (P102L), and only in approximately 
one third of the cases, were brain homogenates derived from patients reproducibly capable of 
inducing disease upon transmission230. The less frequent mutations causing GSS often failed to 
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induce disease after experimental transmission to nonhuman primates and rodents, and in 
many cases transmissibility was never assessed230-231. 
Fatal Familial Insomnia (FFI) is the descriptive name given to a disease identified in 1986. 
Five members of an Italian family presented with insomnia and dysautonomia232. In 1992, the 
disease-causing mutation in the prion protein gene (D178N) was identified, thereby allowing the 
classification of FFI as a genetically determined prion disease233. The final proof that FFI is a 
TSE was achieved when FFI was successfully transmitted to mice234. FFI typically affects the 
thalamus, and accordingly, the core clinical features are disruption of the normal sleep-wake 
cycle, sympathetic overactivity, endocrine abnormalities, and impaired attention227. In addition to 
the pathogenic point mutation D178N, the methionine-valine polymorphism at codon 129 of the 
PRNP gene controls the disease phenotype. Whereas D178N-129MM (homozygosity for 
methionine at codon 129) was associated with FFI, heterozygosity at codon 129 (D178N-
129MV) segregated with the familial CJD subtype235. However, Zarranz et al. reported more 
recently that this genotype-phenotype association is not absolute. In one study, several patients 
have been identified with a CJD phenotype and a D178N-129MM genotype. The authors 
concluded that rather than being separate disease entities, prion disease phenotypes such as 
FFI and CJD represent two extreme manifestations of a continuous disease spectrum236. In 
addition to the familial form of fatal insomnia, a sporadic form of the disease, termed sporadic 
fatal insomnia, was described, which is not associated with mutations in the PRNP gene237-238. 
 
6.1.2 Risk factors determining prion susceptibility 
The pivotal factors determining susceptibility to prion disease of the exposed population remain 
largely unknown. Presence of the cellular prion protein is certainly essential, since the absence 
of PrPC prevents disease in mice inoculated peripherally or intracerebrally with prions33, 35, yet 
PrPC expression alone is not sufficient to sustain prion replication239-240. Intensive research has 
been carried out to identify further risk factors, the major one being the Met/Val polymorphism at 
codon 129 of the PRNP gene241. Almost all vCJD patients to date have been found to be 
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homozygous for Met at this codon6, 242-243 and heterozygosity at codon 219 (219Glu/Lys) is 
associated with decreased risk of developing sCJD244.  
Much less is known about the non-genetic risk factors. Analyses of epidemiological data of 
different prion diseases, including scrapie, BSE, and vCJD suggested that the risk for TSEs 
may be age-dependent245-247, but no further non-genetic risk factors are known. It has been 
known for a long time that injections of the immunomodulatory glucocorticosteroid prednisone 
prolonged incubation time after intraperitoneal, but not intracerebral, injection of scrapie-infected 
brain homogenate248, suggesting that the lymphoid system acts as a “Trojan horse” instead of a 
defense mechanism during scrapie pathogenesis. Indeed, prion replication occurs in lymphoid 
tissues long before neuroinvasion and subsequent detection in the central nervous system 
(CNS)249. 
 
6.1.3 Immune system in prion diseases 
Within secondary lymphoid organs, follicular dendritic cells (FDCs) play a key role in peripheral 
prion replication and disease pathogenesis. FDCs located within germinal centers express high 
levels of PrPC and accumulate PrPSc (Ref 250). Maturation and maintenance of FDCs depend on 
tumor necrosis factor alpha (TNF-) and lymphotoxins (LT- and LT-). Mice lacking TNF-, 
complement components and their receptors, LT-, LT-, or LT- receptor are partially resistant 
to peripheral prion infection251-252. Mice treated with an inhibitor of LT--receptor signaling 
(LT-R-Ig) displayed a reversible dedifferentiation of FDCs. This leads to a decreased 
susceptibility to orally or intraperitoneally administered prions253-255. Accordingly, in inflammatory 
conditions, extravasating immune cells enable prion replication at the sites of chronic 
inflammation256-257 and may even lead to prion excretion258. Newborn mice whose immune 
system has not fully matured were shown to display a strongly reduced susceptibility to 
extracerebrally administered prions259. The increase in susceptibility with age correlated with the 
immunocytochemical detection of PrPC on maturing FDCs260.  
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Mature FDCs are unlikely to transport prions to peripheral nerve terminals. However, the relative 
distance between FDCs and peripheral nerves261, and PrPC expression in the peripheral 
nervous system262 determine prion neuroinvasion efficiency and onset of terminal disease. Also, 
sympathectomy delays or prevents scrapie following intraperitoneal prion inoculation263. The 
precise mechanisms of prion transport from prion replicating germinal centers to peripheral 
nerves remain elusive. While germinal center B-cells do not appreciably contribute to 
intrasplenic prion trafficking264-265, the identity of the crucial actuators of trafficking, be they 
hematopoietic or stromal cells, or even subcellular particles, remains to be determined. The 
presence of antigen presenting cells (APCs) was described to be a prerequisite for lympho- and 
neuroinvasion after peripheral prion infection266-270, although others have questioned their 
importance271.  
It was reported that repeated administration of CpG-containing oligodeoxynucleotides (CpG-
ODN) decreases the susceptibility to prions272. Since CpG-ODN activate the Toll-like receptor 9 
(TLR9), these surprising findings were interpreted as evidence that activation of the innate 
immune system may be protective against prions. However, subsequently it was found that 
repeated injections of CpG-ODN dramatically compromise morphology and functionality of 
murine lymphoid organs273. Due to the mechanisms discussed above, the immunosuppressive 
properties of CpG-ODN are much more likely to account for the reported antiprion effects than 
any conjectured immune activation274. 
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6.2 Scientific aims  
Since the immune system has an essential role in peripheral prion pathogenesis, I hypothesized 
that stimulation of the immune system might increase susceptibility to peripherally administered 
prions274.  
To test this, I first aimed at establishing an experimental protocol that leads to broad stimulation 
of both innate and adaptive components of the immune system for a protracted period of time. 
Subsequently, using the established protocol, I aimed at answering the question of whether 
susceptibility is increased in immunized compared to control wt mice following peripheral and/or 
central administration of prions.  
 
IMPACT OF IMMUNIZATION ON PRION SUSCEPTIBILITY 
 
108
6.3 Mice, material and methods 
6.3.1 Mice and scrapie inoculation 
Female wt (C57BL/6) mice were obtained from Harlan, NL and maintained under specific 
pathogen-free (SPF) conditions. Housing and experimental protocols were in accordance with 
the Swiss Animal Protection Law and mice were held in compliance with the regulations of the 
Veterinäramt, Kanton Zürich. Mice were infected intraperitoneally (i.p.) with 100 µl brain 
homogenate derived from terminally scrapie sick CD-1 mice, homogenized in PBS/0.32M 
sucrose, or intracerebrally (i.c.) with 30 µl brain homogenate. Different doses of prions derived 
from a RML6 infected terminally sick wt mouse were injected intraperitoneally (i.p.) or 
intracerebrally (i.c.) (i.p. doses: 0.33 ng, 10 ng, 300 ng; i.c. doses: 10 pg, 300 pg, 9 ng brain 
homogenate). Mice were euthanized at 0, 70 and 400 dpi or when terminally scrapie sick. 
 
6.3.2 Repetitive immunization 
Repetitive immunization was performed in female wt (C57BL/6) mice by repeated injections of 
CpG-ODN and BSA/alum. BSA was diluted in 200 μl of freshly prepared Al(OH)3 to a final 
concentration of 50 μg BSA per injection per mouse as described265. Intraperitoneal injections of 
either 30 µg CpG-ODN (Coley pharma, ODN 1826) or BSA/alum were performed as indicated in 
Fig.52, starting 6 weeks prior to prion inoculation. 
 
6.3.3 Western blot analysis and NaPTA precipitation 
Tissue homogenates (brain; spleen) were adjusted to 8 mg/ml protein, and treated with 
proteinase K (20-50 µg/ml, 30 min, 37°C). 50 µg of total protein was loaded onto a NuPAGE® 
Novex 12% Bis-Tris Gel (Invitrogen) and separated. Proteins were then transferred to 
nitrocellulose membrane (see below). For detection of PrPSc in spleen homogenates NaPTA 
(sodium phosphotungstic acid) precipitation was performed. 10% spleen homogenates were 
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prepared in PBS on ice. Cellular debris was removed by centrifugation at 500 g for 1-2 min. The 
resulting supernatant was adjusted to 500 μl with PBS, and mixed 1:1 with 4% Sarkosyl in PBS. 
Samples were incubated for 15 min at 37°C under constant agitation. Benzonase and MgCl2 
were added to a final concentration of 50 U/ml and 1 mM respectively, and incubated for 30 min 
at 37°C under continuous agitation. Further, samples were digested with 30 µg/ml proteinase K 
(PK) for 60 min at 37°C with agitation and pre-warmed NaPTA stock solution (pH 7.4) was 
added to a final concentration of 0.3% and the sample was incubated at 37°C for 30 min with 
shaking, followed by centrifugation at 37°C for 30 min at 14.000 g in an Eppendorf 
microcentrifuge. The pellet was resuspended in 30 µl 0.1% Sarkosyl in PBS and the sample 
was heated at 95°C for 5 min in SDS-containing loading buffer before loading onto NuPAGE® 
Novex 12% Bis-Tris Gel (Invitrogen). All gels were transferred to nitrocellulose (Schleicher & 
Schuell) using XCell II Blot Module (Invitrogen). Membranes were blocked with TBST containing 
5% non-fat milk, decorated with monoclonal antibody POM1144, 275 followed by incubation with 
the secondary anti-mouse IgG1 (Zymed) and visualized by enhanced chemiluminescence (ECL, 
Socochim, Pierce).  
 
6.3.4 Histology, immunohistochemistry, and histoblot 
Paraffin sections (2 µm) and frozen sections (5 or 10 µm) of various organs were stained with 
hematoxylin-eosin. Antibodies raised against the following antigens were used for 
immunohistochemistry: FDC-M1 (Mfge8) for mature FDCs (clone 4C11; 1:50; Becton 
Dickinson), B220/CD45R for B-cells (Pharmingen; 1:400), CD35 for CR1 (clone 8C12, 
Pharmingen, San Diego, CA; 1:100), CD3 for T-cells (clone SP7, NeoMarkers; 1:300), F4/80 for 
macrophages (Serotec; 1:50), PNA for germinal center B-cells (Vector L-1070; 1:100), MOMA-1 
for metallophilic marginal zone macrophages (BMA, Augst, Swizerland; 1:50), GFAP for 
astrocytes (DAKO, Carpinteris, CA; 1:300), and Iba-1 for microglia (WAKO; 1:2500).  
PrP stains were performed on formalin-fixed brain tissues treated with concentrated formic acid 
to inactivate prions and postfixed again in formalin. Subsequently, tissues were embedded in 
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paraffin. After deparaffination, sections (2 m) were incubated for 6 min in 98% formic acid and 
washed in distilled water for 30 min. Sections were heated to 100°C in a steamer in citrate 
buffer (pH 6.0) for 3 min, and allowed to cool down to room temperature. Sections were 
incubated in Ventana buffer and stains were performed on a NEXES immunohistochemistry 
robot (Ventana instruments, Switzerland) using an IVIEW DAB Detection Kit (Ventana). After 
incubation with protease 1 (Ventana) for 16 min, sections were incubated with anti-PrP SAF-84 
(SPI bio; 1:200) for 32 min. Sections were counterstained with hematoxylin. Histoblot analysis 
was performed as described276. Image acquisition was performed on an Axiophot-microscope 
(Zeiss) equipped with a JVC digital camera (KY-F70; 3CCD).  
 
6.3.5 In situ hybridization 
Digoxigenin (DIG)-labeled Mfge8 riboprobe was obtained by transcription of pBluescript II KS+ 
(Stratagene) containing the open reading frame of Mfge8 and using a DIG RNA labeling kit 
(Roche). ISH was performed on spleen cryosections. Sections were fixed in 4% 
paraformaldehyde PBS, followed by acetylation. After prehybridization, 200 ng/ml of DIG-
labeled RNA probe was added to the hybridization buffer and incubated at 72°C overnight. DIG-
labeled probes were detected by anti-DIG–alkaline phosphatase Fab-fragments (Roche). Cell 
nuclei were stained with DAPI (4',6-Diamidine-2'-phenylindole dihydrochloride; Roche). For 
more information see also chapter 5.3.10. 
 
6.3.6 RNA isolation from spleen and real-time PCR analysis 
RNA isolation buffer (RLT; Qiagen) was added to flash frozen spleens prior to homogenization 
(Medic tools). RNA was purified using RNeasy (Qiagen) as described by the manufacturer. 
Synthesis of cDNA was performed with QuantiTect, Reverse Transcription kit (Qiagen). 
Samples were analyzed by real-time PCR using QuantiFast SYBR Green PCR kit (Qiagen) and 
7900HT (Fast Real-Time PCR systems; Applied Biosystems). The following primer 
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combinations were used [forward primer (FW), reverse primer (RV)]: Mfge8 FW: 5’-ATA TGG 
GTT TCA TGG GCT TG-3’; Mfge8 RV: 5’-GAG GCT GTA AGC CAC CTT GA-3’; GAPDH FW: 
5’-CCA CCC CAG CAA GGA GAC-3’; GAPDH RV: 5’- GAA ATT GTG AGG GAG ATG CT-3’ 
 
6.3.7 PrPC sandwich ELISA 
96-well plates were coated with 20 ng of purified POM1 antibody overnight at 4°C. Plates were 
washed with PBS containing 0.1% (vol/vol) Tween 20 (PBST), and blocked with 5% Top-Block 
(Fluka) in TBST for 2 h at room temperature (RT). After washing, plates were incubated with 50 
µl of spleen homogenates containing 500 µg/ml total protein in sample buffer (1% Top block in 
PBST). The total protein concentrations of the spleen homogenates were determined using a 
standard colorimetric assay based on bicinchoninic acid (BCA, Pierce). Each sample was 
analyzed in triplicates. For the standard curve, serially diluted recombinant mouse PrP23-230 in 
PBST containing 1% Top Block was used. After 1 h at RT plates were washed extensively and 
then probed with biotinylated POM2144, 275 at a concentration of 200 ng/ml in PBST containing 
1% Top Block, for 1 h at room temperature. After washing, plates were incubated with 
horseradish peroxidase conjugated Avidin (1:1000 dilution, BD-Pharmingen) for 1 h at RT. 
Plates were developed with Stabilized Chromogen SB02 (Biosource). The chromogenic 
reaction was stopped by adding the same volume of 0.5 M H2SO4. Optical density was 
measured at 405 nm. The PrPC concentration in each sample was calculated according to a 
standard curve derived from the values of recombinant PrP. 
 
6.3.8 Fluorochrome labeling 
1 mg of Cy5 NHS ester (Amersham Biosciences; Cat. No. PA15101) was dissolved in 1 ml 
(conc. 1 mg/ml) water-free DMSO. 1 ml of the POM2 antibody144, 275 (conc. 2 mg/ml) and of 0.5 
M borate buffer (pH 8.0) leading to an antibody concentration of 1.81 mg/ml. 2 mg POM2 (1.1 
ml) were used for the labelling reaction (Dye/antibody ratio = 2.5/1). 2 mg POM2 were mixed 
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with 24.80 ml of Cy5 dye (31.25 nmol). The Cy5 dye was added to the antibody while vortexing 
and further on incubated under permanent agitation for 1 h at RT (light protected). The 
unincorporated Cy5 dye was removed in a size-exclusion column and the labeled antibody was 
dialyzed against 2 l of PBS over night. 
 
6.3.9 Flow cytometric analysis 
Splenic cells or blood cells were isolated and incubated with primary antibodies: POM2-Cy5 
(1:250), FITC- or PE-labeled anti-CD11b antibody, FITC- or PE-labeled anti-CD11c antibody, 
PE-labeled anti-CD19 antibody, FITC-labeled anti-B220 antibody, PE-labeled anti-Ly6G 
antibody, PE-labeled anti-CD8, PE-labeled anti-CD3 antibody (all 1:100, Pharmingen), PerCP-
labeled anti-CD4 (1:750), or FITC-labeled anti-CD21 and PE-labeled anti-CD23 (1:100 and 
1:250, respectively). Erythrocyte lysis was performed using BD FACSTM Lysing Solution. Cells 
were washed with PBS containing 2% FCS and live gated blood cells were further analyzed 
with a flow cytometer (DAKO or BD Biosciences) and FlowJow software program. 
 
IMPACT OF IMMUNIZATION ON PRION SUSCEPTIBILITY 
 
113
6.4 Results 
6.4.1 Stimulation of the immune system by repetitive immunization  
Starting 6 weeks prior to prion inoculation, wt mice (C57BL/6) were immunized and repeatedly 
boosted with generic antigens unrelated to prions, with the goal of achieving sustained 
activation of immune cells and activation-related morphological changes within lymphoreticular 
organs. A mixture of CpG-ODN, bovine serum albumin (BSA) and alum was repeatedly injected 
intraperitoneally during a period of two weeks (Fig. 52). For the following two weeks, treatment 
was suspended in order to prevent damage to secondary lymphoid organs, as observed 
following long-term administration of CpG-ODN (data not shown). Mice were then injected every 
other week for 20 weeks with BSA/alum.  
 
 
 
 
 
 
Figure 52: Treatment scheme for immunization. Arrows denote the time points of injections of CpG 
oligodeoxynucleotides and bovine serum albumin (BSA). Treatment included an induction (-6 to -4 
weeks) and a maintenance phase (-2 to +18 weeks). 
 
 
At the time point of prion inoculation, selected animals were sacrificed to evaluate organs and 
blood for histological, cytological, and biochemical evidence of immune stimulation or 
inflammation. Compared to age and gender-matched, non-immunized wt controls, immunized 
animals displayed typical features of immune stimulation. Spleens of immunized mice were 
significantly heavier, yet the concentration of splenic PrPC (weight/weight) remained unchanged 
(Fig. 53a), indicating that the total amount of splenic PrPC was increased. In peripheral blood, 
chronic immunization resulted in significantly elevated cell counts of erythrocytes, neutrophils, 
and monocytes. Lymphocyte counts were marginally increased but did not reach statistical 
significance (Fig. 53b). I investigated serum levels of various cytokines. IL-6 was elevated in 
immunized mice, whereas IL-12 (p70) was reduced and IL-1 was unaltered.  
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IFN- was also increased though not significantly (Fig. 53c), TNF- was below detection limit in 
all animals analyzed (data not shown). 
  
Figure 53: Repetitive immunization of wt mice. (a-d) Selected immunized (i) and non- immunized mice 
(ni) sacrificed at the time point of prion inoculation. (a) Relative spleen weight and splenic PrPC levels as 
determined by ELISA. Prnp-/- spleen served as negative, tga20 spleen as positive control. Hematological 
cell counts (b), serum levels of selected cytokines (c), and blood chemistry (d) (AP: alkaline phosphatase; 
ASAT: aspartate amino transferase; GLDH: glutamate dehydrogenase; ALAT: alanine amino transferase) 
showed mild polyglobulia, leukocytosis, and mild liver damage in immunized mice. Unpaired t-tests: (*) 
p < 0.05; (***) p = 0.001; (n.s.) not significantly different. 
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Splenic white pulp follicles appeared more densely packed upon immunization (3.78 ± 0.31 and 
7.89 ± 2.71 follicles/mm2 in histological sections of non-immunized mice and immunized mice, 
respectively; p=0.029). Immunized mice showed a significant increase in density and size of 
PNA+ germinal centers and Mfge8+ follicular dendritic cell networks in spleens. In addition, I 
observed a loosening of MOMA-1+ metallophilic macrophage festoons in the marginal zone 
following immunization as described previously273 (Fig. 54). Marginal zones were also broader 
in B220 and CD21/35 immunostains. Accordingly, flow cytometry of splenocytes showed a 
higher percentage of CD21/35+CD23- marginal zone B-cells in immunized mice than in control 
mice (Fig.55).  
Mfge8 transcription is not only confined to germinal centers, but also occurs in cells located in 
the marginal zone which were suggested to represent FDC precursors 277. However, in situ 
hybridization did not identify any differences in Mfge8+ cells residing within the marginal zones 
of immunized and control mice (Fig. 56). Instead, immunization increased the prevalence of 
splenic GR1/Ly6g+ granulocytes, as verified by immunohistochemistry and flow cytometry (Fig. 
54-55), and increased the number of CD68+ macrophages in splenic white pulp follicles (Fig. 
54). In contrast, the number of splenic CD11b+ and CD11c+ cells was unaffected (Fig. 55). 
Although total splenic PrPC protein concentration was unaltered, flow cytometry revealed a 
slight, yet significant increase in PrPC surface expression by splenic B220+ and CD4+ cells (Fig. 
55).  
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Figure 54: Splenic histology of immunized mice. (a) Spleens of non-immunized and immunized mice 
were analyzed at the time point of inoculation by histology with hematoxylin-eosin (HE) and 
immunohistochemistry for B-cells (B220), complement receptors (CD21/35), metallophilic marginal zone 
macrophages (MOMA-1), granulocytes (Ly6g), germinal center B-cells (PNA), FDCs (Mfge8), 
macrophages (CD68), and T-cells (CD3). The overall splenic microarchitecture was preserved. 
Immunized mice showed broader marginal zones, some loosening of splenic MOMA-1+ metallophilic 
marginal zone macrophage festoons and a reduction of the density of MOMA-1+ cells compared to non-
immunized animals. Following immunization, granulocytes (Ly6g) in the red pulp and macrophages 
(CD68) in the white pulp (indicated by dashed lines) were increased. (b) Densities and size of PNA+ 
germinal center B-cells and FDC networks (Mfge8) were also increased in immunized mice. Scale bars: 
100 m. Statistics were performed using unpaired t-test, two-tailed.  
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Figure 55: Splenic cell populations in immunized mice. Splenic cells were isolated and co-stained for 
PrPC and B220, CD4, CD8, GR1, CD11c, or CD11b; alternatively co-staining for CD21/35 and CD23 was 
performed. Results from representative samples are shown. Four mice per group were analyzed. 
Numbers in the diagram indicate average percentages of cells ± standard deviation. Statistical analysis 
was performed using unpaired t-test, two-tailed. Significantly different percentages are labeled in the right 
lower scattergram with (*) p < 0.05; (**) p < 0.01; or (***) p < 0.001. 
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Figure 56: In situ hybridization for Mfge8 mRNA. Spleens of non-immunized and immunized mice 
were analyzed at the time point of inoculation by in situ hybridization for Mfge8 mRNA. Consecutive 
sections were hybridized with Mfge8 antisense (AS) and control sense probe (S) as well as DAPI stains. 
Scale bar = 100 m. 
 
Histological analysis of mesenteric lymph nodes (MLNs) showed a trend towards increased 
numbers of lymphoid follicles (non-immunized mice: 6 ± 2.31; immunized mice: 11.75 ± 1.44 
follicles/ lymph node section, p=0.11; Fig. 57a). Furthermore, histology showed that immunized 
mice had a normal architecture of lung, heart, kidney, and pancreas, yet developed lobular 
hepatitis with loss of hepatocytes and multifocal infiltrates of lymphocytes, macrophages, 
eosinophils, and neutrophils (Fig. 57b and data not shown). Hepatocellular damage was 
confirmed by elevation of the liver enzymes glutamate dehydrogenase (GLDH) and aspartate 
amino transferase (ASAT; Fig. 53d). Hepatitis might be explained by the hepatotoxic effects of 
IL-6, which was increased in serum of immunized mice as previously reported278. 
Serum amylase and alkaline phosphatase (AP) levels were normal (Fig. 53d), suggesting that 
there was no damage to the exocrine pancreas and the bile ducts. Finally, immunization 
induced a mild peritonitis with macrophages and lymphocytes in the peritoneum (Fig. 57c). 
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Figure 57: Various organs at the time point of inoculation. (a) Stains and immunohistochemistry on 
mesenteric lymph nodes (MLNs): HE, B-cells (B220), germinal center B cells and FDCs (CD21/35), FDCs 
(Mfge8), germinal centers (PNA) and metallophilic marginal zone macrophages (MOMA-1). (b) Lung, 
kidney, pancreas show normal architecture. Lobular hepatitis in immunized mice: loss of hepatocytes, 
and infiltrates of T cells (CD3), macrophages (F4/80), eosinophils, and neutrophils. (c) Peritonitis in 
immunized mice: T-cells (CD3), and macrophages (F4/80) infiltrating peritoneum. Scale bars = 100 m. 
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6.4.2 Increased prion susceptibility in immunized mice 
Groups of mice (4 ≤ n ≤ 16) were inoculated intraperitoneally (i.p.) or intracerebrally (i.c.) with 
low, medium or high doses of prion infectivity. Upon i.p. inoculation with 10 ng of RML6 brain 
homogenate, 8 of 16 immunized mice (50%) succumbed to scrapie at 223 ± 8.2 days post 
inoculation (dpi). When exposed to the same dose of prions, non-immunized animals (n=16) 
remained scrapie-free for >500 dpi (Fig. 58).  
 
 
Figure 58: Survival of immunized (i) and non-immunized (ni) mice inoculated intraperitoneally (i.p.) 
or intracerebrally (i.c.) with prions. While all mice inoculated i.p. or i.c. with a low dose of prions (0.33 
ng i.p. or 10 pg i.c. RML6 brain homogenate; left panel) survived until 500 dpi, all mice inoculated i.c. with 
a high dose of prions (9 ng; right lower panel) died of scrapie. Seven of 8 mice (87.5%) inoculated i.p. 
with a high dose of prions (300 ng) succumbed to scrapie independently of immunization (right upper 
panel). In the medium dose group (10 ng i.p. or 300 pg i.c.; medium panels) there was no difference in 
survival rates in i.c. inoculated mice (75% in both groups). While non-immunized mice inoculated i.p. with 
a medium dose of prions remained healthy, 50% of the immunized mice developed scrapie. Intercurrent 
deaths (not scrapie-associated) occurred > 400 dpi; time points are marked with a star above the curve. 
All brains of mice dying without clinical signs of scrapie were tested by Western blot and did not contain 
PrPSc (data not shown). 
 
This difference in survival was highly significant (p=0.0024, Fisher's exact test) and could have 
two non-exclusive explanations: 1) immunization may increase the accumulation, spread, 
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and/or propagation of prions, or 2) immunization may promote the progression of subclinical 
infection to clinically overt disease. To study the latter possibility, I investigated non-immunized 
mice that had received the same dose of peripherally administered prions (10 ng) for subclinical 
signs of prion infection at 400 dpi. Non-immunized mice did not display PrPSc in brains and 
spleens, nor did they show any histological signs of prion disease such as astrogliosis and 
microglial activation (Figs. 58-60). In addition, I observed no difference in the time intervening 
between onset of clinical signs and development of terminal scrapie (data not shown). 
Therefore, repeated immunization of wt mice increased the susceptibility to prion diseases by 
modulating prion accumulation, spread, and/or propagation rather than by simply affecting the 
onset of clinical signs. 
While inducing scrapie in immunized mice, the dose of prion inoculum utilized in the previous 
experimental series was insufficient to establish infection in non-immunized mice. I next tested 
the effect of administering a dose that would induce a 100% attack rate in non-immunized mice. 
I inoculated immunized and non-immunized mice i.p. with a 30-fold higher dose of prions (300 
ng RML6 brain homogenate). No difference in the percentage of mice succumbing to disease 
was observed: 7 of 8 mice in both groups (87.5%; Fisher's exact test p=1.0) developed terminal 
scrapie. This indicates that immunization selectively lowers the size of the minimal infectious 
dose, while it does not change the course of the disease when larger doses are administered. 
Accordingly, the incubation times in non-immunized (219 ± 5.7 dpi; n=8) and in immunized mice 
(217 ± 10.3 dpi; n=8) inoculated with the highest dose were similar to those in immunized mice 
that had received the medium dose (223 ± 8.2 dpi, n=16; ANOVA p=0.3). Therefore, stimulation 
of the immune system by repeated immunization does not accelerate the general progression of 
the disease, but rather renders mice susceptible to amounts of peripherally administered prions 
that would be innocuous to non-immunized wt mice. 
I suspected that alterations in lymphoid organs mediate the observed differences in 
susceptibility. As these events are not thought to be relevant to CNS prion pathogenesis, I 
expected that the difference in susceptibility would be abolished in immunized versus non-
immunized mice inoculated i.c. with prions. The injection of 300 pg RML6 brain homogenate 
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caused disease in 2 of 8 mice (25%) in both groups. Survival curves did not significantly differ 
(logrank test, p=1). A 30-fold higher prion dose (9 ng RML6 brain homogenate) inoculated i.c. 
elicited an attack rate of 4 of 4 (100%) in both groups. Although immunization of wt mice 
strongly increased prion susceptibility to i.p. administered prions, prion susceptibility remained 
unchanged after i.c. inoculation. This emphasizes the role of peripheral immune system 
components in determining prion susceptibility. Despite the absence of differential susceptibility, 
there were slight differences in the incubation times at high and medium dose of prion 
challenge. However, in both instances these differences were not statistically significant (high 
dose: 9 ng i.c.; non-immunized: 222 ± 32.8 dpi; immunized: 194 ± 17.4 dpi, unpaired t-test 
p=0.18; medium dose: 300 pg i.c.; non-immunized: 246/258 dpi; immunized: 229/244 dpi).  
I then inoculated immunized and naïve mice i.p. with 0.33 ng RML6 homogenate, or i.c. with 10 
pg RML6 homogenate. None of these mice (immunized or naive) developed scrapie or 
neurological signs up to 500 dpi. These data and the absence of astrogliosis and microglia 
activation in brains of the non-immunized mice (10 ng i.p. at 400 dpi) described above argues 
against any neurotoxic effects of BSA/alum/CpG-ODN. 
 
6.4.3 PrPSc distribution patterns and histopathological features in terminally 
scrapie-sick mice 
Brains of all mice developing clinical signs of scrapie were investigated for histological features 
of prion disease, including astrogliosis, spongiosis, PrP deposition and microglial activation 
(Fig. 59). There were no differences in these histological hallmarks of scrapie. In contrast, those 
non-immunized mice (n=4) inoculated i.p. with prions (10 ng RML6 brain homogenate) that 
remained healthy lacked any histological features of prion disease at 400 dpi. Although the 
SAF84 antibody is commonly used to detect PrP aggregates, it is not specific for PrPSc. 
Therefore, in addition I investigated brains by histoblot (Fig. 59) and immunoblot (Fig. 60). Both 
techniques demonstrated the presence of PrPSc in all clinically scrapie-sick mice.  
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Figure 59: Brain pathology of terminally sick or asymptomatic mice. Immunized (i) and non-
immunized mice (ni) inoculated intracerebrally (i.c.) or intraperitoneally (i.p.) with medium or high dose of 
prions were analyzed by histology. HE stains and immunohistochemistry were performed as indicated: 
astrocytes (GFAP), microglia (Iba1), PrP deposits (SAF84), showing astrogliosis, microglia activation, and 
prion protein deposition in terminally sick mice from each of the experimental groups. Histoblot analyses 
detected PrPSc in the brains of all terminally sick mice with similar distribution patterns. Non-immunized 
mice inoculated i.p. with a medium dose of prions remained healthy up to 500 dpi, and displayed much 
less GFAP+ astrocytes and Iba1+ microglia cells, and lacked both PrP deposits (SAF84) and PrPSc 
(histoblot) at 400 dpi. Scale bars: histoblot = 1 mm; histology = 100 m. 
 
Similarly, spleens of terminally sick mice were investigated histologically and biochemically by 
histoblot and immunoblot. There was no difference in splenic histology of immunized mice 
compared to control (Fig. 61a), and PrPSc deposition pattern (Fig. 61b). Furthermore, I could 
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not detect an overt difference in the PrPSc deposition as determined by immunoblot (Fig. 61c). 
As in brains, PrPSc was not detectable in spleens of healthy non-immunized mice at 400 dpi 
(n=4) that had received 10 ng RML6 brain homogenate i.p. (Fig. 61b-c). 
 
 
Figure 60: PrPSc in brains of terminally sick or asymptomatic mice. Immunized (i) and non-
immunized mice (ni) inoculated (a) intraperitoneally (i.p.) or (b) intracerebrally (i.c.) with medium or high 
doses of prions were analyzed by Western blots for the presence of PrPSc. Brain homogenates were 
analyzed with (+) and without (-) previous proteinase K (PK) treatment as indicated. Homogenate derived 
from a terminally scrapie-sick mouse served as positive control (pos ctr), and healthy wt mouse tissue as 
negative control (neg ctr), respectively. Molecular weights are indicated on the left side of the blots. All 
terminally sick mice showed considerable amounts of PrPSc in the brain. In contrast, non-immunized mice 
inoculated i.p. with a medium dose of prions [i.p. medium (ni)] lacked PrPSc. 
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Figure 61: Histology, histoblots, and Western blots of spleens from terminally sick or 
asymptomatic mice. (a) Spleens of immunized (i) and non-immunized mice (ni) inoculated 
intraperitoneally (i.p.) with medium or high dose of prions were analyzed by histology. Histological and 
immunohistochemical stains were performed as indicated. MOMA-1+ cells were reduced in immunized 
mice. All terminally sick mice of the various experimental groups carried PrPSc in their spleens as shown 
by histoblot (b) and confirmed by Western Blot (c). Asymptomatic, non-immunized mice inoculated i.p. 
with a medium dose of prions [i.p. medium (ni)] were killed at 400 dpi. No PrPSc was detectable by 
histoblot analysis (b) and Western blot analysis (c). Controls and abbreviations are as in Fig. 60. Scale 
bars: histoblot = 1 mm; histology = 200 m. 
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6.4.4 No difference in splenic PrPSc deposition at 70 dpi 
At 70 dpi there was no difference in PrPSc load in spleens of immunized mice vs. non-
immunized controls. PrPSc was detectable after sodium phosphotungstic acid (NaPTA) 
precipitation in spleens of 1 of 4 immunized mice and of 1 of 4 non-immunized mice (Fig. 62a). 
The early presence of PrPSc in spleens (at 70 dpi) did not correlate with the observed difference 
in prion susceptibility. PrPSc was below the limit of detection of the NaPTA immunoblot 
technique in mesenteric lymph nodes of non-immunized and immunized mice at 70 dpi (Fig. 
62a). Since it was previously reported that immune stimulation might increase expression levels 
of PrPC on blood cells279, I further analyzed PrP expression and cellular blood composition by 
flow cytometry analysis. There was no significant increase of PrP on CD19+ B-cells, CD3+ T-
cells, or CD11b+/CD11c+ monocytes in immunized vs. non-immunized mice. However, the 
overall PrP expression on all live-gated blood cells was slightly increased in immunized vs. non-
immunized mice, but this trend was not significant (immunized: 30.4 ± 2.81% of PrP positive 
white blood cells; non-immunized: 25.3 ± 1.57%; unpaired t-test p=0.12, values in 
mean ± standard error of the mean; Fig. 62b and data not shown). 
I did observe a significant increase in PrP signal on live-gated blood cells in prion infected mice 
(immunized and non-immunized: 27.9 ± 1.6% of PrP positive white blood cells) compared to 
non-inoculated, naive mice (16.6 ± 1.8%; unpaired t-test p<0.002; Fig. 62b and data not 
shown). This rise in PrP signal can either be attributed to increased protein expression, 
decreased turn-over, or possibly accumulation of PrPSc on blood cells. As previously shown by 
hematology, there was no significant difference in the percentage of blood lymphocytes. 
However, there was a trend towards an increase of CD19+ B-cells in immunized, vs. non-
immunized mice (Fig. 62b). 
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Figure 62: PrP in spleens, mesenteric lymph nodes (MLNs), and on blood cells of inoculated mice 
at 70 dpi. Mice were inoculated i.p. with a medium dose of prions and analyzed at 70 dpi. (a) NaPTA-
enhanced Western blots of spleen and MLN homogenates. I detected PrPSc in spleens of 1 of 4 mice in 
both, the immunized (i) and non-immunized (ni) group. Controls and abbreviations are as in Fig. 60. No 
PrPSc deposition was detectable in MLNs of the same mice by NaPTA-enhanced Western blotting. (b) 
Flow cytometry analysis of white blood cells from immunized and non-immunized mice inoculated i.p. with 
prions, as well as noninoculated, non-immunized “naive” mice. Co-staining for PrP (Cy5-labeled POM2 
antibody) and CD19 (PE-labeled anti-CD19 antibody) in representative samples. Four mice per group 
were analyzed. Numbers in the diagram indicate averages (as percentages) ± standard deviation. Blood 
from a PrP deficient mouse (Prnp-/-) served as negative control. 
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6.5 Discussion 
6.5.1 Immunization with CpG and BSA/alum enhances prion susceptibility 
The outcome of encounters between a pathogen and its host is determined by two sets of 
parameters: the intrinsic virulence of the pathogen and the susceptibility of the host. 
Susceptibility is a measure of the likelihood to contract disease after exposure to a defined 
inoculum of a given pathogen. In addition to host-intrinsic modifiers, susceptibility to most 
pathogens is profoundly influenced by exogenous cofactors. Whereas immunodeficiencies 
greatly increase susceptibility to most conventional pathogens, theoretical considerations 
prompted me to investigate whether susceptibility to prions may be enhanced by stimulation of 
the immune system. Indeed, I have identified controlled, repetitive immunization as an important 
host factor that dramatically increases the susceptibility to peripherally administered prions. 
Following injection of a low dose of prions, 50% of the immunized mice developed scrapie while 
all non-immunized mice remained scrapie-free for > 500 dpi. 
In most instances, the likelihood of survival after exposure to infectious agents or poisons is 
normally distributed, and therefore cumulative dose-survival curves display sigmoidal responses 
with subthreshold doses failing to elicit disease and high doses plateauing towards maximal 
effects. As a consequence, variations in host susceptibility are typically visible only within a 
limited range of doses. Here, I tested three different doses of prions in immunized and non-
immunized mice. The lowest dose led to 100% survival, whereas the highest dose led to 12.5% 
(i.p.) and 0% (i.c.) survival, in both groups. The medium dose of intraperitoneally administered 
prions was associated with an attack rate of 50% in immunized mice only, which nominally 
corresponds to one LD50 unit (dose causing death in 50% of the exposed hosts) and to the 
turning point of the postulated sigmoid response curve. Therefore, in this paradigm, the medium 
dose allowed for optimal sensitivity in the identification of immunization as a factor altering prion 
susceptibility.  
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6.5.2 Impact of other immue activating conditions on prion diseases  
Treatment with complete Freund's adjuvant (CFA) was reported to prolong survival of prion-
inoculated mice, irrespective of whether the challenge was i.c. or i.p.280. These results implied 
that CFA treatment might have a therapeutic effect in experimental scrapie, possibly by 
reducing the rate of PrPSc accumulation in the brain. In my experiments I did not detect any 
influence on susceptibility to i.c. administered prions, and a sensitizing effect after peripheral 
prion administration. Possible explanations for this discrepancy are (1) the different agents and 
protocols (site of injection, frequency) used for immunization and (2) the different titers of prion 
inocula applied.  
Another study reported that transient systemic inflammation induced by i.p. administration of 
LPS acutely exacerbates cognitive and motor symptoms after inoculation with the mouse-
adapted ovine prion strain Me7 and accelerates disease progression281. Accordingly, I found 
that immunized mice inoculated i.c. with prions became terminally sick slightly earlier than 
controls. Although I investigated the influence of other immunizing agents on another prion 
strain, my finding might well be explained by an acceleration of disease progression, as 
suggested281. In contrast, I focused on differences in disease susceptibility rather than disease 
onset and progression.  
Another study investigated the impact on experimental autoimmune encephalomyelitis (EAE) on 
prion susceptibility and incubation time. Increased prion susceptibility was observed after low 
dose i.c. inoculation282, whereas I could not observe any change in prion susceptibility after low 
dose i.c. inoculation. This may point to additional EAE-related effects on prion transport, e.g. 
disturbance of the blood-brain barrier.  
It was previously reported that susceptibility of mice to BSE and RML5 prions is not affected by 
the activation of dendritic cells271. Also, it was found that chronic lymphofollicular inflammation of 
kidney, pancreas, and liver did not overtly alter susceptibility256. However, in all of these studies 
the scrapie attack rates were 100% in both the experimental and the control groups of mice, 
suggesting that the size of the prion inocula have precluded the sensitive detection of 
susceptibility shifts. This interpretation is congruent with my finding of indistinguishable attack 
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rates in non-immunized and immunized mice peripherally exposed to a relatively large inoculum 
(300 ng of brain homogenate).  
It had been previously reported that repeated injection of CpG-ODN protects mice from prion 
infections272, suggesting beneficial effects of immune hyperactivity on prion susceptibility, but 
this treatment was subsequently found to disturb microarchitecture and functionality of lymphoid 
organs273. Therefore, the interpretation of the current findings crucially relies on the integrity of 
the immune system. Indeed, histology, hematology, and serum chemistry failed to identify 
immuno-suppressive consequences of the herein described treatment. My data add weight to 
the conjecture that immunization increases susceptibility to prions and that the previously 
described protective effects were caused by immuno-disruption rather than by stimulation of the 
immune system. 
 
6.5.3 How might immunization enhance prion susceptibility? 
The increased susceptibility of immunized mice was restricted to peripheral prion exposure and 
was not observed after i.c. prion inoculation. Evidently, immune modulation affects the speed 
and/or the extent of prion replication outside but not within the CNS. This suggests that CNS 
cells are constitutively competent for prion replication, whereas peripheral sites (which may 
comprise not only lymphoid compartments but also e.g. peripheral nerves) appear to be 
susceptible to immunological modifiers.  
The precise mechanisms by which repetitive immunization increases prion susceptibility remain 
unknown. Any of the steps involved in peripheral prion spread, including transfer of prions to 
lymphoid tissues, prion accumulation and propagation within lymphoid tissues, and prion 
transfer from lymphoid tissues to structures of the nervous system, might be affected by 
immunization.  
The kinetics of PrPSc accumulation in lymphatic organs might arguably play an important role in 
susceptibility to peripheral prion administration. While all terminally sick mice carried PrPSc in 
the spleen, PrPSc was undetectable in spleens of all mice that remained healthy. At early time 
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points (70 dpi), before neuroinvasion had taken place35, there was no difference in splenic PrPSc 
load. Hence, chronic inflammation determines the susceptibility towards prions by a mechanism 
that is independent of the early splenic PrPSc accumulation. Also, the absence of PrPSc from 
MLNs at 70 dpi suggests that at least in early stages of disease, and under the conditions 
studied here, MLNs do not play an essential role in prion pathogenesis.  
The absence of PrPSc from spleens at ≥400 dpi despite its presence at earlier stages suggests 
the existence of a splenic prion clearance mechanism. Maybe repetitive immunization of the 
immune system facilitates neuroinvasion by reducing splenic prion clearance. The reduced 
numbers of MOMA-1+ marginal zone macrophages in immunized mice could contribute to an 
inhibited prion clearance. MOMA-1+ cells play an important role in capturing blood borne 
antigens283. Involvement of splenic macrophages in prion clearance in the early phase of 
infection has been reported, and it was even proposed that marginal zone macrophages are 
critically involved in this process 284. This suggests that a decreased prion uptake by MOMA-1+ 
cells might lead to a more efficient prion translocation into germinal centers in immunized mice 
in my study. In this context, it has previously been suggested that CpG-ODN treatment inhibits 
prion clearance by microglial cells in vitro279. 
I have found an increase in marginal zone B-cells in immunized mice. It is conceivable that 
alterations in the number of marginal zone B-cells in combination with a decreased number of 
MOMA-1+ cells might enhance prion uptake into the germinal centers, thereby influencing prion 
susceptibility. APCs were proposed to either support prion clearance or to accomplish prion 
transport266-271. Immunohistochemical as well as flow cytometry analysis of blood and spleen 
from immunized mice did not reveal a significant change of CD11c+ or CD11b+ APCs. 
Therefore, it is very unlikely that quantitative changes in APCs would contribute to the observed 
increase in prion susceptibility.  
FDCs play an important role in prion replication and are known to co-localize with PrPSc. In my 
study, there was an increase in size and density of FDC networks following immunization. This 
might well explain the increased susceptibility in immunized mice. Alternatively, chronic 
stimulation of the immune system may alter the transfer of prions from lymphoid organs to the 
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nervous system. This transfer has previously been shown to be rate-limiting in prion 
pathogenesis, involving FDCs within germinal centers and tyrosine hydroxylase (TH) positive 
sympathetic nerve endings. Since immune activation can alter splenic innervation285, I 
wondered whether the distance between FDCs and terminal nerve endings was changed, 
contributing to the increased prion susceptibility of immunized mice. However, staining for 
tyrosine hydroxylase failed to show altered distances between nerve endings and follicles (data 
not shown).  
Altered PrPC levels in secondary lymphoid organs can potentially impact prion susceptibility or 
prion incubation time. Immunization in this study did not alter the overall splenic PrPC levels as 
determined by ELISA. Interestingly, by flow cytometry, a slight increase in PrPC cell surface 
expression was detected on splenic B- and CD4+ T-cells in immunized mice. I cannot exclude 
that this slightly increased PrPC expression on either of the two cell types contributes to 
increased susceptibility. However, previous studies have shown that PrPC neither on B- nor on 
T-cells alone suffices for efficient prion replication239, 286. Therefore, I presume that PrPC levels 
on B- and T-cells are not the susceptibility determining factors in my study.  
CpG-ODN and LPS treatment can increase the cell surface level of PrPC on macrophages, and 
it has been suggested that macrophages can replicate prions transiently after stimulation with 
LPS or CpG-ODN279. The conditions used here for immunization did not significantly increase 
PrP levels on white blood cells or splenic CD11c+ or CD11b+ cells. Therefore, it is unlikely that 
PrP levels on white blood cells or antigen presenting cells within the spleen determined prion 
susceptibility in my study. 
I have found an increased density of splenic granulocytes following immunization. This might 
have an impact on prion susceptibility. Since the role of granulocytes in prion pathogenesis is 
unknown, no definite conclusions can be drawn. Similarly, the impact of CD68+ cells appearing 
in the white pulp follicles of immunized mice and its effect on peripheral prion replication remain 
unknown. Alum, which was used as an immunization adjuvant in my study, was recently shown 
to induce influx of monocytic dendritic cells into the peritoneum. This Nalp3-dependent influx287 
may conceivably represent a mechanism for efficient transfer of prions to secondary lymphoid 
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organs. It will be interesting to test whether interference with this pathway modulates prion 
susceptibility. 
In summary, I conclude that either (1) increased density and size of FDC networks in splenic 
germinal centers, (2) decreased clearance of prions by changing the cellular compartment of 
the marginal zone (e.g. marginal zone macrophages, marginal zone B-cells), or (3) both, are 
most likely responsible for increased prion susceptibility upon immunization.  
 
6.5.4 Does chronic immune stimulation correlate with CJD risk? 
In the light of the above results, it will be of interest to determine whether stimulation of the 
immune system may contribute to the individual susceptibility of humans towards prions. States 
of chronically stimulated immune system are common in humans, and can occur e.g. in chronic 
infectious diseases, autoimmune disorders, and allergies. Exposure to BSE prions is the 
assumed cause of vCJD, yet it is not known which factors determined that some unfortunate 
individuals among the European population developed vCJD while most others remained 
healthy. Epidemiological retrospective and prospective studies may help to clarify whether 
particular immune stimuli correlate with the likelihood to contract vCJD or other acquired prion 
diseases. 
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